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Abstract:  
The benzimidazoles (BZD), thiabendazole (TBZ), triclabendazole (TCB) and albendazole 
(ABZ), are veterinary agents employed for the eradication of parasitic infections in ruminant 
animals. Treatment with these drugs commonly results in trace residues remaining in the food 
product, thus requiring the development of tests capable of detecting below maximum 
acceptable residue levels (MRLs) as determined by European legislation. This research 
describes the development of novel, rapid, antibody-based methods for benzimidazole residue 
detection below the required MRL.  
 
A recombinant antibody fragment (Fab) generated from a hybridoma secreting an anti-TBZ 
monoclonal antibody was utilised for the development of an ELISA for TBZ with a limit of 
detection (LOD) of 2.5 ng/mL. Thee sensitivity of this Fab was improved two fold by 
generation of a modified plasmid vector which converts the Fab from a mono-valent to a bi-
valent antibody. 
 
An avian polyclonal antibody (pAb) was raised against TCB and ABZ. This antibody was 
incorporated into competitive ELISA and Biacore-based assay with LODs for TCB in spiked 
pasteurised organic milk samples of 609 and 203 pg/mL, respectively. A short chain fragment 
(scFv) antibody library of 5.9 x 10
11
 was also constructed, bio-panned and screened for 
clones specific for TCB and ABZ.   
 
Finally, the anti-TCB IgY was incorporated into a lateral flow immunoassay (LFIA) and a 
novel TCB-green fluorescent protein (GFP) LFIA assay with a detection threshold of 75-100 
ng/ml of TCB in milk, which is at or below the required MRL.   
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1.0 Introduction  
The main aim of this work was the production of recombinant antibodies to the 
benzimidazole (BZD) family of veterinary drugs for their detection in different matrices such 
as liver, milk and fat. This introduction discusses the relevant aspects of the parasites that the 
drugs target, and their life-cycles. It also reviews the history of BZD’s, their structures, 
current detection methods of the target residues, public health concerns and EU legislation. In 
addition, antibody production and phage display techniques are discussed. 
1.1 Parasites 
There are many definitions in the literature that describe a parasite. Chappell (Chappell, 
1980) refers to parasites as protozoans, platyhelminths and nematodes that inhabit, at some 
point in their life-cycle, the body of a larger animal. Wilson (Wilson, 1979) suggested that 
parasitism is just one, among many types of associations, between two organisms and there is 
no single feature which can be used to label an animal undoubtedly a parasite. He states that 
nutritionally a parasite obtains food at the expense of its host by consuming either host tissues 
and fluids, or the contents of the host intestine. According to this definition the parasite may 
be recognised as a foreign invader causing the host harm and to which it can generate an 
immune response. There are three classes of parasitic worms that infect ruminants examples 
of these are shown in figure 1.1: 
 
(1) Cestodes: The cestodes or tapeworms are flat worms chiefly of the alimentary tract of 
vertebrates. They have a complete lack of digestive tract in all stages of development 
(Chandler, 1961). They have a complex life-cycle with one or more intermediate hosts and 
almost invariably gain entry to the vertebrate final host via its food (Wilson, 1979). The 
cestode family include the orders Tetraphyllidea, Trypanorhyncha, Proteocephal, 
Pseudophyllidea and Cyclophyllidea. The latter two orders contain species that infect man 
and ruminants. 
 
(2) Nematodes: The nematodes, more commonly known as parasitic roundworms are found 
in marine, fresh water and terrestrial habitats in addition to parasitizing plants and animals. 
The classification of nematodes is complicated as each of the worms has a remarkable 
similarity in body plan making precise identification difficult, particularly at larval stages. 
Several groups of nematodes have evolved and are important from a veterinary view point. 
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Such groups include the orders Strongylida (Trichostrongyles), Ascardia, Spirurida and 
Trichenellida (Wilson, 1979). 
 
(3) Trematodes: The trematode species are more commonly referred to as flukes. The flukes 
are a class within the phylum Plathyhelminthes that contain two main groups monogenetic 
and diagenetic. The former have no asexual generations and are primarily external or semi 
external parasites of aquatic animals. The latter have two or more asexual generations and an 
alternation of hosts which can be internal parasites of all kinds of vertebrae (Chandler and 
Read, 1969). The sub-class, Dignea, which affects ruminant animals, include the orders 
Strigeatoidea, Echinostomida, Reicolida, Opisthorchiida and Plagiorchiida. 
 
 
Figure 1.1: Examples of the three classes of parasitic worms; (1) cestodes (flatworm); (2) 
nematodes (round worm); and (3) trematodes (fluke). 
1.2 Parasitic life-cycles 
To understand the parasites and to fully comprehend the benzimidazoles mode of action for 
their eradication, an in-depth look at their life-cycles is required. 
1.2.1 Direct life-cycle  
A direct life-cycle is one that requires only one host for completion. One of the most 
important and widely prevalent groups of nematodes that undergo this type of cycle is the 
Trichostrongyle group. This group includes Haemonchus, Ostertagia, Trichostrongylus, 
Mecistocirrus, Cooperia and Nematodirus and the groups Oesophagostomum and 
Bunostomum.  
 A  B  C 
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The adult nematodes inhabit the gastro-intestinal tract of the ruminant animal. The eggs, 
produced by the female, are passed out in the faeces where they embryonate and hatch into 
first-stage larvae (L1). These in turn moult into second-stage larvae (L2) by shedding their 
protective cuticle. The L2 larvae then moult into a third-stage larvae (L3), but still retain the 
cuticle from the previous moult. These double-cuticled L3 are the infective-stage larvae. 
These L3 larvae migrate into herbage, are ingested by grazing ruminants, and pass into the 
abomasums or intestine. The cuticle of the larvae is shed during this infection process 
(Parkins and Holmes, 1989) 
In the Trichostrongyle group, L3 penetrates the mucous membrane (in the case of 
Haemonchus and Trichostrongylus) or enter the gastric glands (Ostertagia). After a number 
of days the L3 moult and develop into larval stage four (L4) which remains in the mucous 
membrane (or in the gastric glands) for about ten to fourteen days. They then emerge and 
moult into a young adult stage (L5). The majority of Trichostrongyles mature and start egg 
production about three weeks after infection (Parkins and Holmes, 1989). 
The parasitic part of the life-cycle of the Oesophagostomum class requires approximately 6 
weeks for completion. The infective L3 penetrate the intestinal wall, and the host responds by 
surrounding the L3 in fibrous nodules. After two weeks the larvae move into the lumen of the 
intestine where they mature for a further four weeks.  
The L3 larvae of Bunostomum can infect ruminants by ingestion or penetration of the host’s 
skin. Following skin penetration, the larvae are carried in the venous blood through the heart 
to the lungs, where they penetrate the alveoli, are coughed up and then swallowed, and thus 
pass to the small intestine. Here they moult and mature eight-nine weeks after infection 
causing damage to the host (Olsen, 1986). 
1.2.2 Indirect cycle 
Most parasites have a direct life-cycle. However, the flukes or trematodes undergo an indirect 
life-cycle with two distinct stages within two different hosts. The adult fluke lays its eggs in 
the liver of the host ruminant. The eggs pass through the bile duct into the intestine where 
they are excreted in the faeces. While on the ground the egg develops further and releases a 
miracidium which invades a suitable snail intermediate host within twenty four hours. The 
miracidium continues its development from sporocysts to rediae to cercariae in the snail host. 
The resulting cercariae are released from the snail as metacercariae where they can survive 
31 
 
for approximately 10 months on aquatic vegetation or other surfaces. Mammals acquire the 
infection by eating the vegetation. After ingestion, the metacercariae encyst in the duodenum 
and migrate through the intestinal wall, the peritoneal cavity and the liver parenchyma into 
the biliary ducts, where they develop into adults. The migration causes severe damage to the 
liver, particularly when large numbers of fluke are involved. It takes ten to twelve weeks 
from time of ingestion to maturation of the flukes (Zajac, 2006)  
1.3 Economic impacts of parasitic infections 
Infections caused by the parasites described in section 1.2 play a huge role in farming 
production losses as they affect feed ingestion and digestibility. These infections alter the 
value of animals and their products at slaughter as they reduce their weight gain, yield and 
quality of products. Some infections may also affect the animal’s capacity for work, decrease 
the production of dung for fuel and fertiliser and more serious infections may cause 
premature death (Perry, and Randolph, 1999). The environment also plays a key role in 
supporting development stages of larvae and must be therefore considered in the eradication 
of parasites. However, the complexity of the environmental influences, severely reduce the 
prospect of complete obliteration. Hence, the use of anthelmintics or anti-parasitic drugs such 
as the benzimidazoles (BZD) is essential for, if not the eradication, but the control of these 
disease-causing parasites.  
1.4 Benzimidazole (BZD) structure 
The BZD structure is a bi-cyclic ring system in which benzene is fused to the 4 and 5 
positions of the heterocyclic (imidazole) ring (Figure 1.4.1). BZD compounds are white 
crystalline powders, with high melting points and are insoluble, or minimally soluble, in 
water (Lanusse and Prichard, 1993). The synthetic pathways of most BZDs proceed through 
two steps. The first step is the formation of a benzene ring containing the desired 
substituent’s and a 1,2-diamine grouping, followed by a closure of the 1,2- diaminobenzene 
derivative to construct the imidazole ring. Different modifications at the 2 and 5 position of 
the BZD ring have provided a range of anthelminthics that exhibit high efficacy against 
parasitic worms. For example, the sulphur-containing derivatives of BZD, such as 
albendazole (ABZ) and fenbendazole (FBZ) possess a high efficacy against lungworms and 
inhibit larval stages of most GI nematodes (Townsend and Wise, 1990).  
 
The preparation of ABZ (Fig 1.4.1) is a five step process, where the required propylthio 
group is attached to the benzene ring prior to the closure of the structure (Lanusse and 
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Prichard, 1993). A study carried out by (Lacey, 1990) showed that a carbamate substitution at 
the 2 position on the benzene ring was crucial for inhibition of microtubule formation in 
parasites. This work also suggested that both the chemical substitution at the 5 position and 
its conformational arrangement are relevant for access of the drugs to the active site and anti-
parasitic activity. 
Since their discovery, the BZD’s have proven to be the least toxic of anthelmintic drugs, a 
major factor in their worldwide use over the last fifty years (Lanusse and Prichard, 1993). 
BZD’s were originally introduced for the control of GI infections in livestock, however, they 
were later used for the treatment of GI infections in domestic animals. They offer many 
advantages in relation to spectrum (broad), efficacy against mature and immature stages of 
fluke, safety for the host and ovicidal activity. However, BZD’s have a disadvantage as they 
have poor GI absorption and low water solubility therefore reducing their flexibilty for drug 
formulation in some drug preparations (Alvarez et al., 2009). There are a number of BZD’s 
available in the veterinary market today. These can be classified into four groups based on 
their structure and addition of methyl and thiol groups: 
 
1. Benzimidazole thiazolyls including thiabendazole (TBZ) (Fig 1.4.1) 
2. Benzimidazole methylcarbamates including mebenazole (MBZ), albendzole (ABZ) 
(Fig 1.4.1), and Fenbendazole (FBZ). 
3. Halogenated benzimidazole thiols such as triclabendazole (TCB) (Fig 1.4.1). 
4. Pro-benzimidazoles including fenbetal (FBT) and netobitim (NTB). 
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Benzimidazole: General structural form. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Albendazole: Methyl -[6-(propylthio)-1H-
benzoimidazol-2-yl]carbamate  
Albendazole Sulphone  Albendazole Sulphoxide 
(B) 
Thiabendazole:  4-(1H-1,3-benzodiazol-2-yl)-
1,3-thiazole. 
(C) 
(A) 
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Figure 1.4.1: Chemical structures of benzimidazoles and their metabolites targeted within this 
research. These include (A) General benzimidazol structure; (B) albendazole, albendazole 
sulphone and albendazole sulphoxide; (C) thiabendazole and its metabolite thiabendazole 
NH2 , and (D) Triclabendazole and its metabolites triclabendazole sulphone and sulphoxide.  
1.5 Benzimidazole discovery and history. 
The BZDs utilised for the prevention and treatment of the parasitic infections, discussed 
previously in section 1.3, was discovered in the 1944. Wayne Wooley, a leading expert in 
anti-metabolics at the time, noted that there was a similarity in structure of BZD to adenine 
and hypothesized that the former may act as an anti-metabolite. This research further 
demonstrated that the BZD molecule could inhibit the growth of bacteria and fungi thus 
proving its pesticide capabilities (Woolley, 1946). In 1953 research at the University of 
Michigan showed that subcutaneous injections of BZD in mice infected with poliomyelitis 
had a lowered mortality rate (Gillespie et al., 1954) thus encouraging Merck researchers to 
synthesise BZD as a potential anti-viral drug. During routine screening of this drug for 
chemotherapeutic activity it was discovered that 2-phenylbenzamidazole had anti-helmintic 
properties. After examining hundreds of BZD analogues, it became apparent that 
thiabendazole (TBZ) was one of the most potent chemotherapeutic agents ever discovered. It 
was found to prevent the development of ascaris eggs in-vitro (Brown et al., 1961), and 
Triclabendazole: 5-chloro-6-(2,3-
dichlorophenoxy)-2-(methylthio)-1-benzimidazole. 
Triclabendazole Sulphone  Triclabendazole Sulphoxide 
(D) 
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became the drug of choice for the treatment of strongyloidiasis which is a human/ animal 
parasitic disease caused by the nematode Strongloides stercoralis (Sneader,  2005). 
Merck researchers screened analogues of TBZ that could resist metabolic inactivation thus 
allowing for improved penetration of the larvae. In order to achieve this they prevention of 
the enzymatic hydroxylation at the 5 position of the ring structure using aryl, alkyl, and halo 
substitutions was required. However, these approaches were unsuccessful due to metabolic 
conversion at the 5-position of the ring structure (Sneader, 2005). To overcome this, 
carbamates were produced, which are a group of organic compounds sharing a common 
functional group. From the carbamates synthesised, the compound Cambendazole was 
generated and was shown to be a highly potent, broad spectrum anti-helmintic (Hoff et al., 
1970). Following this discovery, the drug mebendazole which exhibited potent efficacy 
characteristics and broad spectrum activity was synthesized. Research continues on the 
production of anti-parasitic drugs resulting in a number of compounds which are safe for 
veterinary use and have broad spectrum activity against all stages of liver fluke and gastro 
intestinal parasites (Sneader, 2005). 
1.6 Modes of action of benzimidazoles  
In this section the mechanism by which the benzimidazoles eradicate parasitic infections is 
briefly discussed. The primary mode of action of these drug molecules involves their 
interaction with the eukaryotic cytoskeleton protein, tubulin. Tubulin provides the structural 
skeleton to the cell, and aids in the movement of chromosomes during cell division (Bell 
1998). Tubulin (the microtubulin sub unit) is a dimeric protein consisting of α and β subunits 
of approximately 50 kDa each (Lacey, 1990). 
 
Microtubules exist in balance with tubulin, and the ratio of dimeric tubulin to microtubulin is 
controlled by a number of regulatory proteins and co-factors known as micro-tubule 
inhibitors. These inhibitors bind to tubulin to prevent the self-association of the α and β 
subunits onto the microtubules (Lacey, 1990). This process is known as capping, where the 
inhibitor caps the microtubule at the associating end while the microtubule continues to 
dissociate from the opposite end resulting in loss of microtubule length. The benzimidazoles 
mebendazole and fenbendazole, were first discovered as inhibitors to induce the loss of 
microtubules of the tegumental and intestinal walls of cestodes and nematodes (Van den 
Bossche et al., 1982). This resulted in a loss of transport of secretory vesicles, a decrease 
uptake in glucose and an increased utilisation of stored glycogen. With the disruption of the 
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intestinal cell wall the parasite undergoes slow onset starvation and inhibition of egg 
production thus preventing further infection of the host animal (Martin et al., 1997) 
 
1.7 Benzimidazole residues and the EU directives   
The employment of these veterinary drugs as preventatives for parasitic infections is essential 
for animal production. However, trace residues of benzimidazole may be found in the final 
meat or meat products. The control of these residues is important for public health, thus 
highlighting the requirement for rapid analytical methods for regulatory monitoring 
(Bergwerff and Van Knapen, 2006). By definition a residue is a trace of a substance, present 
in a matrix (meat, blood, urine etc) after some sort of administration (for example within the 
framework of veterinary practice and illegal use) to an animal. In all cases concentration 
levels in the ppb (µg/kg) range or even lower (ng/kg) have to be detected (Scarth et al., 
2009).  
According to the EU directive 96/23/EC residues are divided into two major groups A and B. 
Group A includes illegal growth promoters that are abused for animal fattening, and the no 
maximum residue level substances. These can be sub-divided into four main groups; anabolic 
or anabolic steroids, thyreostats, beta-agonists and annex IV substances. Group B contains 
the veterinary drugs such as the benzimidazoles or veterinary medicinal products (VMPs) that 
include antibacterial substances, anthelmintics, coccidiostats, carbamates, pyrethroids, 
sedatives, non-steroidal anti-inflammatory drugs and other pharmacologically active 
substances.  
The analytical requirements for both groups are different, for group A residues, the 
substances have to be identified in a large range of matrices at a low concentration level (zero 
tolerance principle). This requires a qualitative multi-residue method, closely followed by 
quantitative methods. For group B substances a less stringent approach is used whereby a 
qualitative method may be employed to confirm for the presence of such residues. A more 
detailed investigation of the screening methods available for the benzimidazole’s detection is 
discussed in section 1.8.   
 
The Veterinary Medicines Evaluation unit, as part of the European Agency for the Evaluation 
of Medicinal products (EMEA), compiles experimental data in order to determine maximum 
residue limits (MRLs) for veterinary drugs. These MRLs are established to prevent any 
contaminated food products reaching consumers (EMEA/CVMP/765/99-Rev.23). Included in 
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the section (1.7.1) is a summary of the key information reviewed from the EU directives 
regarding the targeted drugs in this research i.e. ABZ, TBZ and TCB. Some of the 
information reviewed here is not available from journals and are mainly based on the 
unpublished findings from the department of agriculture funded research projects. 
 
1.7.1 Albendazole  
EU directive number EMEA/MRL/865/03 
A comprehensive series of developmental studies carried out in mice, rats, rabbits, and sheep 
showed albendazole to be teratogenic. The malformations included visceral, craniofacial and 
bone defects (including shortened limbs). The lowest no observable effects level (NOEL) for 
ABZ was 5 mg/kg of body weight (bw)/day. Netobimin (Prodrug of albendazole) and 
albendazole sulphoxide were also teratogenic with similar potency to albendazole 
(EMEA/MRL/865/03, 2004) 
Reproductive effects of ABZ were investigated in multi-generation oral-dosing studies in 
rats. The drug reduced survival and growth of pups during the post-natal lactation period, 
with an NOEL for this effect of 5.8 mg/kg (EMEA/MRL/865, 2005). 
Albendazole demonstrated negative results in bacterial mutation tests using numerous 
different strains of organisms. It produced no clastogenicity in an in-vitro metaphase analysis 
of Chinese hamster ovary (CHO) cells, and was negative in an in-vitro cell transformation 
assay in BALB/3T3 mouse cells. However, an in-vivo mouse bone marrow micronucleus test 
on ABZ, which had been isolated from a formulated product, gave a positive result. This 
result indicated that albendazole was an in-vivo somatic cell mutagen. In the absence of any 
tests on germ cells, it remains unclear whether or not ABZ can induce heritable mutations. 
Further studies showed that ABZ and NTB are in-vivo aneugens. A maximum/ minimum 
level of exposure to ABZ that presents a mutagenic risk to consumers was not identified. 
 
ABZ was adequately tested in carcinogenicity bioassays, giving no evidence of neoplasia in 
either rats or mice, while albendazole sulphoxide was found to be non-irritant for the skin or 
eyes of rabbits (EMEA/MRL/865/03 2004). 
 
ABZ may be administered to humans and domestic animals for the treatment of cestode 
parasitic infections. In human field trials of ABZ, 17 women in the first trimester of 
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pregnancy were given a single oral dose of 400 mg/person without any adverse effects on 
mother or child being apparent (EMEA/MRL/865/03 2004). 
 
In cattle given 14C-labelled albendazole as a single dose of 15 mg/kg bw, the total residues in 
liver depleted from more than 20 mg/kg one day after treatment to 6 mg/kg four days after 
treatment and around 1.2 mg/kg 20 days after treatment. The liver has the highest residue 
levels and the kidney has the next highest and most persistent residue levels. Muscle and fat 
tissues have much lower residue levels and deplete rapidly (e.g. for muscle a level of 5 mg/kg 
one day after treatment reduced to 64 μg/kg four days after treatment and 20 μg/kg after 20 
days). Ruminant species such as bovine, ovine and caprines share a similar gastro-intestinal 
physiology. The available pharmacokinetic and residue depletion data do not indicate any 
significant variability between cattle and sheep, therefore, the EMEA concluded that other 
ruminants were unlikely to show any significant differences in these parameters. 
Consequently, they recommended that the same MRL values would apply to all animal 
species tissues and organs. The same MRL for ABZ was also established for milk (Table 
1.7.1). Based on the MRLs shown below it was calculated that the daily intake of extractible 
residues would amount to 310 µg/day i.e., 103 % of the ADI. It was considered that this 
would not constitute as a risk to consumers because at least 73 % of the residues in tissue 
were not bioavailable (EMEA/MRL/865/03 2004). 
 
 Table 1.7.1: Marker residue, target tissues and MRLs for Albendazole.  
Pharmacologically 
active substances 
Marker residue MRL’S Tissue 
Albendazole Sum of albendazole suphoxide, 
sulphone and 2-amino sulphone 
expressed as albendazole. 
100 µg/kg 
1,000 µg/kg 
500 µg/kg 
100 µg/kg 
100 µg/kg 
Muscle 
Fat 
Liver 
Kidney 
Milk 
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1.7.2 Thiabendazole 
EU directive EMEA/ MRL/868 
According to the EMEAs review on the toxic and mutagenic affects of TBZ, low acute 
toxicity is exhibited when TBZ is administered via the oral route. In mice oral LD50 values 
significantly varied from 2,400 to 3,810 mg/kg and 3,300 to 8,600 mg/kg in rats, and 3,850 
mg/kg in rabbits. When administered by intraperitoneal injection and intravenously, LD50 
values for mice were 430 and 130 mg/kg bw and for rats were 1,850 and 150 mg/kg bw, 
respectively. The signs of acute toxicity seen at high doses included weight loss, inanition, 
ataxia, narcosis and central nervous system depression, with subsequent death from 
respiratory failure (EMEA/ MRL/868, 2002). 
 
Tada (1996) investigated the subchronic toxic effects of thiabendazole (TBZ) administered in 
the diet at levels of 0 (control), 0.8 and 1.6 % for 13 weeks to male and female ICR mice. 
Mean body weights of male mice fed 0.8 or 1.6 % TBZ showed a significant decrease 
compared with controls. Red blood cell parameters in male mice of treated groups were 
significantly lower than controls. Spleen or liver weights were significantly increased in male 
and female mice of treated groups. Relative kidney weights of treated mice tended to be 
increased in comparison with controls. In the liver, sinusoidal dilatation and enlargement of 
liver cells were found in treated mice. In the kidney, atrophy of tubules with peritubular 
fibrosis, cell infiltration and some tubular necrosis were found in treated mice. Slight 
hyperplasia was found in the urinary bladder of treated mice. The findings in the present 
study indicate that TBZ caused a slight anaemia and liver or kidney injury at both levels 
tested, under these conditions (Tada et al., 1996). 
 
Mice given TBZ in oral gavage doses of 250 or 500 mg/kg bw/day for up to seven days 
showed renal damage to the tubules and glomeruli. In pilot studies of three and six weeks 
duration, mice were fed diets which gave them doses of 0, 50, 150, 300, 600 and 900 mg/kg 
bw/day of TBZ with no effect on mortality or clinical appearance, but food intake and 
bodyweight gain were decreased at doses of 600 mg/kg bw/day or more. When treated with 
higher dosages over a thirteen week period both female and male mice showed decreases in 
red blood cell parameters (red blood cells, packed cell volume, MCHC, MCH). They also had 
an increased platelet count and a mild neutrophilia with concurrent lymphopaenia. Serum 
transaminases were raised in both male and female mice. The weights of the liver, spleen and 
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kidneys were increased in groups receiving high doses of TBZ. There was also centrilobular 
hepatocellular necrosis, bile duct proliferation, splenic haemosiderosis, necrosis, fibrosis and 
atrophy of renal tubules and urothelial hyperplasia (EMEA/ MRL/868, 2002). 
 
Studies were carried out by (Lankas and Wise, 1993) that assessed the developmental toxicity 
of TBZ in New Zealand white rabbits and Sprague-Dawley rats. In rabbits, TBZ was 
administered orally at doses ranging from 24 to 600 mg/kg body weight/day in two separate 
studies. In rats, TBZ was administered at doses of 10, 40 or 80 mg/kg body weight/day. In all 
studies, TBZ was administered daily by gavage on gestation days 6 to 17. In the first rabbit 
study, weight loss occurred in the 600 mg/kg/day group and weight gain decreased for the 
rabbits administered with 120 mg/kg/day group. In addition, there were four complete litter 
resorptions and four abortions in the 120 and 600 mg/kg/day groups, respectively. This study 
was repeated and they found that there was a decreased maternal weight gain and decreased 
foetal weights at 600 mg TBZ/kg/day, but there was no evidence of selective developmental 
toxicity. During the rat study TBZ produced decreased maternal weight gain associated with 
slight decreases in foetal weights at doses of 30 and 80 mg/kg/day. No changes were found at 
10 mg TBZ/kg/day and no evidence of selective developmental toxicity or teratogenicity was 
found at any dose. Based on these results they concluded that TBZ is not teratogenic or 
selectively foetotoxic in rats or rabbits (Lankas and Wise, 1993). 
 
Mudry de Pargament (1987) reported the chromosomal damage produced by TBZ that was 
evaluated by “in-vivo” and “in-vitro” cytogenetic tests. Doses of 50, 100 and 200 mg/kg body 
weight were assayed in adult mice by the sister-chromatid exchange (SCE) and micronucleus 
tests. These doses were selected as they were within the range of those used in human 
antihelminthic treatments. SCE frequency was increased only in the last dose. A significant 
increase of micronucleated cells was shown in the 3 doses assayed. A notable increase in 
abnormal anaphase-telophase cells was only detected with the two highest concentrations 
assayed (0.60–0.24 μg/mL) p <0.01 and p <0.05 respectively. They state that the genotoxic 
effects of this residue indicate that TBZ itself is a mutagenic agent (Mudry de Pargament et 
al., 1987). According to studies carried out by the EMEA their data indicates that TBZ does 
not produce gene mutations in bacterial tests (no mammalian cell gene mutation tests 
available), structural damage to chromosomes in-vitro (metaphase analyses), nor in Syrian 
hamster embryo (SHE) cell-transformation assays. The results of tests in fungal and 
mammalian cell systems (including in-vitro metaphase analyses, in-vitro 
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micronucleus/kinetochore assays, induction of mitoses, and yeast aneuploidy assays), 
however, provide consistent evidence of aneugenicity (mutations which cause the loss or gain 
of whole chromosomes) in-vitro (EMEA/ MRL/868, 2002). 
 
They further concluded that the in-vitro aneugenicity of TBZ was shown to be a consequence 
of it binding to tubulin, which results in dysfunction of the spindle mechanism at cell 
division. All of the validated oral route in vivo mutagenicity assays in either, somatic cells 
(bone marrow metaphase analyses and bone marrow micronucleus tests) or germ cells 
(dominant lethal assays), were interpreted as being negative (EMEA/ MRL/868, 2002).  
A study was carried out by (Ogata et al., 1984) where TBZ was suspended in olive oil and 
tested for teratogenicity using pregnant Jcl:ICR mice at different stages of organogenesis. All 
foetuses were removed from the uterus on day 18 of gestation, and were examined for 
external and skeletal anomalies. In mice given 700, 1,300 or 2,400 mg TBZ/kg body 
weight/day on days 7–15 of gestation, dose-dependent external and skeletal anomalies, 
especially cleft palate and fusion of vertebrae, were observed. In mice given a single dose of 
TBZ (2,400 mg/kg) on any one of days 6–13, they observed an increased number of 
malformations. Various types of malformation occurred, especially in the mice treated on day 
9. Reduction deformity of limbs was found in mice given TBZ on days 9–12. They also 
determined a dose-response relationship, whereby they administered groups of mice with one 
of 17 doses of TBZ (30–2,400 mg/kg) on day 9 of gestation. The number of litters having 
foetuses with reduction deformity of limbs and of those having foetuses with skeletal fusion 
increased in proportion to the dose of TBZ, thus proving that high doses of TBZ causes foetal 
abnormalities and mutations (Ogata et al., 1984). 
 
According to  recent studies carried out by the  EMEA the great weight of evidence indicates 
that thiabendazole does not cause any in vivo genotoxic effects when it was administered by 
the oral route, it was concluded that thiabendazole residues in food do not give rise to 
concern with respect to mutagenic hazards to consumers (EMEA/ MRL/868, 2002). 
 
There is no significant variability between MRL’s for different animal species. MRL’s for 
milk were also established (Table 1.7.2). Based on these MRL’s, the theoretical daily intake 
of total thiabendazole-related residues in milk and meat corresponds to around 7 % of the 
ADI. 
 
42 
 
 
Table 1.7.2: Marker residue, target tissues and MRLs of thiabendazole 
Pharmacologically 
active substances 
Marker residue MRL’S Target 
tissue 
Thiabendazole Sum of thiabendazole and 
5-hydroxy-thiabendazole 
100 µg/kg 
100 µg/kg 
100 µg/kg 
100 µg/kg 
100 µg/kg 
Muscle 
Fat 
Liver 
Kidney 
Milk 
 
1.7.3 Triclabendazole 
EU directive EMEA/CVMP/320386 
Triclabendazole has low acute toxicity when administered by the oral, intraperitoneal, dermal 
and inhalation routes. The sulphoxide and sulphone metabolites of triclabendazole also have 
low acute oral toxicity, produce minimal skin irritation, no eye irritation and had limited 
potential for skin sensitisation. TCB showed no teratogenicity in rats or chinchilla rabbits, 
although foetal development was retarded (low foetal body weight and low ossification) at 
doses which caused maternal toxicity (100 mg\kg bw in rats and 10mg/kg bw in rabbits). Oral 
administration to sheep up to 50 µg/kg bw had no adverse effects in reproductive parameters 
(EMEA/CVMP/32038, 2004). 
 
TCB appeared negative in numerous in-vitro and in vivo mutagenicity tests. A 
carcinogenicity study was conducted in mice where the only pathological findings were 
increased serum levels of hepatic enzymes, increased liver-weight and benign hepatomas in 
females with a dietary supplement of 300 mg/kg of feed. Another study in rats also 
demonstrated no significantly adverse effects on tumour incidences at any dose 
(EMEA/CVMP/320386, 2004). 
 
The bioavailability of the drug was assessed using the rat model and a number of different 
methods; these methods established that the rat’s bioavailability from feed was approximately 
70 %. The metabolism of rats is comparable to that of sheep, goats and cattle and it was 
therefore concluded that the residues of toxicological concern would be similar. The studies 
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also showed that the bioavailability of incurred residues was very low following 
administration of triclabendazole intravenously and orally, which allowed for an increase in 
previously established MRL’s. Based on the MRL’s below (Table 1.7.3), and taking into 
account the bioavailability of the residues in the tissues, the daily intake represents about 70 
% of the ADI which is approximately 63 µg/day (EMEA/CVMP/32038, 2004). 
 
Table 1.7.3: Marker residues, target tissues and MRL’s of triclabendazole 
Pharmacologically 
active substances 
Marker residue MRL’S Target tissue 
Triclabendazole Sum of the extracted residues 
that may be oxidised to keto-
triclabendazole 
225 µg/kg 
100 µg/kg 
250 µg/kg 
150 µg/kg 
100 µg/kg               
Muscle 
Fat 
Liver 
Kidney 
Milk  
 
1.8 Screening methods for the detection of benzimidazoles.  
Screening methods are defined according to commission decision 2002/657 as “methods that 
detect the presence of an analyte or class of analytes at the level of interest. These methods 
have the capability for a high sample throughput and are used to sift large numbers of 
samples for potential non-compliant results. They are specifically designed to avoid false 
compliant results”. The level of interest referred to is the MRL.  
1.8.1 Methods of detection for benzimidazoles. 
A number of methods are available for the detection and quantification of benzimidazole 
residues and their metabolites. These include high performance liquid chromatography 
(HPLC), liquid chromatography (LC), gas chromatography (GC), mass spectrophotometry 
(MS) and thin layer chromatography (TLC). There are approximately 20 BZD residues that 
can be found in animal tissue (Danaher et al., 2007).  
Detection methods for BZD were developed soon after its discovery. Initial methods included 
direct spectrometric detection with fluorescence and colourmetric detection.  However, these 
assays were only suitable for quantitation at high levels of BZD and a more selective 
chromatographic separation was required prior to spectrometric detection (Pease and 
Gardiner, 1969). TLC, which is a suitable technique for the semi-quantification of residues, 
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was further developed as a detection method. Norman et al. developed a TLC assay which 
was capable of detecting TBZ in citrus fruits (Norman et al., 1972). Subsequently high 
performance TLC (HPTLC) was developed for the determination of benzimidazole residues 
in crops and the sensitivity was compared to that of HPLC which proved to be more sensitive 
a technique (Corti et al., 1991). However, TLC methods had a higher limit of detection and 
were above EU regulations and standards as described in Tables 1.7.1-1.7.3.  
 
The physical and chemical properties of BZD residues vary significantly thus making the 
advancement of chromatographic methods difficult. When developing these assays there are a 
number of things to take into account such as peak sharpness, resolution and run-time. A 
number of studies were carried out on LC-based systems investigating the use of columns 
with different bore sizes (Porter et al., 1993) and concluded that using a narrow bore column 
reduced solvent usage, analysis time and pump water. Another study utilised different pH 
gradients and ion pair reagents to shorten retention time (Botsoglou et al., 1994). Advances in 
separation techniques have led to the development of LC detection systems which are 
coupled with ultra-violet (UV), fluorescence and MS to determine BZD in different matrices 
such as milk, serum, tissue and crops. BZD possesses a strong UV chromophore and ABZ, 
TCB and TBZ possess naturally fluorescing chromphores which also make them suitable for 
detection by LC - fluorescence  (Danaher et al., 2007). Sorenson and Peterson developed a 
LC-UV method that allowed for the detection of eight benzimidazoles including ABZ, 
fenbendazole (FBZ) and ABZ-SO2, a metabolite of ABZ in milk (Sorensen and Peterson, 
1995) Kinabo and Bogan developed a LC-fluorescence method that had the ability to detect 
TCB and its metabolites TCB-SO and TCB-SO2 at levels down to 40 µg/kg for both TCB and 
TCB-SO and 20 µg/kg for TCB-SO2  (Kinabo and Bogan, 1988). Even though the detection 
methods described have well documented sensitivity, the technique of choice for the sensitive 
and selective detection of BZD’s is predominantly LC-MS.  
 
LC-MS facilitates the detection of residues in a range of matrices, and, when compared to 
LC-UV or fluorescence, can be used as a stand-alone method for the detection, confirmation 
and identity of benzimidazole residues. Takeba et al. described a confirmatory assay for TCB 
with a Limit Of Detection (LOD) range between 4 and 6 µg/kg in bovine milk (Takeba et al., 
2000). Improvement of the LC-MS system have allowed for the development of methods 
which can detect a number of residues simultaneously. Bushway et al. detected residues of 
TBZ and carbendazim (MBC) in fruit juices with a Limit of Quantification (LOQ) of 2 µg/kg  
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(Bushway et al., 1994). Another study carried out by Balizs et al. used a triple-quadruple 
instrument to detect 15 different benzimidazole residues with the LOQ ranging between 5 
and 30 µg/kg (Balizs and Erbach, 1999).  
 
BZD determination can also be achieved by gas chromatography (GC). This method is a 
challenge for some BZD and its derivatives because of their low volatility. However, TCB 
and TBZ are sufficiently volatile to enable measurement in samples derived from crops and 
fruit juices with detection limits of approximately 10 µg/kg (Oishi et al., 1994). The number 
of derivitisation steps required for GC may be time consuming and difficult. To eliminate 
long sample preparation and derivitisation steps a more rapid method can be employed for the 
detection and measurement of these residues such as enzyme-linked immunosorbent assay 
(ELISA) and biosensor assays 
1.8.2 Enzyme-linked immunosorbent assay and Biosensor assays. 
An ELISA is a quick, quantitative and robust system and may be used for the screening and 
determination of veterinary drug residues. It measures the biochemical interactions between 
specific antigens and antibodies for detection of residues in a sample.  In 1992 a monoclonal 
antibody capable of detecting TBZ and its metabolites in bovine liver samples at levels down 
to 20 µg/kg was generated (Brandon et al., 1992). This antibody was later used to detect TBZ 
in fruit, vegetable and fruit juices and a monoclonal (mAb) that had a cross reactivity with 11 
of the benzimidazoles was also developed (Brandon et al., 1994). A polyclonal antibody  
(pAb) that showed cross reactivity to 8 of the benzimidazole carbamates with limits of 
detection in serum of 2.6 µg/kg was also reported (Johnsson et al., 2002). Increasing concern 
about the level of exposure of ruminants to veterinary drug residues necessitates the 
development of a rapid screening method for their determination in food. ELISA is a method 
that may be regularly used for confirmation and quantification of benzimidazole residues; 
however, the use of surface plasmon resonance (SPR) allows the development of an 
automated rapid screening assay for veterinary residues. SPR-biosensor assays employ label-
free detection and have proven to be versatile, robust and capable of producing rapid and 
reliable results with minimum sample preparation  (Baxter et al., 2001). Keegan et al. 
developed an SPR-based assay, combined, with a well developed extraction procedure, for 
the determination of 11 benzimidazole residues in bovine milk with a LOD of 5 µg/kg 
(Keegan et al., 2009). Brandon et al. (Brandon et al., 2002) developed an inhibition biosensor 
assay to determine benzimidazole residues in serum and plasma using a monoclonal antibody 
46 
 
with a LOD of 5 µg/kg (Brandon et al., 2002). There are few reports in the literature on the 
use of biosensors for the detection of BZD in food matrices. 
 
In this research an ELISA assays were developed using a recombinant antibody binding 
fragment (Fab) which facilitated the detection of TBZ. ELISA, BIAcore™ and lateral flow 
immunoassays (LFIA) were also developed utilising an avian pAb for the detection of TCB 
in spiked milk samples.  The use of recombinant antibodies has many advantages such as 
ease of production, immortalisation and most importantly the ability to modify properties 
through genetic modifications such as CDR walking, site directed mutagenesis and chain 
shuffling.  The next sections describe the general structure of an antibody and its recombinant 
counterparts. It also describes the process of selection of highly specific and sensitive 
antibodies by the phage display technique. 
1.9 Introduction to antibody structure and production.  
1.9.1 Antibody structure 
An antibody molecule is composed of four polypeptide chains linked by disulphide bonds 
consisting of 2 heavy chains and 2 light chains with molecular weights of 50 kDa and 25 
kDa, respectively. The heavy chain is comprised of one variable (VH) region which is 
involved in the antigen binding and three constant regions (CH1, CH2, CH3) (Fig 1.9.1). The 
light chain is composed of one variable (VL) region and is an integral part of the antigen 
binding site, and one constant (CL) region (Feige et al., 2009). 
There are five classes of immunoglobulins (Ig). They are all distinguished by their heavy 
chains, these include, IgG, IgM, IgE, IgA and IgD. There are two types of light chain lambda 
(λ) and kappa (κ) which combine with heavy chains to form a complete Ig molecule. IgG is 
targeted for library construction as it is one of the major class of antibody which is produced 
during the immune response (Padoa and Crowther, 2006). The Fc portion of the antibody 
consists of the three constant heavy domains and these contribute to the effector functions of 
the antibody such as complement activation (Padoa and Crowther, 2006). The antigen 
binding region of the molecule consists of both the variable light and heavy domains that 
bring together the hyper variable loops known as the complementary determining regions 
(CDR). These regions usually have little difference in their sequence between classes; 
however, can exhibit a high level of sequence diversity (Conroy et al., 2009). 
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1.9.2 Production of Antibodies 
Antibodies have been used extensively as diagnostic and therapeutic applications and residual 
confirmatory tools (Borrebaeck, 2000). Initially immunoassays were dependent on the use of 
polyclonal antisera from immunised animals that provided a significant immunse response to 
the selected antigen (Borrebaeck, 2000). By definition, a polyclonal anti-serum contains 
many different antibody molecules varying in specificity and affinity. However, their supply 
is not limitless (Lee and Morgan, 1993). In 1975 the reporting of the discovery of monoclonal 
antibody (mAb) generation technology potentially led to the immortilisation of a single clone 
in-vitro and the availability of unlimited amounts of identical antibodies (Köhler and 
Millstein, 1975). Monoclonal antibodies are generated by the fusion of antibody-producing B 
cells to myelomas (malignant B cells). The fusion may be facilitated by the use of 
polyethylene glycol, a polywax that promotes cell adherence and the exchange of nuclei. To 
select for successful cell fusions, the cells are grown in a medium containing hypoxanthine 
aminopeterin and thymidine (HAT medium) in which only the hybrid cells can propagate. 
Following testing for specificity, the cultures are cloned by limiting dilution to obtain a 
homogenous cell clone secreting mAbs (Little et al., 1988). Monoclonal antibodies offer 
several advantages over polyclonal antibodies as they have the ability to monitor precise 
conformational changes in biopolymers, or to target specific epitopes. However, a third 
recombinant method was developed for antibody production which have several advantages 
over mAb generation including, time necessary for production, the ability to locate epitopes 
that are inaccessible to larger antibody molecules: the ability to immobilise many more 
fragments on a small support such as a lateral flow or dipstick device  (Lee and Morgan, 
1993). 
1.9.3 Recombinant antibody fragments 
The development of an expression system by Pluckthun and Skerra (Skerra, A. 1988) 
allowing the production of a completely functional antigen binding fragment (Fab) in E-coli 
was a pivotal point in recombinant antibody engineering. This system showed that the 
assembly pathway for the Fv fragment is similar to that of the whole IgG molecule in 
eukaryotic cells (Skerra and Pluckton, 1988). The advent of this recombinant technology has 
allowed for the generation of smaller fragments that exhibit the stability and specificity of the 
larger IgG molecule (Conroy et al., 2009). The smallest of the antibody fragments is the Fv 
portion which comprises of non-covalently associated VH and VL. These have the same 
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affinity of the whole IgG molecule. High yields of this fragment can be produced in bacterial 
systems; however, the dissociation of the two variable domains may vary the stability (Bittar 
et al., 1996). A more stable scFv fragment can be generated from this by incorporating a 
glycine serine flexible linker (Gly4Ser)3 (Verma et al., 1998). The Fab fragment consists of 
the light chain and the Fd region, which is the VH and CH1 region of the heavy chain with part 
of the hinge region. Since the Fab’s antigen binding site is still intact, it binds in a similar 
fashion to the parent antibody molecule.  It is composed of two chains: VH-CH1 and VL-CL 
and mimics the binding of the parental IgG. Diabodies can be prepared by fusing a shorter 
polypeptide linker to two scFv fragments thus increasing the affinity of the fragment. Similar 
to this, a dimeric scFv can be produced by introducing a natural dimeric protein to attach both 
scFv fragments. Once these fragments are generated they  (Welsh et al., 1998) can then 
employed to select highly sensitive and specific antibodies from an extensive library 
(Bradbury and Marks, 2004). 
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Figure 1.9.3.1: An illustration of a typical IgG molecule (i) (~150 kDa) and some of its 
recombinant antibody formats. The red triangles represent the antigen binding sites and the 
disulphide bonds are indicated as black lines. The Fv (ii) consists of the VH (Yellow) and VL 
(Orange) chains. The scFv (iii) consists of the Fv region with a flexible linker joining the 
terminal ends of the VH and VL. The dimeric scFv (iv) is a fusion of two scFv’s via a naturally 
occurring protein such as a leucine zipper or a four helix bundle structure. The dimeric bi-
valent scFv (v) incorporates an alkaline phosphatase label (star) to facilitate direct detection. 
The Fab fragment (vi) consists of fv fragments with both CH (green) and CL (blue) chain. The 
F(ab´)2 involves the linking of two Fab fragments with disulphide bonds. This can also be 
achieved by enzymatic cleavage of the full IgG molecule.  
1.9.4 Phage display  
Phage display was first introduced for the affinity selection of proteins fragments synthesized 
and expressed for cDNA fragments (Smith, 1985). This technique rapidly evolved to generate 
antibodies that recognised specific antigens with high affinity (Dennis and Lowman, 2004). 
Phage display can easily be described as the molecular link between phenotype and genotype. 
In general terms the protein is expressed on the surface of a phage particle as a fusion protein 
with a phage coat protein and the corresponding gene is inserted into the chromosome of the 
gene that is located within the phage particle (Jestin, 2008). 
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More specifically, the filamentous phage, M13, f1 and fd, from the genus Inovirus, are 
viruses that infect gram negative bacteria by using their pili as receptors (Zani and Moreau, 
2010)(Figure 1.9.1). They are circular single stranded DNA that are packaged into a 
cylindrical shape known as a capsid. They are non lytic and do not assemble in the cytoplasm 
of the cell, instead they are continuously secreted across the bacterial membrane.  The outer 
coat of the capsid is made up of five structural proteins. The more important of these 5 are the 
major coat proteins pVIII and pIII (Zani and Moreau, 2010). These proteins have both N-
terminus region exposed to the exterior of the phage particle, and the sequences that are to be 
displayed on the surface are generally inserted at the N-terminus of the pVIII between the 
signal sequence and the beginning of the mature protein coding sequence. However, only 
small sequence may be inserted at this region as the sequence length prevents the correct 
phage assembly (Dennis and Lowman, 2004). The pIII protein located at the end of the phage 
is regularly utilised for most phage display functions as it allows long sequences to be 
inserted (Dennis and Lowman, 2004).  
 
Figure 1.9.4.1: Structure of a filamentous phage displaying scFv fragments on its surface 
(Smith et al., 2005). 
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The protein of interest can also be displayed on the surface of the phage using a phagemid 
vector where the heterlogous sequence is inserted directly into the coding sequence of PIII or 
using a phage based phagemid vector that contains only the fusion protein gene (Zani and 
Moreau, 2010). Phagemid vectors are widely used because of their size and ease of cloning. 
The cDNA can be displayed by cloning into a small plasmid under the control of a weak 
promoter. Usually a phagemid vector carries both a plasmid origin of replication and a f1 
origin of replication. The f1 ori allow the synthesis of a single stranded DNA and the 
formation of virions. These virions are produced from E.coli cells that possess these vectors 
by infecting the cells with helper phage. Infected cells then express wild type coat proteins 
encoded by the helper phage genome and a small amount of the fusion protein encoded by the 
phagemid vector. Finally, most virions contain the phagemid genome, as the helper phages 
genome has altered the packaging efficiency, therefore the linkage between genotype and 
phenotype is preserved (Zani and Moreau, 2010). Surface display of the antibodies then 
allows for affinity selection by antigen in-vitro, mimicking antigen selection in natural 
immunity (Petrenko and Vodyanoy, 2003). Affinity selection is achieved by passing the 
library over immobilised antigen molecules that are adsorbed to an immuno-sorbent material, 
binding clones are captured, while non binding clones are washed away. The specific phage 
particles can be eluted from antigen without losing infectivity and can then be propagated for 
another round of affinity selection (Petrenko and Vodyanoy, 2003). 
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Figure 1.9.4.2: Diagrammatic representation of the typical steps involved in the panning of 
combinatorial phage-displayed libraries. (1) The phage-displayed antibody  
repertoire is packaged and isolated from E.coli. (2) Phage are subjected to selective pressure 
on immobilised antigen. (iii) Non-specific phage are removed by repetitive washing (4) 
Specific bound phage are eluted from immobilised antigen using specific conditions (i.e. 
acidic or basic solutions) (5) Eluted phage are analysed by ELISA. (6 and 7) Exponential 
growth phase E.coli containing F' plasmid are infected with eluted phage and allowed to 
amplify. Following infection monoclonal phage-antibodies can be obtained by isolating 
single infected colonies on selective agar (represented by red block arrow). (8) Panned phage 
amplified in E. coli are purified from bacteria and subjected to subsequent rounds of panning. 
Adapted from Christensen, 2001. 
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1.10 Thesis outline 
The aim of the work presented in this thesis is the production and characterisation of 
recombinant antibody fragments for the detection of benzimidazoles in different matrices. 
Figure 1.10.1shows a schematic of the strategy employed during this research The production 
of a sensitive recombinant Fab fragment which was used in the development of an ELISA 
assay capable of detection of TBZ significantly below the MRL of 100 µg/kg is described. 
Recombinant antibody generation techniques included the production of phage-display Fab 
library from hybridoma cell lines secreting anti-TBZ monoclonal antibody. Twelve soluble 
Fab antibodies were isolated, expressed and purified from this library. These clones were 
then characterised by ELISA, SDS-PAGE and Western blotting. Subsequently, antibodies 
were evaluated by the development of inhibition immunoassays for the detection of TBZ in 
extraction buffer which contains 5 % (v/v) methanol.  
 
The second section focuses on the improvement of the Fab’s sensitivity by restructuring the 
pComb vector to contain a double helix gene which would create a bivalent Fab fragment. 
The dHLX gene was amplified by PCR from the pAK500 system.  Positive clones were 
selected and characterised by ELISA, SDS-PAGE and Western blotting. Further confirmation 
of bivalency was carried out by HPLC. The development of the assay was initially carried out 
by ELISA. Working assays with desired performance characteristics (i.e. sensitivity and 
reproducibility) were again validated for the detection of TBZ in buffer.  
 
Chapter four focuses on the generation of an avian polyclonal fromIgY from egg yolk and its 
subsequent implementation into an ELISA assay for the detection on TCB and ABZ in 
extraction buffer. This work outlines the optimisation of the assay, and the antibodies 
stability in a variety of buffers. Inter and intra assays were performed for sensitivity and 
reproducibility. Following this an avian scFv library was constructed and panned against the 
conjugates TCB-BTG and ABZ-BSA. Positive clones were selected and expression studies 
were carried out using a range of E.coli strains. 
 
Chapter five describes the further development of an ELISA assay implementing the anti-
TCB pAb for the detection of TCB extracted from spiked milk samples. Following this 
Biacore™ and lateral flow immunoassays were generated for the detection of TCB in spiked 
buffer and milk samples. The final section of this research details the conjugation of the TCB 
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hapten molecule to green flourescent protein (GFP) for the novel development of a rapid 
lateral flow immunoassay for the detection of TCB in buffer and milk samples.  
 
 
 
Figure 1.10.1: Diagram outlining the strategy employed for the generation of antibodies to 
the benzimidazoles and their application.  
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Chapter 2 
Materials and Methods 
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2.0 Materials and methods 
2.1 Equipment. 
The following tables describe the equipment, media and buffer components, commercial 
antibodies and bacterial strains used though-out the course of this research. 
 
Table 2.1.1: Equipment used over the course of this research and associated suppliers. 
Equipment  Supplier  
 
Biometra TGRADIENT PCR machine 
 
LABREPCO, 
101 Witmer Road, 
Suite 700, Horsham,  
PA 19044, 
USA. 
 
Nanodrop™ ND-1,000 NanoDrop Technologies, Inc.,                                                                                               
3411 Silverside Rd, 
100BC,                                                                       
Wilmington, DE 19810-4803,  
USA. 
Gene Pulser Xcell ™ electroporation  
System 
 
 
 
 
ORBI-safe TS netwise orbital  
shaking incubator 
Bio-rad Laboratories, Inc. 
200 Alfred Nobel Drive, 
Hercules, 
California 94547, 
USA. 
 
Sanyo Europe Ltd., 
18 Colonial Way, 
Watford,  
WD24 4PT, 
United Kingdom 
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Equipment        Supplier  
 
Trans-Blot
®
 Semi-dry Transfer  
cell 
 
Bio-Rad Laboratories,  
2,000 Alfred Nobel Drive,  
Hercules,  
California 94547,  
USA. 
 
Roller mixer SRT1 Sciencelab, Inc., 
14025 Smith Rd. 
Houston,  
Texas 77396,  
USA. 
 
Safire 2 plate reader Tecan Group ltd  
Seestrasse103,                                                                                  
CH-8708, 
  Männedorf,         
 Switzerland.                                                              
  
Biacore™ 1,000 and 3,000    GE Healthcare Bio-Sciences AB, 
   SE-751 84, 
   Uppsala, 
   Sweden. 
  
Vibra Cell™ sonicator 
 
 
 
  
   Sonics and Materials Inc., 
   53 Church Hill Road, 
   Newtown, 
   CT 06470-1614,  
   USA. 
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Equipment  Supplier 
Camag Linomat 5 (Lateral Flow 
Instrument) 
 
 
 
 
Typhoon 8600 variable mode 
flourescence imager. 
 
 
 
 
MiVac Quattro centrifugal concentrator 
Mason Technologies,  
Greenville Hall,  
228 South Circular Road,  
Dublin 8,  
Ireland. 
 
Mason Technologies,  
Greenville Hall,  
228 South Circular Road,  
Dublin 8,  
Ireland. 
 
Mason Technologies,  
Greenville Hall,  
228 South Circular Road,  
Dublin 8,  
Ireland. 
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2.2 Media compositions 
Table 2.2.1: Media components used throughout the course of this research and their 
corresponding weights or volumes per litre. All media components were purchased from 
Cruinn Diagnostics, 5B/5C Hume centre, Parkwest Industrial estate, Nangor Road, Dublin 
12, Ireland.  
Media  Component Weights/volumes per litre 
 
2 x Ty  
 
Tryptone 
 
16.0 g 
 Yeast extract 10.0 g 
 NaCl   5.0 g 
 
Super Broth (SB) MOPs 10.0 g 
 Tryptone 30.0 g 
 Yeast extract 20.0 g 
 
Super Optimal Catabolite (SOC)  Tryptone 20.0 g 
 Yeast extract   5.0 g 
 NaCl   0.5g 
 1 M MgCl2 
1 M MgSO4 
   10.0 mL 
   10.0 mL 
 1 M Glucose    16.0 mL 
 
Terrific Broth (TB) 
 
Tryptone 
 
               12.0 g 
 Yeast extract                  5.0 g 
 Glycerol     4.0 mL 
 KH2PO4                  2.3 g 
 K2HP04                12.5 g 
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Table 2.2.2: Cell culture media components used throughout the course of this research and 
their corresponding volumes per litre. All cell culture media and components were purchased 
from Sigma Aldrich, 3050 Spruce StreetSt. Louis, MO 63103,USA. 
 
Media     Components Volume (mL) per litre 
 
Supplemented 
RPM1 1640 
 
     100 mM Hepes 
     100 mM Sodium pyruvate 
     100 mM NEA 
     Streptomycin 
     15 % foetal calf serum 
     10 % Briclone 
     RPM1 1640 
 
10 
10 
10 
10 
150 
100 
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2.3 Bacterial cells and plasmids for cloning and expression 
2.3.1: Bacteria strains used for gene cloning:  
All bacterial cells used throughout the research were purchased from Statagene, Agilent 
Technologies, Unit 3, Euro House, Euro Business Park , Little Island, Cork, Ireland.  
 
E. coli TOP10 F  strain: {lacI
q
, Tn10(Tet
R
)} mcrA (mrr-hsdRMS-mcrBC) 80lacZ M15 
lacX74 recA1 araD139 (ara-leu)7697 galU galK rpsL (Str
R
) endA1 nupG 
 
E. coli XL1-Blue strain: recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F′ proAB 
lacI
qZ∆M15 Tn10 (TetR)]. 
 
E.Coli Rosetta™ 2:  F-ompT hsdSB(rB
-
 mB
-
) gal dcm(DE3) pRARE2 (Cam
R
)  
2.3.2: Plasmid vectors  
Pcomb 3Xss and Pcomb 3xTT were donated by Carlos Barbas III, The Scripps Research 
Institute, 10550 north Torrey pines road, IA Jolia, CA, 92037, USA.  
PaK 500 vector was donated by Andreas Pluckthun, University of Zurich, Switzerland 
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2.4 Buffer components  
2.4.1 ELISA Buffer Components 
Table 2.4.1: Buffer components used throughout the course of this research and their 
corresponding weights or volumes, as appropriate, per litre. All buffer components were 
purchased from Sigma Aldrich, 3050 Spruce StreetSt. Louis, MO 63103, USA. 
 
Buffer Component Weights or 
volumes per litre 
 
Phosphate buffered saline (PBS),  
pH 7.5 
 
150 mM NaCl 
2.5 mM KCl 
10 mM Na2HPO4 
18 mM KH2PO4 
 
 
8.0 g 
0.2 g 
1.4 g 
0.2 g 
PBSTween 20 (0.05 % (v/v) PBST), 
pH 7.5 
150 mM NaCl 
2.5 mM KCl 
10 mM Na2HPO4 
18 mM KH2PO4 
0.05 % (v/v) Tween 
20 
          8.0 g 
          0.2 g 
          1.4 g 
          0.2 g 
    0.5 mL 
 
Milk-PBST (MPBST), pH 7.5 
 
150 mM NaCl 
2.5 mM KCl 
10 mM Na2HPO4 
18 mM KH2PO4 
0.05 % (v/v) Tween 
20 
Specified % (w/v) 
milk marvel powder 
           
          8 .0 g 
          0.2 g 
1.4 g 
0.2 g 
   0.5 mL 
0.5-5 % (w/v) 
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2.4.2 ELISA optimisation buffer components  
Table 2.4.2: Buffers used for the optimisation of the coating concentrations for ELISA 
development and their weights or volumes, as appropriate, per 100 mL. All buffer 
components were purchased from Sigma Aldrich, 3050 Spruce StreetSt. Louis, MO 63103, 
USA 
Buffer Buffer Component 
 
Weights or  
volumes per 100 mL 
 
Citrate buffer, pH 4.7 
 
Citric Acid 
Sodium citrate 
 
1.30 g 
1.10 g 
 
Acetate buffer, pH 4.8 
 
Sodium acetate 
Glacial acetic acid 
 
 
0.10 g 
    0.06 mL 
 
Carbonate buffer, pH 10.3 
 
Sodium carbonate  
Sodium bi-carbonate 
 
0.07 g 
0.15 g 
 
Tris buffer pH 7.4 
 
Tris Base 
Sodium chloride  
 
0.30 g 
0.40 g 
 
Tris Buffer pH 8.0 
 
Tris Base 
Sodium chloride 
 
0.30 g 
0.40 g 
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2.5 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and 
Western Blotting. 
Table 2.5.1: Components used for the SDS-PAGE gel electrophoresis and their 
corresponding volumes for a 6 mL gel. All SDS-PAGE and Western Blot components were 
purchased from Sigma Aldrich, 3050 Spruce StreetSt. Louis, MO 63103, USA 
12.5 % Separation gel Volume per 6 mL gel  
 
1 M Tris HCl, pH 8.8    
30 % (w/v) acrylamide  
2 % (w/v) methylamine bisacrylamide  
Distilled water  
10 % (w/v) sodium dodecyl sulfate (SDS) 
10 % (w/v) APS  
TEMED         
 
1.5 mL 
2.5 mL 
1.0 mL 
0.9 mL 
 0.04 mL 
 0.04 mL 
 0.01 mL 
 
Table 2.5.2: Components used for SDS-PAGE gel electrophoresis and its corresponding 
volumes for a 2.6 mL gel.  
4. 5 % Stacking Gel Volume per 2.6 mL gel 
 
1 M TrisHCl, pH 6.8   
30 % (w/v) acrylamide   
2 % (w/v) methylamine bisacrylamide 
Distilled water   
10 % (w/v) SDS    
10 % (w/v) APS    
TEMED   
                   
    0.30 mL 
    0.37 mL 
    0.15 mL 
    1.74 mL 
    0.02 mL 
    0.02 mL 
    0.01 mL 
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Table 2.5.3: Components used for 10 x electophoresis buffer and its corresponding weights 
per litre. 
10 x Electrophoresis buffer  Weight per litre 
 
50 mM Tris, pH 8.3 
196 mM Glycine  
0.1 % (w/v) SDS 
Distilled water  to 1 L 
    
             30.0 g 
           144.0 g 
             10.0 g 
 
 
Table 2.5.4: Components used for the SDS-PAGE gel electrophoresis loading buffer and its 
corresponding volumes for a 10 mL solution.   
SDS loading dye                                                        Volume per 10 mL  
 
Tris 0.5M, pH 6.8   
Glycerol    
2-mercaptoethanol  
20 % (w/v) SDS  
20 ppm Bromophenol blue  
Distilled water  
 
  2.5 mL 
  2.0 mL 
  0.5 mL 
  2.5 mL 
  0.2 mg 
  2.5 mL 
  
 
Table 2.5.5: Components used for the coomassie stain and its corresponing  volumes and 
weights per litre  
Coomassie Stain Volume or weights per litre 
 
Coomassie blue R-250 
Methanol biotechnology grade, 99.93 % 
Distilled water 
Acetic acid ReagentPlus
®, ≥ 99 % 
 
                 1.0 g 
      450 mL 
      450 mL 
      100 mL 
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Table 2.5.6: Components used for the coomassie de-stain solution and its corresponding 
volumes per litre.  
De-stain solution            Volume (mL) per litre 
 
Acetic acid ReagentPlus
®, ≥ 99 % 
 
          200 mL 
Methanol biotechnology grade, 99.93 %           400 mL 
Distilled water                          600 mL 
 
 
Table 2.5.7: Transfer buffer components for Western blotting and its volumes per litre  
Transfer buffer             Volume (mL) per litre 
 
1 x electrophoresis buffer (Table 2.5.4) 
 
             800 mL 
Methanol biotechnology grade, 99.93 %             200 mL  
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2.6 Commercial kits 
Table 2.6.1: Commercial kits used over the course of this research and their associated 
suppliers.  
Kit       Supplier  
 
Superscript III reverse transcriptase kit 
  
 
 
 
 
Perfectprep Gel Cleanup kit   
  
 
 
 
 
Wizard Plus SV Miniprep™ kit  
  
      
  
 
 
 
 
QIAquick™ gel extraction kit   
      
 
 
 
 
Pierce™ “Eggcellent” kit   
 
 
Invitrogen Corporation, 
5791 Van Allen Way, 
Carlsbad, CA 92008, 
 USA. 
 
Eppendorf AG, 
Barkhausenweg 1, 
Hamburg 22339, 
Germany. 
 
Promega, 
2800 Woods Hollow Road, 
Madison,  
WI 53711, 
USA. 
 
Qiagen, 
28159 Avenue Stanford, 
Valencia,  
CA 91355,  
USA. 
 
Fisher Scientific, 
Suite 3, 
Plaza 212, 
Blanchardstown corporate park 2, 
Ballycoolin,  
Dublin 15,  
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Invitrogen Superscript™ III reverse 
transcriptase kit 
 
 
 
 
 
BIAcore™ CM5 dextran chips  
and immobilisation solutions  
Ireland.  
 
Invitrogen Corporation, 
791 Van Allen Way, 
Carlsbad,  
CA 92008,  
USA . 
 
GE Healthcare Bio-Sciences AB, 
SE-751 84 Uppsala, 
Sweden. 
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2.7: Lists of commercial antibodies, enzymes and chemicals used during this research.  
2.7.1 Commercial antibodies 
Table 2.7.1: Commercial antibodies used over the course of this research and the associated 
suppliers. 
Antibodies Supplier 
 
Anti-M13 antibody (HRP-labelled)  
  
 
 
Mouse anti-HA (HRP-labelled) mAb  
  
. 
 
 
Anti-histidine (HRP-labelled) mAb  
  
 
 
 
Anti-chicken  (HRP-labelled) mAb 
    
 
 
 
Anti- chicken (AP-labelled) mAb  
  
 
 
 
Anti- mouse (HRP-labelled)      
 
 
GE Healthcare Bio-Sciences AB, 
SE-751 84 Uppsala, 
Sweden. 
 
Roche Diagnostics, 
Grenzacherstrasse 124, 
Basel 4070,  
Switzerland 
 
Sigma Aldrich,  
3050 Spruce Street 
St. Louis, MO 63103, 
USA. 
 
Sigma Aldrich 
3050 Spruce Street 
St. Louis, MO 63103, 
USA. 
 
Sigma Aldrich 
3050 Spruce Street, 
St. Louis, MO 63103, 
USA. 
 
Sigma Aldrich 
3050 Spruce Street 
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  Anti-GFP mAb                               
St. Louis, MO 63103, 
USA. 
Sigma Aldrich 
3050 Spruce Street 
St. Louis, MO 63103, 
USA. 
 
2.7.2 Commercial Enzymes 
Table 2.7.2: Commercial enzymes used over the course of this research and the associated 
suppliers. 
Enzymes Supplier 
Restriction enzymes 
Sfi1, Bspe1,Bsiw1   
 
 
 
 
 
Antarctic phosphatase   
. 
 
 
 
 
 
T4 Ligase    
 
 
 
 
 
 
 
New England BioLabs,  
75-77 Knowl Piece,  
Wilbury Way, 
Hitchin, 
SG4 OTY, 
 
United Kingdom. 
New England BioLabs,  
75-77 Knowl Piece,  
Wilbury Way, 
Hitchin, 
SG4 OTY, 
 
United Kingdom. 
New England BioLabs,  
75-77 Knowl Piece,  
Wilbury Way, 
Hitchin, 
SG4 OTY, 
United Kingdom. 
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Dream Taq™    
 
 
   
 
 
 
 
Phusion Taq 
 
 
 
 
 
 
Green Taq Polymerase 
 
 
 
Fisher Scientific, 
Suite 3, 
Plaza 212, 
Blanchardstown corporate park 2, 
Ballycoolin,  
Dublin 15,  
Ireland.  
 
New England BioLabs,  
75-77 Knowl Piece,  
Wilbury Way, 
Hitchin, 
SG4 OTY, 
United Kingdom. 
 
Invitrogen Corporation, 
791 Van Allen Way, 
Carlsbad,  
CA 92008,  
USA 
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2.7.3 Chemicals 
able 2.7.3: Miscellaneous chemicals used over the course of this research and the associated 
suppliers. All chemicals were supplied by Sigma Aldrich unless otherwise stated. 
Chemicals  Supplier 
Rnase Zap™  
Chlorform 
Trizol™ 
Isoproponal (2-proponal) 
Glycerol 
Polyethylene Glycol  
Bovine Serum Albumin 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) 
MgSO4 
Imidazole 
Tween 20 
Freunds Adjuvant Complete  
Freunds Adjuvant Incomplete  
Protein G Fast flow 
Ammonium sulphate  
NaCl 
C18 sorbent 
Aceto Nitrile 
DMSO  
Ethanol 
Methanol 
EDTA  
Kanamycin 
Carbencillin 
Tris [2-carboxyethyl]phosphine hydrochloride 
 and Sulfo GMBS  
 
 
 
Sigma Aldrich 
3050 Spruce Street 
St. Louis,  
MO 63103, 
SG4 OTY, 
USA. 
 
 
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fisher Scientific, 
Suite 3, 
Plaza 212, 
Blanchardstown corporate park 2, 
Ballycoolin, Dublin 15. 
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2.8 Generation and characterisation of mouse anti-TBZ Fab phage library 
2.8.1 Recovery of anti-TBZ hybridoma cell line.  
Anti-TBZ hybridoma (mouse/huma) cells donated by Dr. David Brandon of the United States 
Department of Agriculture (USDA) were recovered from liquid nitrogen frozen stocks and 
transferred to a T25 culture vessel containing supplemented RPM1 1640 (section 2.2). The 
flasks were incubated at 37ºC in a humidified 5 % (v/v) CO2 incubator. Cells were allowed to 
grow until they reached 70 % confluency in T25 flasks, the cells were removed from the flask 
surface by vigorous pipetting and pelleted by centrifugation at 2,000 x g for 10 min (Hereus 
Chist, Labofuge 6000) at room temperature (R.T.) and re-suspended in 2 mL fresh media. 
The re-suspended cells were transferred to two T75 culture flasks containing 14 mL 
supplemented media. Flasks were incubated at 37ºC until greater than 70 % cell viability was 
reached i.e. until the flask surface was covered with more than 70 % of cells.  
This method was adapted from Alfredo Sheehan, (2006).The production of polyclonal, 
monoclonal and genetically-derived scFv antibody fragments for the detection of the ß-
lactam antibiotic, cephalexin, in milk. PhD thesis, DCU, Ireland.  
2.8.2 Iso-typing of the anti-TBZ monoclonal supernatant.  
Supernatant from the hybridoma cells was collected by continuously culturing cells in RPM1 
1640 media. This was stored at 4°C with the addition of sodium azide (0.02 %, (w/v)). The 
sample was diluted 1:100 by adding 5 μL of supernatant to 495 μL of sample diluent 
provided. To each cassette 150 μL of the diluted sample was applied to each of the wells. A 
successful test will results in a red band at the “C” or control location and another band at one 
of the three iso-types location on each cassette. (Product insert instruction for Pierce Rapid 
Antibody Isotyping kit.) 
2.8.3 Ammonium sulphate precipitation of anti-TBZ monoclonal antibody for protein-G 
purification. 
Ammonium sulphate (99 % purity) was added to the monoclonal culture supernatant to a 
final concentration of 45 % (w/v). The mixture was stirred at 85 x g at R.T. for 30 min. The 
resulting precipitate was centrifuged at 4,500 x g for 20 min at 4°C and the pellet re-
suspended with 1/5
th
 of the original volume of PBS containing 0.15 M NaCl, pH 7.4. 
Ammonium sulphate was added to a final concentration of 40 % (w/v), and stirred at 85 rpm 
until fully precipitated the mixture was centrifuged at 4,500 g at 4°C for 20 min. The 
resulting pellet was re-suspended with 1/2 of the original volume of PBS containing 0.15 M 
73 
 
NaCl, pH 7.4 and dialysed overnight with 5 L of PBS containing 0.15 M NaCl, pH 7.4. 
(Darcy et al., 2010) 
2.8.4: Purification of the anti-TBZ monoclonal antibody via protein G. 
A 2 mL volume of Protein G Fast Flow sepharose in 20 % (v/v) ethanol was added into a 
clean column to settle, and any excess ethanol was drained off without letting the column run 
dry. The column was equilibrated with approximately 20 mL of sterile-filtered PBS 
containing 0.5 M NaCl, pH 7.4. The dialysed ammonium sulphate precipitated 
immunoglobulin (2 mL) was added to the column and the flow rate adjusted 1 mL/min. The 
flow-though was collected and applied to the column two more times. Wash buffer PBS (25 
mL) containing 0.3 M NaCl, pH 7.4 though the column. The affinity captured antibody was 
eluted with 0.1 M glycine-HCl buffer (pH 2.5) and collected in 500 µl fractions. This was 
neutralised immediately with 150 μL of 2 M Tris/HCl, pH 8.7 (Darcy et al., 2010) 
2.8.5 Extraction and isolation of total RNA from anti-TBZ hybridoma cell line. 
A Gelaire BSB 4 laminar unit was sprayed with both IMS and RNase™ ZAP. The cells 
secreting the TBZ monoclonal antibodies were pelleted from 2 x T75 flasks containing 15 
mL of culture at 1,500 x g, at R.T. for 10 min (Hereus Chist, Labofuge 6000). The resulting 
pellet was re-suspended with 1 mL of Trizol™, transferred to 2 mL RNase-free Eppendorf 
tubes and incubated for 5 min at R.T. Chloroform (200 µL) was then added to the tube 
containing the supernatant, thoroughly mixed and incubated for 15 min at R.T. The addition 
of chloroform leads to the separation of the cells into an upper aqueous phase (containing 
RNA) and a lower organic phase (containing DNA and protein). The resultant mixture was 
centrifuged at 17,500 x g (Eppendorf centrifuge 5810R) for 15 min at 4°C. The centrifugation 
produced 3 layers, consisting of a lower red phenol/chloroform phase, a protein interphase 
and a colourless liquid upper phase containing the RNA. The upper aqueous phase was 
carefully transferred (ensuring no lower layer contamination) into a 2 mL tube and subjected 
to RNA precipitation by addition of 0.5 mL of isopropanol. The RNA was allowed to 
precipitate for 10 min at R.T. and then centrifuged at 17,500 x g (Eppendorf centrifuge 
5810R) for 10 min at 4°C, resulting in a white RNA pellet. The isopropanol supernatant was 
carefully decanted and the pellet washed with 1 mL of 75 % (v/v) ethanol by centrifugation at 
17,500 x g for 10 min at 4°C. Finally, the pellet was allowed to air dry in the laminar hood 
before re-suspension in 50-100 µL of molecular grade water. Method adapted from Alfredo 
Sheehan, (2006). The production of polyclonal, monoclonal and genetically-derived scFv 
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antibody fragments for the detection of the ß-lactam antibiotic, cephalexin, in milk. PhD 
thesis, DCU, Ireland.  
2.8.6 Reverse transcription of total TBZ RNA to cDNA. 
Following extraction the RNA was converted to cDNA using the commercial reverse 
transcription kit Superscript™ III. Method was taken from the product insert provided. This 
kit is fully optimized to synthesize first strand cDNA from total RNA.  
 
Table 2.8.6.1: Components of mixture 1 for the reverse transcription of RNA to cDNA. 
Mixture 1 Component        10 µL Volume            Conc. in 10 µL reaction 
 
Total RNA         5.0 µL     5.0 µg 
Oligo (dT) primer        1.0 µL                0.5 µg 
dNTP mix         1.0 µL                1.0 mM 
Molecular grade H2O        3.0 µL                  N/A 
 
 
Table 2.8.6.2: Components of mixture 2 for the reverse transcription of RNA to cDNA. 
Mixture 2 Component           10 µL Volume                    Conc. in 10 µL reaction 
 
10 X RT Buffer                      2.0 µL      2 x 
MgCl2                                     4.0 µL               2.5 mM 
DTT                                  2.0 µL             20.0 mM 
RNase Out                                 1.0 µL                40 U 
Superscript Ш enzyme                     1.0 µL              200 U 
 
A 20 x reaction for mixture 1 was set up on ice and then split up into 8 x 25 µL aliquots in 
sterile PCR tubes. The 8 PCR tubes were incubated at 65°C for 5 min and placed on ice, 
whilst a 20 x reaction for mixture 2 was set up. Next, 25 µL of the incubated mixture 2 was 
added to all 8 of the 25 µL aliquots of mixture 1 and left to incubate at 50°C for 50 min, 
followed by 85°C for 5 min. Finally, 5 µL of RNase ™ H was added to each of the 8 x 50 µL 
reactions and incubated at 37°C for 20 min. The addition of RNase H increases the sensitivity 
of this step by removing the RNA template from the cDNA: RNA hybrid by digestion. 
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2.9 Construction of the anti-TBZ Fab murine library 
2.9.1 PCR primers and illustration of the amplification of mouse Fab (pComb series) 
The primers listed below were obtained from Eurofins-MWG-Operon (318 Worple Road, 
Raynes Park, London, SW20 8QU) and are compatible with the primers set described by 
Barbas and co-workers (Barbas et al., 2001) for the pComb vector system. All methods 
described from 2.9.1-2.9.13 were adapted from Barbas et al., 2001. 
 
Variable light chain 5´ Sense Primers  
MSCVK-1  
5´ GGG CCC AGG CGG CCG AGC TCG AYA TCC AGC TGA CTC AGC C 3´  
MSCVK-2  
5´ GGG CCC AGG CGG CCG AGC TCG AYA TTG TTC TCW CCC AGT C 3´  
MSCVK-3  
5´ GGG CCC AGG CGG CCG AGC TCG AYA TTG TGM TMA CTC AGT C 3´   
MSCVK-4  
5´ GGG CCC AGG CGG CCG AGC TCG AYA TTG TGY TRA CAC AGT C 3´  
MSCVK-5  
5´ GGG CCC AGG CGG CCG AGC TCG AYA TTG TRA TGA CMC AGT C 3´   
MSCVK-6  
5´ GGG CCC AGG CGG CCG AGC TCG AYA TTM AGA TRA MCC AGT C 3´   
MSCVK-7  
5´ GGG CCC AGG CGG CCG AGC TCG AYA TTC AGA TGA YDC AGT C 3´   
MSCVK-8  
5´ GGG CCC AGG CGG CCG AGC TCG AYA TYC AGA TGA CAC AGA C 3´  
MSCVK-9  
5´ GGG CCC AGG CGG CCG AGC TCG AYA TTG TTC TCA WCC AGT C 3´  
MSCVK-10  
5´ GGG CCC AGG CGG CCG AGC TCG AYA TTG WGC TSA CCC AAT C 3´  
MSCVK-11  
5´ GGG CCC AGG CGG CCG AGC TCG AYA TTS TRA TGA CCC ART C 3´  
MSCVK-12  
5´ GGG CCC AGG CGG CCG AGC TCG AYR TTK TGA TGA CCC ARA C 3´  
MSCVK-13  
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5´ GGG CCC AGG CGG CCG AGC TCG AYA TTG TGA TGA CBC AGK C 3´   
MSCVK-14  
5´ GGG CCC AGG CGG CCG AGC TCG AYA TTG TGA TAA CYC AGG A 3´   
MSCVK-15  
5´ GGG CCC AGG CGG CCG AGC TCG AYA TTG TGA TGA CCC AGW T 3´   
MSCVK-16  
5´ GGG CCC AGG CGG CCG AGC TCG AYA TTG TGA TGA CAC AAC C 3´   
MSCVK-17  
5´ GGG CCC AGG CGG CCG AGC TCG AYA TTT TGC TGA CTC AGT C 3´   
 
Variable light chain 3´ Reverse Primers  
MHybJK12-B  
5´ AGA TGG TGC AGC CAC AGT TCG TTT KAT TTC CAG YTT GGT CCC 3´   
MHybJK4-B  
5´ AGA TGG TGC AGC CAC AGT TCG TTT TAT TTC CAA CTT TGT CCC 3´   
MHybJK5-B  
5´ AGA TGG TGC AGC CAC AGT TCG TTT CAG CTC CAG CTT GGT CCC 3´   
 
Variable 5´ heavy chain sense primer  
MHyVH1 
5´ GCT GCC CAA CCA GCC ATG GCC CTC GAG GTR MAG CTT CAGGAGTC 3´  
MHyVH2 
5´ GCT GCC CAA CCA GCC ATG GCC CTC GAG GTB CAG CTB CAG CAGTC 3´  
MHyVH3 
5´ GCT GCC CAA CCA GCC ATG GCC CTC GAG GTG CAG CTG AAG SAS TC 3´  
MHyVH4 
5´ GCT GCC CAA CCA GCC ATG GCC CTC GAG GTC CAR CTG CAA CAR TC 3´  
MHyVH5 
5´ GCT GCC CAA CCA GCC ATG GCC CTC GAG GTY CAG CTB CAG CARTC 3´  
MHyVH6 
5´ GCT GCC CAA CCA GCC ATG GCC CTC GAG GTY CAR CTG CAG CAGTC 3´  
MHyVH7 
5´ GCT GCC CAA CCA GCC ATG GCC CTC GAG GTC CAC GTG AAG CAGTC 3´  
MHyVH8 
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5´ GCT GCC CAA CCA GCC ATG GCC CTC GAG GTG AAS STG GTG GAA TC 3´  
MHyVH9 
5´ GCT GCC CAA CCA GCC ATG GCC CTC GAG GTG AWG YTG GTG GAG TC 3´ 
MHyVH10 
5´ GCT GCC CAA CCA GCC ATG GCC CTC GAG GTG CAG SKG GTG GAG TC 3´  
MHyVH11 
5´ GCT GCC CAA CCA GCC ATG GCC CTC GAG GTG CAM CTG GTG GAG TC3´  
MHyVH12 
5´ GCT GCC CAA CCA GCC ATG GCC CTC GAG GTG AAG CTG ATG GAR TC 3´  
MHyVH13 
5´ GCT GCC CAA CCA GCC ATG GCC CTC GAG GTG CAR CTT GTT GAG TC 3´  
MHyVH14 
5´ GCT GCC CAA CCA GCC ATG GCC CTC GAG GTR AAG CTT CTC GAG TC 3´  
MHyVH15 
5´ GCT GCC CAA CCA GCC ATG GCC CTC GAG GTG AAR STT GAG GAG TC 3´  
MHyVH16 
5´ GCT GCC CAA CCA GCC ATG GCC CTC GAG GTT ACT CTR AAA GWG TST G 3´  
MHyVH17 
5´ GCT GCC CAA CCA GCC ATG GCC CTC GAG GTC CAA CTV CAG CAR CC 3´  
MHyVH18 
5´ GCT GCC CAA CCA GCC ATG GCC CTC GAG GTG AAC TTG GAA GTG TC 3´  
MHyVH19 
5´ GCT GCC CAA CCA GCC ATG GCC CTC GAG GTG AAG GTC ATC GAG TC 3´ 
 
VH 3´ heavy chain reverse primers  
MHyIgGCH1-B1  
5´ CGA TGG GCC CTT GGT GGA GGC TGA GGA GAC GGT GAC CGT GGT 3´  
MHyIgGCH1-B2  
5´ CGA TGG GCC CTT GGT GGA GGC TGA GGA GAC TGT GAG AGT GGT 3´  
MHyIgGCH1-B3  
5´ CGA TGG GCC CTT GGT GGA GGC TGC AGA GAC AGT GAC CAG AGT 3´  
MHyIgGCH1-B4  
5´ CGA TGG GCC CTT GGT GGA GGC TGA GGA GAC GGT GAC TGA GGT 3´  
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Primers for the amplification of the human constant region and the pelB leader 
sequence from a cloned human Fab  
HKC-F (sense)  
5´ CGA ACT GTG GCT GCA CCA TCT GTC 3´  
Lead-B (reverse)  
5´ GGC CAT GGC TGG TTG GGC AGC 3´  
Primers for amplification of the human CH1 chain from a cloned human Fab  
HIgGCH1-F (sense)  
5´ GCC TCC ACC AAG GGC CCA TCG GTC 3´  
dpseq (reverse)  
5´ AGA AGC GTA GTC CGG AAC GTC 3´  
Primers for PCR assembly of mouse VL sequences with the human C. PCR product.  
RSC-F (sense)  
5´ GAG GAG GAG GAG GAG GAG GCG GGG CCC AGG CGG CCG AGC TC 3´  
Lead-B (reverse)  
(see above)  
Primers for PCR Assembly of Mouse VH  sequences with the Human CH1 PCR 
product. 
leadVH (sense)  
5´ GCT GCC CAA CCA GCC ATG GCC 3´  
dpseq (reverse)  
(see above)  
Primers for PCR assembly of chimeric light-chain Fab sequences with chimeric heavy-
chain (Fd) Sequences. 
RSC-F (sense)  
(see above)  
dp-EX (reverse)  
5´ GAG GAG GAG GAG GAG GAG AGA AGC GTA GTC CGG AAC GTC 3´ 
 
79 
 
 
 
Figure 2.9.1: Schematic diagram illustrating the combination of genes by splice by overlap 
extension for the construction of a Fab fragment. The genes for the variable and constant 
regions are amplified separately. (B) Heavy-chain Fd and light chain DNA are assembled by 
variable regions and their constant counterpart respectively using over lap PCR. (C) Fd and 
light chain are fused to form Fab encoding sequences by over lap PCR. (D) Fab Genes are 
directionally cloned into Pcomb 3x phagemid vector where both the L chain fragment and Fd 
region are transported to the periplasmic space (Li et al., 2010) 
 
2.9.2 Amplification of antibody variable domain genes using the pComb primer series. 
The following  protocols describe the construction of a chimeric mouse/human Fab library by 
overlap extension PCR. It allows the expression and selection of chimeric Fabs that contain 
variable regions obtained from the mouse hybridoma, and light and heavy chains constant 
regions from a clone human Fab.  
A 1 x reaction mix for amplification of the variable domains was formulated using the 
following components: 
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Table 2.9.1: Components of the PCR for the amplification of the murine variable domains 
and their subsequent volumes and concentrations in 50 µL. 
Component 50 µL total volume Conc in 50 µL reaction 
5 x Buffer  10.0 µL 1 x  
VL/VH Forward Primer   0.6 µL 60.0 pM 
VH/VL Back Primer    0.6 µL 60.0 pM 
cDNA    1.0 µL                   1.0 µg 
dNTP   2.0 µL    1.0 mM 
MgCl2     6.0 µL                   3.0 mM 
H2O 28.8 µL N/A 
Green Taq ® Polymerase  1.0 µL 1U 
 
The PCR for the amplification of the mouse antibody variable domain genes was performed in 
the Biometra TGRADIENT PCR machine under the following conditions: 
 
Table 2.9.2: The PCR programme for the amplification of the murine variable domains. 
Stage  Temp (
o 
C) Time (seconds) 
1 (1 cycle) 94                    300 
2 (30 cycle) 94 
56 
72 
                     15 
                     30 
                   120 
3 (1 cycle) 72 
4 
600 
                    600  
 
2.9.3 Amplification of the constant kappa domain.  
The constant kappa (Cκ) and pelB leader sequence was amplified from the pComb3xTT. The 
sense primer was specific for the 5’ region of the human Cκ, the region used in the overlap 
extension PCR to create the chimeric light chain. The reverse primer was specific for the 3’ 
end of the pelB leader sequence. 
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Table 2.9.3.1: Components of the PCR for the amplification of the human constant domains 
and their subsequent volumes and concentrations in 50 µL. 
Component 50 µL total volume Conc in 50 µL reaction 
5 x Buffer 20.0 µL 2 x 
HKC Forward Primer    0.6 µL 60.0 pM 
Lead B Back Primer   0.6 µL 60.0 pM 
pComb3xTT     1.0 µL                  1.0 µg 
dNTP   2.0 µL   1.0 mM 
MgCl2   10.0 µL   5.0 mM 
H2O 14.8 µL N/A 
Green Taq ® Polymerase  1.0 µL 1U 
 
Table 2.9.3.2: The PCR programme for the amplification of the human constant domains.  
Stage  Temp (
o 
C) Time (seconds) 
1 (1 cycle) 94                    300 
2 (30 cycle) 94 
56 
72 
                     15 
                     30 
                   120 
3 (1 cycle) 72 
4 
600 
                    600  
 
2.9.4 Amplification of the human gamma chain. 
The constant domain CH1 was amplified from the pComb3xTT vector. The sense primer was 
specific for the 5’ region of the CH1 region that was used in the overlap extension PCR to 
create the heavy-chain (Fd) fragment. The reverse primer was specific for the decapeptide 
sequence that is located downstream of the CH1 fragment and the 3´ Sfi1 site of pComb3xTT. 
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Table 2.9.4.1: Components of the PCR for the amplification of the human gamma chain and 
their subsequent volumes and concentrations in 50 µL. 
Component 50 µL total volume Conc in 50 µL reaction 
5 x Buffer 10.0 µL 1 x  
HIgGCH1-F  Forward   0.6 µL 60.0 pM 
dpseq Back    0.6 µL 60.0 pM 
pComb3xTT     0.2 µL                  1.0 µg 
dNTP   2.0 µL   1.0 mM 
MgCl2     3.0 µL   1.5 mM 
H2O 32.6 µL N/A 
Green Taq ® Polymerase  1.0 µL 1U 
 
 
Table 2.9.4.2: The PCR programme for the amplification of the human gamma chain. 
Stage  Temp (
o 
C) Time (seconds) 
1 (1 cycle) 94                    300 
2 (30 cycle) 94 
56 
72 
                     15 
                     30 
                   120 
3 (1 cycle) 72 
4 
600 
                    600  
 
2.9.5 Purification of VH and VL variable gene fragments using the Promega clean-up kit. 
The VH and VL PCR products were resolved on a 1 % (w/v) agarose gel until single bands for 
both the variable heavy and variable light chains were observed. Both bands were excised 
using sterile scalpels and transferred into clean 1.5 mL micro-centrifuge tubes. Next, thee 
volumes of binding buffer was added for every one volume of gel slice and incubated at 50°C 
until the gel fragments had completely dissolved (approximately 10 min). The binding buffer 
contains guanidine isothiocyanate that allows for sufficient binding of the DNA to the silica 
membrane columns. One volume of isopropanol, equal to the original of the gel slice volume, 
was added and mixed to allow for precipitation of the DNA. The mixture was transferred to a 
binding column and collection tube and centrifuged at 17,500 x g (Eppendorf centrifuge 
5810R) for one min to remove any residual buffer. The “flow-through” was discarded and the 
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column was washed first by centrifugation with 750 µL wash buffer and then with 250 µL 
wash buffer. The column was centrifuged at 17,500 x g (Eppendorf centrifuge 5810R) for 2 
min to ensure all residual ethanol was removed and the DNA was eluted from the column 
using 50 µL molecular grade H2O and was subsequently quantified using the Nanodrop™ 
ND-1000. 
2.9.6 Splice by Overlap extension (SOE) PCR. 
Gene Splicing by Overlap Extension or "gene SOEing" is a PCR-based method of 
recombining DNA sequences without reliance on restriction sites and of directly generating 
mutated DNA fragments in vitro. By modifying the sequences incorporated into the 5'-ends 
of the primers, any pair of polymerase chain reaction products can be made to share a 
common sequence at one end. Under polymerase chain reaction conditions, the common 
sequence allows strands from two different fragments to hybridize to one another, forming an 
overlap. Extension of this overlap by DNA polymerase yields a recombinant molecule 
(Horton et al., 1990). The mouse VL PCR products, that have a human constant sequence tail, 
were combined with the human constant–pelB products to create chimeric light-chain–pelB 
fragments. The sense extension primer (RSC-F) recognizes the sequence created by the first-
round PCR VL primers. The lead-B reverse primer recognizes the 3´ end of the pelB leader 
sequence that was amplified together with the human constant region from pComb3xTT. The 
3´ end of the pelB sequence serves as the overlap region in the final overlap extension PCR.  
The mouse VH PCR products, that have a human CH1 sequence tail, are combined with the 
human CH1 PCR products to create the chimeric Fd fragment. The sense extension primer 
(leadVH) recognizes the pelB leader sequence tail created by the first-round PCR VH primers. 
The same reverse primer (dpseq) that was used for the generation of the CH1 fragment was 
used in the overlap extension PCR of the heavy-chain fragment. The 3´ end of the pelB leader 
sequence served as the overlap region in the final overlap extension PCR.  
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Table 2.9.6.1: Components of the PCR for the overlap extension of the variable and constant 
light chains and their subsequent volumes and concentrations in 50 µL. 
Component 50 µL total volume Conc in 50 µL reaction 
5 x Buffer 10.0 µL 1 x 
Forward primer    0.6 µL 60.0 pM 
Back Primer    0.6 µL 60.0 pM 
VL chain    1.5 µL                 100 ng 
CL chain   2.5 µL                 100 ng 
dNTP   2.0 µL   1.0 mM 
MgCl2     3.0 µL    1.5 mM 
H2O  28.8 µL N/A 
Green Taq ® Polymerase  1.0 µL 1U 
 
 
Table 2.9.6.2: Components of the PCR for the overlap extension of the variable and constant 
heavy chains and their subsequent volumes and concentrations in 50 µL. 
 Component 50 µL total volume Conc in 50 µL reaction 
5 x Buffer 10.0 µL 1 x 
Forward primer    0.6 µL 60.0 pM 
Back Primer    0.6 µL 60.0 pM 
VH chain    2.4 µL                 100 ng 
CH chain   0.4 µL                 100 ng 
dNTP   1.0 µL   1.0 mM 
MgCl2    10.0 µL   5.0 mM 
H2O  23.0 µL                    N/A 
DMSO    1.0 µL                                      N/A 
Green Taq ® Polymerase  1.0 µL 1U 
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Table 2.9.6.3: The PCR programme for the splice by overlap extension of the variable and 
constant genes.  
Stage Temp (
o
C) Time (seconds) 
1 (1 cycle) 94 300 
2 (20 cycle) 94 
56 
72 
                     15 
  30 
120 
3 (1 cycle) 72 
4 
600 
600 
 
2.9.7 Final splice by overlap extension (SOE). 
The final overlap extension PCR combined the chimeric light chain–pelB fragment and the 
Fd fragment for the construction of the final mouse chimeric Fab library. The 3´end of the 
pelB leader sequence served as the overlap region for the two PCR products. The sense 
extension primer (RSC-F) used in this round of PCR was also used in the overlap extension 
amplification of the light chain and the reverse extension primer recognizes the decapeptide 
sequence downstream of the CH1 region.  
 
Table 2.9.7.1: Components of the PCR for the final overlap extension of the variable and 
constant heavy chains and their subsequent volume and concentration in 50 µL. 
Component 50 µL total volume Conc in 50 µL reaction 
5 x Buffer 10.0 µL 1 x 
Forward primer    0.6 µL 60.0 pM 
Back Primer    0.6 µL 60.0 pM 
VL+H chain    1.5 µL                 100 ng 
CL+H chain   2.5 µL                 100 ng 
dNTP   2.0 µL   1.0 mM 
MgCl2   10.0 µL   5.0 mM 
H2O 20.3 µL N/A 
DMSO    1.5 µL                                     N/A 
Phusion Taq® Polymerase  1.0 µL 1U 
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Table 2.9.7.2: The PCR programme for the final splice by overlap extension.   
Stage Temp (
o
C) Time (seconds) 
1 (1 cycle) 94 300 
2 (15 cycle) 94 
56 
72 
 15 
 30 
                   120 
3 (1 cycle) 72 
4 
600 
600 
 
2.9.8 SfiΙ restriction digests of the purified SOE-PCR fragment and ligation into the     
pComb3xSS vector. 
The Fab fragment and pComb3xSS vector used for phage selection were digested using SfiΙ 
restriction enzyme. The SfiΙ enzyme allows for the unidirectional cloning of Fab fragment 
into the pComb phage display vector. The enzyme recognises 8 bases which are interrupted 
by 5 non-recognised nucleotides (5′ggccnnnnnggcc3′), thus virtually eliminating internal 
digestion in antibody sequences. Both digestions (outlined below) were carried out for 5 h at 
50°C. 
 
Table 2.9.8.1: Components for the restriction digest of the Fab PCR product and pComb 
vector. 
SOE-PCR product SfiΙ digest    pComb vector SfiΙ digest 
Component  150 µL volume Component  50 µL volume 
SOE product 90.0 µL pComb vector              18.9 µL 
10 x Buffer 2  15.0 µL 10 x Buffer 2   5.0 µL 
100 x BSA            1.5 µL 100 x BSA            0.5 µL 
H20          31.5 µL  H20             7.6 µL 
SfiΙ          12.0 µL SfiΙ          18.0 µL 
 
Following a 5 h incubation at 50°C, the digested pComb3xSS vector was treated with 
Antarctic phosphatase™ enzyme to prevent self-ligation. This enzyme catalyzes the removal 
of 5′ phosphate groups from DNA. The loss of the 5′ phosphoryl termini, therefore, prevents 
the ligase enzyme from working. To the digested vector 5 µL of Antarctic phosphatase buffer 
(10x) followed by 2 µL of antarctic phosphatase enzyme. 
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The mixture was incubated for 15 min at 37°C and then the enzyme was heat inactivated at 
65°C for 5 min. Both digests were resolved via electrophoresis on a 1 % (w/v) agarose gel for 
the digested PCR product and a 0.6 % (w/v) gel for the digested vector. These were gel-
purified, as described in section 2.9.6. The restricted Fab gene was then ligated into the 
pComb3xSS vector in a 1:2 (insert:vector) ratio under the conditions below and left at R.T. 
O/N. 
 
Table 2.9.8.2: Components for the ligation of the Fab gene fragment into the pComb3xSS 
vector  
Component         100 µL volume Conc in 100 µL reaction 
5 x ligase buffer 10.0 µL 1 x 
Digested pComb3xSS  14.8 µL 1.4 µg 
Digested Fab gene  37.8 µL 0.7 µg 
H2O 32.4 µL N/A 
T4 DNA Ligase   5.0 µL 400 U 
 
Following ligation the mix was ethanol precipitated using the following reagents. 
   
Table 2.9.8.3: Components for the ethanol precipitation of the ligated gene fragment. 
Component  Volume 
Ligation mixture  
3M sodium acetate, pH 5.2 
100 %  (v/v) ethanol   
                100 µL 
 10 µL 
250 µL 
 
The precipitation was incubated O/N at -20°C and the DNA was harvested by centrifugation 
at 17,500 x g (Eppendorf centrifuge 5810R) for 20 min at 4°C. The ethanol supernatant was 
decanted and the pellet was washed by addition of 1 mL of 70 % (v/v) ethanol and 
centrifuging at 17, 500 x g (Eppendorf centrifuge 5810R) for 20 min at 4°C. The pellet was 
allowed to air-dry briefly and dissolved in 20 µL of molecular grade H2O. 
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2.9.9 Electro-transformation of Fab-containing plasmid into XL1-Blue E. coli cells. 
Transformation of the ligated product was performed by electroporation into a commercially 
available strain of XL1-Blue E. coli cells (Stratagene). The apparatus used was a Gene Pulser 
Xcell ™ electroporation  system with the parameters set to 25 µF, 1.25 kV and gene pulse 
controller at 200 Ω. After thawing on ice, 50 µL of the E. coli cells were added to the 5 µL of 
ligation product, mixed and left on ice for a 1 min incubation. The mixture was transferred to 
a chilled 0.2 cm electroporation cuvette, and placed into the ‘Shockpod’. A pulse was passed 
though the cuvette, and immediately flushed with 1 mL of pre-warmed SOC medium using a 
sterile tip. The 1 mL of electroporated cells were transferred into a sterile 50 mL Falcon tube 
containing a further 2 mL of pre-warmed SOC medium. The 3 mL of transformant 
suspension was incubated for 1 h at 250 x g at 37°C and plated out on SB agar plates 
supplemented with 100 µg/mL carbenicillin. A negative control was also incorporated into 
the experiment by plating the XL1-Blue cells containing no plasmid onto the agar plates. All 
plates were incubated O/N at 37°C and scraped into SB medium containing 20 % (v/v) 
glycerol for long term storage at -80°C. 
2.9.10 Phage rescue and precipitation of TBZ Fab library. 
A conical flask containing 600 mL of sterile SB medium (100 µg/mL carbenicillin) was 
inoculated with 600 µL of the transformed library glycerol stocks and incubated at 220 rpm 
and 37°C until the O.D. reached 0.4 at 600nm. Helper phage (2 x 10
11 
cfu) was added. The 
culture was left static at 37°C for 30 min before transferring it to a shaking incubator at 37°C 
at 220 rpm for 1.5 h.  Kanamycin was added to a final concentration of 50 µg/mL, before 
leaving the culture O/N at 37°C and 220 rpm. The O/N culture was centrifuged at 18,500 x g 
(Eppendorf centrifuge 5810R) for 20 min at 4°C and the phage supernatant transferred into 3 
sterile 250 mL Sorvals™ centrifuge tubes containing 8 g of PEG 8,000 and 6 g of sodium 
chloride. The Sorvals™ were agitated at 220 rpm until the PEG/NaCl went into solution. The 
phage was precipitated for 1 h at 4°C. The phage was harvested by centrifugation at 6,440 x g 
for 25 min at 4°C and re-suspended in 2 mL of 1 % (w/v) BSA-PBS solution. The re-
suspended phage pellets were added to a clean 1.5 mL micro-centrifuge tube and centrifuged 
at 20,000 x g for 5 min at 4°C to remove any bacterial debris. The remaining supernatant was 
refrigerated until ready for use.  
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2.9.11 Panning of the TBZ phage library against immobilized conjugates. 
An immuno-tube (Maxisorp™, Nunc) was coated O/N at 4°C with 500 µL of 50 µg/mL 
TBZ-BSA in PBS. The tube was blocked for 1 h at 37°C with 3 % (w/v) BSA in PBS. 
Following one wash with PBST, 500 µL of the rescued phage (input phage) (Section 2.9.10) 
was added to the immuno-tube and incubated on a roller for 2 h at R.T. The immuno-tube 
was washed with PBST (x3) and PBS (x3) to remove non-specific phage. Specific phage was 
eluted by incubation with 1 mL of 10 mg/mL of trypsin in PBS for 30 min at 37°C. The 
trypsin eluted phage was removed after harsh pipetting and 800 µL was added to 5 mL of 
mid-exponential phase XL1-Blue cells. This was allowed to infect for 15 min static at R.T. 
and 6 mL of pre-warmed SB media containing 1.6 µL of 100 mg/mL carbenicillin and 12 µL 
of 5 mg/mL tetracycline was added (at this point 100 µl sample was removed for output titre 
determination). This 12 mL culture was incubated at 220 rpm at 37°C for 1 h. Carbenicillin 
(2.4 µL of 100 mg/mL) was added and incubated at 220 rpm at 37°C for 1 h. To this 12 mL 
culture, 800 µL of commercial helper phage (New England Biolabs) was added, followed by 
88 mL of SB media supplemented with carbenicillin and tetracycline (final concentrations of 
50 µg/mL and 10 µg/mL, respectively) and incubated for 2 h at 37°C at 220 rpm. Kanamycin 
was added to a final concentration of 70 µg/mL and incubated O/N at 220 rpm and 37°C.    
An output titre was performed by making a 1 in 10 and 1 in 100 dilution of the XL1-Blue 
infected cells in SB media. These dilutions were plated out on SB agar plates containing 100 
µg/mL of carbenicillin and incubated O/N at 37°C. 
 
An input titre was performed by making serial dilutions (10
-1
-10
-12
) of the PEG-precipitated 
phage in exponential growth phase XL1-Blue cells. Following a 15 min infection at 37°C, the 
10
8
 - 10
12
 serial dilutions were plated out on SB agar plates containing 100 µg/mL 
carbenicillin and incubated O/N at 37°C. All of the subsequent rounds of panning were 
performed as described above.  
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Table 2.9.11.1: Parameters varied during the panning of murine anti-TBZ Fab library. 
Variables Pan 1  Pan 2  Pan 3  
Culture Volume  600 mL  100 mL  100 mL  
TBZ-BSA coating concentration 100 µg/mL 50 µg/mL 25 µg/mL 
Washes  3 x PBST, 
3 x PBS 
3 x PBST,  
3 x PBS 
3 x PBST,  
3 x PBS 
 
2.9.12 Fab gene insert check via ‘colony-pick’ PCR. 
Single colonies (10) were randomly selected from all thee rounds of panning. A colony-pick’ 
PCR was performed to ensure the vector incorporated the Fab fragment. A sterile tip was 
used to pick a single colony into the mixture described in 2.9.14.1, which was placed in a 
Biometra TGRADIENT PCR machine. The amplified Fab fragments were analysed via gel 
electrophoresis on a 1 % (w/v) agarose gel. 
 
Table 2.9.12.1: Components of the PCR for the amplification of the Fab gene insert from a 
single colony and their volumes and concentrations in a 50 µL reaction.  
Component 50 µL total volume Conc in 50 µL reaction 
10 x Buffer HF  10.0 µL 1 x 
Forward primer    0.6 µL 60.0 pM 
Back Primer    0.6 µL 60.0 pM 
dNTP   2.0 µL   1.0 mM 
MgCl2   10.0 µL   5.0 mM 
H2O 24.3 µL N/A 
DMSO    1.5 µL                                     N/A 
Phusion Taq® Polymerase 
Colony  
                 1.0 µL 
                   1                                    
 
1U 
N/A 
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Table 2.9.12.2: PCR programme for the Fab colony pick PCR. 
Stage Temp (
o
C) Time (seconds) 
1 (1 cycle) 94 300 
2 (30 cycle) 94 
56 
72 
 15 
 30 
120 
3 (1 cycle) 72 
4 
600 
Pause 
 
2.9.13 Direct and inhibition ELISA of Fab fragments in XL1-Blue for all thee rounds 
Individual colonies (288 in total) were selected and grown O/N at 200 x g and 37°C in single 
wells containing 100 μL SB media with 100 μg/mL carbenicillin (stock plates). The 3 x 96 
well stock plates were then sub-cultured into fresh SB media (180 μL) containing 1 x 505 
(0.5 % (v/v) glycerol, 0.05 % (v/v) glucose final concentration), 1mM MgSO4 and 100 
μg/mL carbenicillin. Glycerol was then added to the O/N stock plates to a final concentration 
of 20 % (v/v) and then transferred to a -80°C freezer for long-term storage. Meanwhile, the 
sub-cultured plates were incubated at 37°C at 220 rpm until the cell suspension reached an 
O.D.of ~0.6. Expression was then induced by adding IPTG to a final concentration of 1mM 
and incubating at 30°C (200 rpm) O/N.  
 
Also, for each plate of clones, 2 x 96 well plates (Maxisorp™, Nunc) were coated with 1 
μg/mL TBZ-BSA in PBS solution (100 μL per well) and left O/N at 4°C. The following day, 
the antigen-coated plate was then blocked with a 5 % (w/v) milk-PBS solution (200 μL per 
well) for 1 h at 37°C. Meanwhile, the O/N plates of expressed clones were removed from 
30°C and subjected to a freeze-thaw protocol for cell lysis. In this protocol the plates are 
placed at -80°C until frozen and then thawed at 37°C (this step was repeated a total of 3 
times). The plates were centrifuged at 3,220 x g (Eppendorf centrifuge 5810R) for 15 min. 
The supernatant was removed added (100 μL per well) to its corresponding coated/blocked 
well and incubated at 37°C for 1 h. 
  
A competitive ELISA was also performed, whereby the lysate was added to the wells 
followed by several concentrations of the free TBZ). Following incubation, the plates were 
washed using PBST (x3) and PBS (x3) to remove any unbound Fab. The antigen–antibody 
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complex was detected with 100 μL per well of 1/2,000 dilution of a HRP-labelled anti-HA 
that detects proteins tagged with the haemagglutinin epitope YPYDVPDYA. After a 1 h 
37°C incubation with the secondary mAb, TMB was added (100 μL per well) and left react 
for 15 min at R.T. The reaction was quenched by the addition of 50 μL per well of 10 % (v/v) 
HCl, after which the absorbance was read at 450 nm on a Safire 2 plate reader.  
This method was adapted from Alfredo Sheehan, (2006).The production of polyclonal, 
monoclonal and genetically-derived scFv antibody fragments for the detection of the ß-
lactam antibiotic, cephalexin, in milk. PhD thesis, DCU, Ireland.  
2.9.14 Large-scale protein expression of anti-TBZ Fab and extraction from bacterial 
cultures. 
Approximately 5 mL of SB media, containing 100 μg/mL carbenicillin, was inoculated with 
100 μL of stock transformant and grown O/N at 37°C. A 5 mL volume of this culture was 
then inoculated into 500 mL TB media containing 100 μg/mL carbenicillin, 1 mM MgSO4, 
0.5 % (v/v) glycerol and 0.05 % (w/v) glucose. The sub-cultured clone was incubated at 37°C 
at 250 rpm until the cell suspension reached ~0.6 (OD 600 nm). Expression was then induced 
by adding IPTG to a final concentration of 1mM and transferring to 30°C (250 rpm) O/N.  
The O/N expressed culture was then transferred to 2 x 250 mL sorval tubes and centrifuged at 
15,000 x g in a GSM rotor for 20 min (‘brake on’), to pellet the bacterial cells. The media 
supernatant was discarded into a bucket of Virkon™ and the excess media removed by 
inversion of the sorval tube onto a paper towel. Each cell pellet was thoroughly re-suspended 
in 20 mL of sonication buffer (1 x PBS, pH 7.4, 0.5 M NaCl and 20 mM imidazole). Each 
aliquot was sonicated on ice for 45 seconds (3 second intervals) at an amplitude of 40, using a 
microtip Vibra Cell
TM
 sonicator and the cell debris removed by centrifuging at 20,817 x g for 
10 min at 4°C. The lysate supernatant was passed though a 0.2 μm filter to remove any 
residual cell debris.  
This method was adapted from Alfredo Sheehan, (2006). The production of polyclonal, 
monoclonal and genetically-derived scFv antibody fragments for the detection of the ß-
lactam antibiotic, cephalexin, in milk. PhD thesis, DCU, Ireland.  
2.9.15 Purification of anti-TBZ Fab fragments using immobilised metal affinity 
chromatography (IMAC). 
Immobilized metal affinity chromatography is based on the interaction of amino acids, 
particularly histidine, to metals. This technique allows histidine tagged proteins with an 
affinity for metal ions such as Ni
+
-NTA to be retained in a column and eluted with either a 
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low pH or high imidazole buffer. A 3 mL aliquot of Ni
+
-NTA agarose resin (QIAgen) was 
added to a 1.45 x 5.0 cm  (final volume 10 mL) column and equilibrated with 20 mL of 
running buffer (1 x PBS, 0.5 M NaCl, 20 mM imidazole and 1 % (v/v) Tween-20).  The 
filtered lysate was applied to the equilibrated column and the flow-though collected in a 50 
mL tube. The column was washed with 20 mL of running buffer to remove any loosely 
bound non-specific proteins, again collecting the flow-though in a 50 mL tube. The Fab 
fragment was eluted using 100 mM NaAc, pH 4.4, and collected in 24 x 400 μL aliquots in 
1.5 mL micro-centrifuge tubes containing 100 μL of filtered neutralisation buffer (50 μL 100 
mM NaOH and 50 μL of 10 x PBS). The 12 mL of neutralised Fab was then thoroughly 
buffer exchanged against filtered PBS (1 x) using a 5 kDa cut-off Vivaspin™ 6 column 
(AGB, VS0611). The buffer-exchanged Fab was quantified using the Nanodrop™ ND-1,000 
and aliquoted into clean PCR tubes and stored at -20°C. 
This method was adapted from Alfredo Sheehan, (2006).The production of polyclonal, 
monoclonal and genetically-derived scFv antibody fragments for the detection of the ß-
lactam antibiotic, cephalexin, in milk. PhD thesis, DCU, Ireland.  
 
2.9.16 Transfer of purified anti-TBZ Fab to nitrocellulose membrane and Western blot 
analysis. 
Six sheets of Whatmann™ filter paper and one sheet of 3 mm nitrocellulose (per gel) were 
cut to the same dimensions of the SDS gel (see section 2.5). Each of the layers of filter paper, 
the nitrocellulose membrane and the SDS gel were soaked in transfer buffer for 30 min. The 
first 3 sheets of filter paper were positioned on the trans blot, followed by the SDS Gel, 
nitrocellulose membrane and finally the filter paper. All air bubbles were removed by rolling 
the gel/filter paper sandwich with a disposable 10 mL serological pipette. Proteins were 
transferred from the acrylamide gel to the nitrocellulose using a Trans-Blot
®
 Semi-Dry 
Transfer cell (BioRad) at 15 V for 15 min. The nitrocellulose membrane was transferred into 
a large weighing boat containing 20 mL of 5 % (w/v) milk-PBS solution and blocked for 2 h 
at R.T. or at 4°C O/N with agitation. The membrane was washed twice with PBS to remove 
any excess blocking agent. Following blocking, the blot was washed 3 times in PBS buffer 
and incubated with primary antibody (at the appropriate dilution in dilution buffer i.e. PBST 
containing 0.5 % (w/v) skimmed milk powder) for 1.5 h at R.T. while rocking. The blot was 
washed 3 times in PBS and 3 times in PBST prior to incubation with enzyme-labelled 
secondary antibody (e.g. HRP-labelled anti-HA) diluted in PBST containing 5 % (w/v) 
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skimmed milk for 1.5 h at R.T. The blot was washed 3 times in PBST then PBS. Next the 
membrane was developed using appropriate substrate solution (i.e. 3,3′,5,5′-tetramethyl-
benzidine (TMB) for HRP-labelled and 5-bromo-4-chloro-3’-indolyphosphate / nitro blue 
tetrazolium chloride (BCIP/NBT) for alkaline phosphatase-labelled secondary antibodies).  
The colour was developed at R.T. until the bands were clearly visible. The reaction was 
stopped by washing with distilled water or by rinsing with 100mM EDTA. 
This method was adapted from Alfredo Sheehan, (2006).The production of polyclonal, 
monoclonal and genetically-derived scFv antibody fragments for the detection of the ß-
lactam antibiotic, cephalexin, in milk. PhD thesis, DCU, Ireland.  
 
2.9.17 ELISA to determine the working concentration of the purified murine anti-TBZ 
Fab. 
A 96 well plate (Maxisorp™, Nunc) was coated with 1 μg/mL TBZ-BSA conjugate solution 
(100 μL per well) and incubated O/N at 4°C. The following day, the antigen-coated plate was 
then blocked with 200 μL per well of PBS (containing 5 % (w/v) milk) and incubated for 1 h 
at 37°C. Any excess blocking solution was removed with a single wash with PBST. Serial 
dilutions were prepared from the purified stock of anti-TBZ in PBST (containing 0.5 % (w/v) 
milk). A 100 μL aliquot of each of the dilutions were added in triplicate to the coated/blocked 
wells and incubated for 1 h at 37°C. Following incubation, the plates were washed using 
PBST (x3) and PBS (x3) to remove any unbound Fab. The antibody–antigen complex was 
detected using a 100 μL per well of a 1/2,000 dilution of a HRP-labelled anti-HA secondary 
mAb. After a 1 h incubation at 37°C, 100 µL per well of TMB was added and incubated for 
15 min at R.T. and the reaction quenched with 50 µL per well of HCl.  The absorbance was 
read at 450 nm on a Safire 2 plate reader. 
This method was adapted from Alfredo Sheehan, (2006).The production of polyclonal, 
monoclonal and genetically-derived scFv antibody fragments for the detection of the ß-
lactam antibiotic, cephalexin, in milk. PhD thesis, DCU, Ireland.  
 
2.9.18 Competitive ELISA for the purified murine anti-TBZ Fab  
A 96 well plate (Maxisorp™, Nunc) was coated with 1 μg/mL TBZ-BSA conjugate solution 
(100 μL per well) and incubated O/N at 4°C. The following day, the antigen-coated plate was 
blocked with 200 μL per well of PBS (containing 5 % (w/v) milk) and incubated for 1 h at 
37°C. The wells were washed once with PBS and an aliquot of 50 μL/well primary Fab 
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antibody solution (1:40 in PBST 0.05 % (v/v) Tween 20 containing 1 % (w/v) powdered milk 
and 5 % (v/v) MeOH) was added to each well. TBZ standards were serially diluted in 200 µL 
volumes of dilution buffer (PBST 0.05 % (v/v) Tween 20 containing 1 % (w/v) powdered 
milk and 5 % (v/v) MeOH). Each dilution was added to the corresponding wells (50 μL/well) 
and incubated for 1 h at 37°C. The plate was washed 3 times with PBST and 3 times with 
PBS. After washing, 100 μL/well of peroxidase-labelled secondary antibody (1:2,000 in 
dilution buffer) was added and incubated for 1 h at 37°C. After a 1 h incubation at 37°C, 100 
µL per well of TMB was added and incubated for 15 min at R.T. and the reaction quenched 
with 50 µL per well of HCl. The absorbance was then read at 450 nm on a Safire 2 plate 
reader. 
This method was adapted from Alfredo Sheehan, (2006).The production of polyclonal, 
monoclonal and genetically-derived scFv antibody fragments for the detection of the ß-
lactam antibiotic, cephalexin, in milk. PhD thesis, DCU, Ireland.  
 
2.10 Generation of the pComb double helix vector for the enhancement of the anti-TBZ 
Fab. 
2.10.1 Plasmid preparation of anti TBZ-Fab and pAK500. 
Plasmid DNA purification was performed using the Wizard® Plus SV miniprep DNA 
purification kit (Promega) and the method performed as detailed in the product insert.. Single 
E. coli colonies containing plasmid (e.g. E.coli XL1-Blue containing pAK500 phagemid 
vector and pComb3xTT containing anti-TBZ Fab) were picked from a stock agar streak plate 
and used to inoculate 2 x 5 mL of SB supplemented with 30 µg/mL of chloramphenicol 
(pAK500) and 100 µg/mL carbenicillin (pComb3xTT). The cultures were grown O/N at 37°C 
with vigorous shaking. The cells were then pelleted by centrifugation for 5 min at 3,500 x g 
(Eppendorf 5810R). The supernatant was carefully decanted and the pellets thoroughly re-
suspended in 250 μL re-suspension buffer (50 mM Tris-HCl, pH 7.5, 10 mM EDTA and 10 
μg/mL RNase A) and transferred to sterile 1.5 mL micro-centrifuge tube. Cell lysis solution 
(250 μL of 0.2 M NaOH and 1 % (w/v) SDS) was added to the re-suspended cells and mixed 
by inverting 4 times. The resulting mixture was incubated at R.T. for 5 min prior to the 
addition of 10 μL of alkaline protease solution and further mixing by inverting the tube 4 
times and incubation for 5 min. Alkaline protease was added in order to inactivate 
endonucleases and other proteins released during cell lysis that can adversely affect the 
quality of DNA. 350 μL of neutralisation solution (buffer containing 4.09 M guanidine 
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hydrochloride, 0.76 M potassium acetate and 2.12 M glacial acetic acid, pH 4.2) was added 
and again mixed by inverting the tube 4 times. The resulting mixture was centrifuged at 
14,000 x g for 10 min at R.T. The cleared lysate (supernatant) was carefully decanted into a 
spin column in a fresh 1.5 mL tube and centrifuged at 14,000 x g for 1 min at R.T. The 
column ‘flow-though’ was discarded from the 1.5 mL tube and 750 μL of wash solution 
(162.8 mM potassium acetate, 22.6 mM Tris-HCl, pH 7.5, and 0.109 M EDTA) pre-diluted 
with 95 % (v/v) ethanol as per manufacturers’ guidelines, was added. The spin column was 
re-inserted in the micro-centrifuge tube and centrifuged at 14,000 x g for 1 min at R.T. and 
the ‘flow-though’ discarded again. The wash procedure was repeated using 250 μL of wash 
solution and centrifuged at 14,000 x g for 2 min. The ‘flow-though’ was again discarded. The 
spin column was transferred to a fresh sterile 1.5 mL micro-centrifuge tube and the plasmid 
DNA finally eluted by adding 100 μL of ultra-pure molecular grade water to the column, 
followed by centrifugation at 14,000 x g for 1 min at R.T. The volume collected in the 1.5 
mL tube was kept for further analysis and the spin column discarded. DNA was stored at -
20ºC until required. This method was adapted from Alfredo Sheehan, (2006).The production 
of polyclonal, monoclonal and genetically-derived scFv antibody fragments for the detection 
of the ß-lactam antibiotic, cephalexin, in milk. PhD thesis, DCU, Ireland.  
 
2.10.2 Amplification of the Double Helix (dHLX) gene from pAK500. 
To further enhance the anti-TBZ Fab a modified pComb vector system for the improvement 
of antibody fragments was constructed whereby the dHLX gene is inserted down-stream of 
the Fab gene insert and upstream of the amber stop codon. The double helix region was 
amplified from the pAK500 using the designed primers shown. The forward primer was 
designed to amplify the N-terminus of the dHLX domain from pAK500 for cloning into 
pComb3xSS via the BsiWI site. The back primer was designed to amplify the C-terminus of 
the dHLX domain including the 5 histidines from pAK500 and for cloning into pComb3xSS 
via the BspEI site in pComb3xSS (deleting the HA tag). 
 
 dHLX forward  
ACCCGTACGGACCCAAACCTAGCACCCCCCCT  
 dHLX reverse  
TAGTCCGGAACATGGTGATGATGGTGCGGGCGC 
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Table 2.10.2.1: The components of the PCR c for the amplification of the dHLX gene. 
and their volumes and concentrations in a 50µL volume. 
Component       50  µL total volume  Conc. in 50 µL reaction  
10 x Buffer 5.0 µL 1 x 
dHLX Forward Primer 0.5 µL 60.0 pM 
dHLX Back Primer 0.6 µL 60.0 pM 
dNTP 2.0 µL    1.0 mM 
H2O                  40.9 µL N/A 
Dream Taq polymerase 1.0 µL 1 U 
 
The PCR for the amplification of the double helix gene was performed in the Biometra 
TGRADIENT PCR machine under the following conditions: 
 
Table 2.10.2.2: PCR conditions for the amplification of the dHLX gene. 
Stage Temp(
o
C) Time (seconds) 
1 (1 cycle) 96 300 
2 (20 cycle) 96 
56 
72 
  15 
  30 
  30 
3 (1 cycle) 72 
4 
 600 
 600 
 
Five µg of the pComb3xTT vector and Fab E6 were digested with 180 units of SfiI (New 
England Biolabs). The digested Fab insert was ligated into the pComb3xTT vector using T4 
ligase (New England Biolabs) and subsequently transformed into XL1-Blue cells. The dHLX 
gene fragment and the vector containing the Fab were sequentially digested with the 
restriction enzymes Bspe I and Bsw 1. These were ligated together with T4 ligase and 
transformed into electrocompetent XL1-Blue cells. Colonies were picked and checked for 
both the Fab and dHLX insert by PCR amplification.  
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Table 2.10.2.3: The components for the restriction digest of the Fab gene fragment and 
pComb vector. 
      Anti-TBZ Fab SfiΙ digest (5 µg)             pComb3xTT SfiΙ digest (20 µg) 
Component  50 µL total volume Component 50 µL total volume 
Plasmid prep 10.0 µL pComb vector 20.0 µL 
10 x Buffer 2   5.0 µL 10 x Buffer 2     5.0 µL 
100 x BSA   0.5 µL 100 x BSA                         0.5 µL 
H20 25.5 µL H20      6.5 µL 
SfiΙ   9.0 µL SfiΙ   18.0 µL 
 
Table 2.10.2.3: The components for the sequential restriction digest of the pComb vector and 
the double helix gene fragment. 
        Double helix gene digest (5 µg)             pComb3xTT containing Fab digest (20 µg) 
Component              50 µL volume             Component                   90 µL volume 
Plasmid prep    14.0 µL   pComb vector           67.0 µL 
10 x Buffer 3     5.0 µL  10 x Buffer 3               9.0 µL 
H20               26.0 µL  H20               8.9 µL 
BspEI      5.0 µL                       SfiΙ               5.0 µL 
 
The reactions were incubated at 37°C for 1 h. The enzyme was inactivated at 80
o
C for 20 
min. To each reaction 5 µL of BsiWI was added and incubated at 55
o
C for 1 h and inactivated 
at 80
o
C for 20 min. 
Both components were ligated together as outlined in section 2.9.8.  
 
Table 2.10.2.4: The components for the ligation of the pComb vector with the double helix 
gene fragment.  
Component         60 µL Volume Conc. in 60 µL reaction 
Digested pComb  vector                 39.0 µL                  1.4 µg 
Digested dHLX  gene                      8.5 µL 0.7 µg 
5 x Ligase buffer   6.0 µL  1 X 
H2O   3.5 µL N/A 
T4 DNA Ligase   3.0 µL 400 U 
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Following ligation, the reaction was inactivated, ethanol precipitated and transformed as 
described in sections 2.9.10-2.9.13. A colony pick PCR was performed to determine the 
clones that contained the dHLX and Fab insert as described in section 2.9.15. 
2.10.3 ELISA for the titration of the positive anti-TBZ Fab dHLX clones selected. 
Positive clones were selected and O/N cultures were prepared in 10 mL of SB media 
containing 100 µg/mL of carbenicillin and were allowed to shake at 220 rpm at 37°C. Each 
clone was then sub-cultured into the same volume of media and grown until the O.D. reached 
0.6 at 600 nm. These cultures were then induced with 1mM IPTG and continued to grow O/N 
at 30°C shaking at 220 rpm. The cultures were centrifuged at 3,500 x g for 10 min at 4°C. 
The pellet was re-suspended in 1 mL of PBS (pH 7.4) and subjected to cell lysis by 3 cycles 
of freeze-thawing. These cultures were then centrifuged at 3,500 x g at 4°C. The resulting 
supernatant was stored at 4°C. A nunc maxisorb plate (Maxisorp F96, Fisher Scientific 
Ireland) was coated with 100 μL/well of 1 μg/mL of the TBZ-BSA conjugate (donated by 
USDA) in PBS (pH 7.4) O/Nat 4°C. Subsequently, the plate was blocked with 200 μL/well of 
blocking solution (5 % (w/v) skimmed milk in PBS) for 1h at 37°C. The antibody supernatant 
was serially diluted in PBS (pH 7.4) and 50 µL of each dilution was transferred to the wells 
of the ELISA plate and incubated for 1 h at 37°C. The plate was washed 3 times with PBST 
and 3 times with PBS. After washing, 100 μL/well of peroxidase-labelled secondary antibody 
(1:2,000 in dilution buffer) was added and incubated for 1 h at 37°C. After the wells were 
washed 3 times with 300 μL/well of PBST and PBS, 100 μL/well of 3,3´,5,5´-tetra-
methylbenzidine (TMB) was added and incubated for 15 min at R.T. The reaction was 
stopped by adding 50 μL/well of 1 M HCl and the absorbance measured at 450 nm.  
These positive clones were purified by IMAC as described in section 2.9.15. 
This method was adapted from Alfredo Sheehan, (2006).The production of polyclonal, monoclonal 
and genetically-derived scFv antibody fragments for the detection of the ß-lactam antibiotic, 
cephalexin, in milk. PhD thesis, DCU, Ireland.  
2.10.4 High performance liquid chomatography (HPLC) of the anti-TBZ Fab and anti-
TBZ Fab DHLX. 
The composition of the two IMAC purified antibody fragments (dHLX and Fab E6) were 
determined by size exclusion chomatography. Protein separations were performed on a Bio-
Sep-SEC-S2000 stationary phase column (Phenominex 300 x 7.8 mm) with 1 x PBS pH 7.4 
selected as a mobile phase. The samples (50 µL) were assayed at a flow rate of 0.5 mL/min 
using a UV detection 280 nm) and confirmation of the sample size was determined by 
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referencing against a range of protein standards namely, bovine thyroglobulin (670 kDa), 
immunoglobulin G (150 kDa), ovalbumin (44 kDa), myoglobin (17 kDa). This method was 
adapted from an in-house protocol entitled “HPLC-based analysis” written exclusively for the 
Applied Biochemistry group by Dr Barry Byrne. 
2.11 Generation and characterization of chicken anti-TCB/ABZ antibodies 
2.11.1 Immunisation of a Leghorn chicken with both TCB-BTG and ABZ-HRP conjugates 
and subsequent the antibody titre determination. 
A white Leghorn chicken, aged 5-8 weeks, was immunised with the conjugates TCB-BTG 
and ABZ-HRP. On day 1, the chicken was immunised with 250 μg/mL of each conjugate in 
600 µL of PBS, mixed in a 1:1 ratio with 600 µL of Freund’s complete adjuvant (FCA). 
Freund’s complete adjuvant is an emulsified mineral oil antigen solution used as an 
immunopotentiator (Bennett, B. 1992). The conjugate was mixed with the Freund’s adjuvant 
and was vortexed until a stable emulsion was formed. This was passed twice though a 1 mL 
syringe with a 0.5 x 25 mm needle to disperse any air bubbles. On day 14, 35, 49 and 70, 
boosts were given to the chicken using 125 μg/mL of both conjugates in PBS, mixed in a 1:1 
ratio with Freund’s incomplete adjuvant (FICA). This solution was injected over four 
separate subcutaneous sites of each chicken for immunisation. A bleed was taken from the 
chickens 10 days after each injection and the antibody titre against TCB and ABZ 
determined. Once a high response from each hapten was obtained, the chicken was given a 
final boost, sacrificed 6 days later and the spleen and bone marrow removed. Eggs contain a 
high level of IgY comparable to that from the serum, therefore eggs were collected 
continuously though-out the immunisation period and from the yolk TCB/ABZ IgY was 
purified (section 2.8.3).  
This method was adapted from Barry Mc Donnell (2010). Development of novel antibody-
based diagnostics for the early and rapid detection of cardiac markers. PhD Thesis, DCU, 
Ireland. 
2.11.2 Extraction and isolation of total RNA from the TCB/ABZ immunised chicken. 
The inner surface of a Gelaire BSB 4 laminar unit was sprayed with both IMS and RNase 
ZAP to remove any RNases that may degrade RNA during the isolation procedure. The 
spleen and bone marrow were removed from the chicken and all excess fat was removed 
from the spleen before being transferred into a 50 mL ‘RNase-free’ tube containing 30 mL of 
Trizol ™ reagent. A homogenizer, previously autoclaved at 120°C for 15 min and baked O/N 
at 180°C, was used to homogenize the spleen/bone marrow. The mixture was incubated for 5 
101 
 
min at R.T. to allow for the total dissociation of nucleoprotein complexes while maintaining 
the integrity of the RNA. The homogenized spleen/bone marrow was centrifuged at 2,465 x g 
(Eppendorf centrifuge 5810R) for 10 min at 4°C to pellet any excess cell debris and the 
supernatant transferred into a 50 mL polypropylene Oakridge tube. Chloroform (6 mL) was 
added to the tube containing the supernatant, thoroughly mixed though and incubated for 15 
min at R.T. The resultant mixture was centrifuged at 17,500 x g (Eppendorf centrifuge 
5810R) for 15 min at 4°C. This centrifugation step produced 3 layers, a lower red 
phenol/chloroform phase, a protein inter-phase and a colourless liquid upper phase containing 
the RNA. The upper aqueous phase was carefully transferred (ensuring no lower layer 
contamination) into an 85 mL polycarbonate Oakridge tube and the RNA was precipitated by 
addition of 15 mL of isopropanol for 10 min at R.T.. It was centrifuged at 17,500 x g 
(Eppendorf centrifuge 5810R) for 25 min at 4°C resulting in a white RNA pellet. The 
isopropanol was carefully decanted and the pellet washed with 30 mL of 75 % (v/v) ethanol 
by centrifugation at 17,500 x g (Eppendorf centrifuge 5810R) for 10 min at 4°C. The pellets 
were air dried in the laminar hood and re-suspended in 500 µL of molecular grade water. The 
RNA preparation was quantified using the Nanodrop™ ND1000. 
This method was adapted from Barry Mc Donnell (2010).Development of novel antibody-
based diagnostics for the early and rapid detection of cardiac markers. PhD Thesis, DCU, 
Ireland. 
2.11.3 Reverse transcription of total TCB/ABZ RNA to cDNA. 
Following extraction the RNA was converted to cDNA using the commercial reverse 
transcription kit Superscript™ III. Method was taken from the product insert provided. This 
kit is fully optimized to synthesize first strand cDNA from total RNA.  
 
Table 2.11.3.1: The components of mixture 1 for the reverse transcription of RNA to cDNA. 
Mixture 1 Component     10 µL Volume     Conc. in 10   µL reaction                                  
Total RNA         5.0 µL              5.0 µg 
Oligo (dT) primer        1.0 µL              0.5 µg 
dNTP mix         1.0 µL              1.0 mM 
Molecular grade H2O        3.0 µL              N/A 
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Table 2.11.3.2: The components of mixture 2 for the reverse transcription of RNA to cDNA. 
Mixture 2 Component  10 µL Volume       Conc. in 10 µL  
                                                                                                     reaction 
10 X RT Buffer                  2.0 µL                2 X 
MgCl2                   4.0 µL                         2.5 mM 
DTT                               2.0 µL                       20.0 mM 
RNase Out                              1.0 µL              40 U 
Superscript Ш enzyme                 1.0 µL                        200 U 
2.11.4 PCR primers for amplification of the avian scFv library (pComb series). 
The primers listed below were obtained from Eurofins-MWG-Operon (318 Worple Road, 
Raynes Park, London, SW20 8QU) and are compatible with the primers set described by 
Barbas and co-workers (Barbas, C.F. 2001) for the pComb vector system. All methods 
described from 2.11.4-2.11.10 were adapted from (Barbas et al., 2001) unless otherwise 
stated. 
 
Variable heavy chain:  
CSCVHo-F (sense) 
5´ GGT CAG TCC TCT AGA TCT TCC GCC GTG ACG TTG GAC GAG 3´ 
CSCG-B (reverse) 
5´ CTG GCC GGC CTG GCC ACT AGT GGA GGA GAC GAT GAC TTC GGT CC 3´ 
 
Variable light chain: 
CSCVK (sense) 
5´ GTG GCC CAG GCG GCC CTG ACT CAG CCG TCC TCG GTG TC 3´ 
CKJo-B (reverse) 
5´ GGA AGA TCT AGA GGA CTG ACC TAG GAC GGT CAG G 3´ 
Splice by overlap extension (SOE) primers 
CSC-F (sense) 
5´ GAG GAG GAG GAG GAG GAG GTG GCC CAG GCG GCC CTG ACT CAG 3´ 
CSC-B (reverse) 
5´ GAG GAG GAG GAG GAG GAG GAG CTG GCC GGC CTG GCC ACT AGT GGA 
GG 3´ 
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The following  protocols describe the construction of an avian scFv gene construct by overlap 
extension PCR. It allows the expression and selection of scFv that contain variable regions 
obtained from the spleen and bone marrow of the immunised chicken. 
A 1 x reaction mix for amplification of the variable domains was formulated using the 
following components. 
 
Table 2.11.4.1: Components of the PCR for the amplification of the the avian variable 
domains and their subsequent volumes and concentrations in 50 µL. 
Component 50 µL total volume Conc in 50 µL reaction 
10 x Buffer    5.0 µL                   1 x 
VL/VH Forward Primer   0.6 µL 60.0 pM 
VH/VL Back Primer    0.6 µL 60.0 pM 
cDNA    1.0 µL                  1.0 µg 
dNTP   2.0 µL   1.0 mM 
MgCl2     4.0 µL                  2.0 mM 
H2O                 36.6 µL N/A 
Dream Taq ® Polymerase  0.2 µL 1U 
 
The PCR for the amplification of the avian antibody variable domain genes was performed in 
the Biometra TGRADIENT PCR machine under the following conditions: 
 
Table 2.11.4.2: The PCR programme for the amplification of the variable heavy and light 
scFv chains. 
Stage  Temp(
o
C) Time (seconds) 
1 (1 cycle)                      94                  300 
2 (30 cycle) 94 
56 
72 
                   15 
                   30 
                 120 
3 (1 cycle) 72 
4 
                 600 
                 600 
2.11.5  Purification of VH and VL variable gene fragments using the Promega clean-up kit. 
The VH and VL PCR products were resolved on a 1 % (w/v) agarose gel until single bands for 
both the variable heavy and variable light chains were observed. Both bands were excised 
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using sterile scalpels and transferred into clean 1.5 mL micro-centrifuge tubes. Next, thee 
volumes of binding buffer was added for every one volume of gel slice and incubated at 50°C 
until the gel fragments had completely dissolved (approximately 10 min). The binding buffer 
contains guanidine isothiocyanate hat allows for sufficient binding of the DNA to the silica 
membrane columns. One volume of isopropanol, equal to the original of the gel slice volume, 
was added and mixed to allow for precipitation of the DNA. The mixture was transferred to a 
binding column and collection tube and centrifuged at 17,500 x g (Eppendorf centrifuge 
5810R) for one min to remove any residual buffer. The “flow-through” was discarded and the 
column was washed first by centrifugation with 750 µL wash buffer and then with 250 µL 
wash buffer. The column was centrifuged at 17,500 x g (Eppendorf centrifuge 5810R) for 2 
min to ensure all residual ethanol was removed and the DNA was eluted from the column 
using 50 µL molecular grade H2O and subsequently quantified using the Nanodrop™ ND-
1000. 
 
Table 2.11.5.1: The components for the PCR to combine the two variable regions of the scFv 
subsequent volume and concentration in 50 µL. 
Component 50 µL total volume Conc in 50 µL reaction 
10 x Buffer   5.0 µL                   1 x 
CSC Forward Primer   0.6 µL 60.0 pM 
CSC Back Primer    0.6 µL 60.0 pM 
VH purified product   0.5 µL                 100 ng  
VL purified product   1.0 µL                 100 ng 
dNTP   2.0 µL   1.0 mM 
DMSO   2.0 µL                   N/A 
MgCl2     4.0 µL                  2.0 mM 
H2O                 34.1 µL N/A 
PlatinumTaq® Polymerase  0.2 µL 1U 
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Table 2.11.5.2: The PCR programme for the splice by overlap extension of the variable light 
and heavy chains. 
Stage  Temp(
o
C) Time (seconds) 
1 (1 cycle)                      94                  120 
2 (25 cycle) 94 
56 
72 
                   15 
                   15 
                   90 
3 (1 cycle) 72 
4 
                 600 
                 600 
 
2.11.6  SfiΙ restriction digests of the purified SOE-PCR fragment and ligation into the 
pComb3xSS vector. 
The scFv fragment and pComb3xTT vector used for phage selection were digested using SfiΙ 
restriction enzyme. The SfiΙ enzyme allows for the unidirectional cloning of scFv fragment 
into the pComb phage display vector. The enzyme recognises 8 bases which are interrupted 
by 5 non-recognised nucleotides (5′ggccnnnnnggcc3′), thus virtually eliminating internal 
digestion in antibody sequences. Both digestions (outlined below) were carried out for 5 h at 
50°C. 
 
Table 2.11.6.1: Components for the restriction digest of the Fab PCR product and pComb 
vector. 
Component  Vector digest 
200µL volume 
Spleen digest 
200µL volume 
Bone digest 
200µL volume 
Template                86               40               46 
10 x buffer 20 20 20 
100 x BSA  2 2 2 
SfiΙ 6 12.5 12.5 
H2O 86            125.5           119.5 
 
Following a 5 h incubation at 50°C, the digested pComb3xSS vector was treated with 
Antarctic phosphatase™ enzyme to prevent self-ligation. This enzyme catalyzes the removal 
of 5′ phosphate groups from DNA. The loss of the 5′ phosphoryl termini, therefore, prevents 
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the ligase enzyme from working. To the digested vector 5 µL of Antarctic phosphatase buffer 
(10 x) followed by 2 µL of antarctic phosphatase enzyme. 
The mixture was incubated for 15 min at 37°C and then the enzyme was heat inactivated at 
65°C for 5 min. Both digests were resolved via electrophoresis on a 1 % (w/v) agarose gel for 
the digested PCR product and a 0.6 % (w/v) gel for the digested vector. These were gel-
purified, as described in section 2.9.6. The restricted scFv gene was then ligated into the 
pComb3xTT vector in a 1:2 (insert:vector) ratio under the conditions below and left at R.T. 
O/N. 
 
Table 2.11.6.2: Components of the ligation of the scFv gene fragment into the pComb vector.  
Component         200 µL volume Conc in 200 µL reaction 
5 x ligase buffer                    20 µL                   1 x 
Digested pComb3xTT     25 µL 1.4 µg 
Digested scFv spleen gene     29 µL 0.7 µg 
H2O  116 µL N/A 
T4 DNA Ligase    10 µL 800 U 
 
Table 2.11.6.3: Components of the ligation of the scFv gene fragment into the pComb vector.  
Component         200 µL volume Conc in 100 µL reaction 
5 x ligase buffer                   20 µL                    1 x 
Digested pComb3xTT    25 µL 1.4 µg 
Digested scFv bone gene    50 µL 0.7 µg 
H2O   95 µL N/A 
T4 DNA Ligase                   10 µL 800 U 
 
Following ligation the mix was ethanol precipitated using the following reagents.   
 
Table 2.11.6.4: Components for the ethanol precipitation of the ligated gene fragment. 
Component  Volume 
Ligation mixture  
3M sodium acetate, pH 5.2 
100 %  (v/v) ethanol   
                            200 µL 
                              20 µL 
                            500 µL 
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The precipitation was incubated O/N at -20°C and the DNA was harvested by centrifugation 
at 17,500 x g (Eppendorf centrifuge 5810R) for 20 min at 4°C. The ethanol supernatant was 
decanted and the pellet was washed by addition of 1 mL of 70 % (v/v) ethanol and 
centrifuging at 17, 500 x g (Eppendorf centrifuge 5810R) for 20 min at 4°C. The pellet was 
allowed to air-dry briefly and dissolved in 20 µL of molecular grade H2O. 
2.11.7 Electro-transformation of scFv-containing plasmid into XL1-Blue E. coli cells. 
Transformation of the ligated products was performed by electroporation into a commercially 
available strain of XL1-Blue E. coli cells (Stratagene). The apparatus used was a Gene Pulser 
Xcell ™ electroporation  system with the parameters set to 25 µF, 1.25 kV and gene pulse 
controller at 200 Ω. After thawing on ice, 50 µL of the E. coli cells were added to the 5 µL of 
ligation product, mixed and left on ice for a 1 min incubation. The mixture was transferred to 
a chilled 0.2 cm electroporation cuvette, and placed into the ‘Shockpod’. A pulse was passed 
though the cuvette, and immediately flushed with 1 mL of pre-warmed SOC medium using a 
sterile tip. The 1 mL of electroporated cells were transferred into a sterile 50 mL Falcon tube 
containing a further 2 mL of pre-warmed SOC medium. The 3 mL of transformant 
suspension was incubated for 1 h at 250 x g at 37°C and plated out on SB agar plates 
supplemented with 100 µg/mL carbenicillin. A negative control was also incorporated into 
the experiment by plating the XL1-Blue cells containing no plasmid onto the agar plates. All 
plates were incubated O/N at 37°C and scraped into SB medium containing 20 % (v/v) 
glycerol for long term storage at -80°C. 
2.11.8 Phage rescue and precipitation of TCB/ABZ scFv library 
A conical flask containing 600 mL of sterile SB medium (100 µg/mL carbenicillin) was 
inoculated with 600 µL of the transformed library glycerol stocks (bone and spleen) and 
incubated at 220 rpm and 37°C until the O.D.reached 0.4 at 600nm. Helper phage (2 x 10
11 
cfu) was added. The culture was left static at 37°C for 30 min before transferring it to a 
shaking incubator at 37°C at 220 rpm for 1.5 h.  Kanamycin was added to a final 
concentration of 50 µg/mL, before leaving the culture O/N at 37°C and 220 rpm. The O/N 
culture was centrifuged at  18,500 x g (Eppendorf centrifuge 5810R) for 20 min at 4°C and 
the phage supernatant transferred into 3 sterile 250 mL Sorvals™ centrifuge tubes containing 
8 g of PEG 8,000 and 6 g of sodium chloride. The Sorvals™ were agitated at 220 rpm until 
the PEG/NaCl went into solution. The phage was precipitated for 1 h at 4°C. The phage was 
harvested by centrifugation at 6,440 x g for 25 min at 4°C and re-suspended in 2 mL of 1 % 
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(w/v) BSA-PBS solution. The re-suspended phage pellets were added to a clean 1.5 mL 
micro-centrifuge tube and centrifuged at 20,817 x g for 5 min at 4°C to remove any bacterial 
debris. The remaining supernatant was refrigerated until ready for use.  
2.11.9 Panning of the TCB/ABZ phage library against immobilized conjugates. 
An immuno-tube (Maxisorp™, Nunc) was coated O/N at 4°C with 500 µL of 100 µg/mL 
TCB-HRP and ABZ-HRP in PBS. The tube was blocked for 1 h at 37°C with 3 % (w/v) BSA 
in PBS. Following one wash with PBST, 500 µL of the rescued phage (input phage) (Section 
2.9.10) was added to the immuno-tube and incubated on a roller for 2 h at R.T. The immuno-
tube was washed with PBST (x3) and PBS (x3) to remove non-specific phage. Specific phage 
was eluted by incubation with 1 mL of free TCB/ABZ in PBS for 2 h at 37°C. The 
competitively eluted phage was removed after harsh pipetting and 800 µL was added to 5 mL 
of mid-exponential phase XL1-Blue cells. This was allowed to infect for 15 min static at R.T. 
and 6 mL of pre-warmed SB media containing 1.6 µL of 100 mg/mL carbenicillin and 12 µL 
of 5 mg/mL tetracycline was added (at this point 100 µl sample was removed for output titre 
determination). This 12 mL culture was incubated at 220 rpm at 37°C for 1 h. Carbenicillin 
(2.4 µL of 100 mg/mL) was added and incubated at 220 rpm at 37°C for 1 h. To this 12 mL 
culture, 800 µL of commercial helper phage (New England Biolabs) was added, followed by 
88 mL of SB media supplemented with carbenicillin and tetracycline (final concentrations of 
50 µg/mL and 10 µg/mL, respectively) and incubated for 2 h at 37°C at 220 rpm. Kanamycin 
was added to a final concentration of 70 µg/mL and incubated O/N at 220 rpm and 37°C.    
 
An output titre was performed by making a 1 in 10 and 1 in 100 dilution of the XL1-Blue 
infected cells in SB media. These dilutions were plated out on SB agar plates containing 100 
µg/mL of carbenicillin and incubated O/N at 37°C. 
An input titre was performed by making serial dilutions (10
-1
-10
-12
) of the PEG-precipitated 
phage in exponential growth phase XL1-Blue cells. Following a 15 min infection at 37°C, the 
10
8
 - 10
12
 serial dilutions were plated out on SB agar plates containing 100 µg/mL 
carbenicillin and incubated O/N at 37°C. All of the subsequent rounds of panning were 
performed as described above. 
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Table 2.11.9.1: Parameters varied during the panning of avian scFv TCB/ABZ library 
Round Free drug 
 concentration µmol 
Coating 
concentration µg/mL 
Wash 
conditions 
          1                  100               100 5 x PBST, 5  x            
PBS 
2 50 50 5 x PBST, 5  x 
PBS 
3 25 25 5 x PBST, 5  x 
PBS 
4 12.5 12.5 5 x PBST, 5  x 
PBS 
5 6.5 6.5 5 x PBST, 5  x 
PBS 
 
2.11.10 ScFv gene insert check via ‘colony-pick’ PCR. 
Single colonies were randomly selected from both the spleen and bone transformed stock 
plates. A ‘colony-pick’ PCR was performed to ensure the vector incorporated the scFv 
fragment. A sterile tip was used to pick a single colony into the mixture described in 2.9.14.1, 
which was placed in a Biometra TGRADIENT PCR machine. The amplified scFv fragments were 
analysed via gel electrophoresis on a 1 % (w/v) agarose gel. 
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Table 2.11.10.1: PCR components for amplification of the scFv gene fragment from selected 
clones. 
Component 50 µL total volume Conc in 50 µL reaction 
10 x Buffer    5.0 µL                    1 x 
Colony  1 N/A 
CSC Forward Primer   0.6 µL 60.0 pM 
CSC Back Primer    0.6 µL 60.0 pM 
dNTP   2.0 µL   1.0 mM 
DMSO   2.0 µL                   N/A 
MgCl2     4.0 µL                  2.0 mM 
H2O                 35.6 µL N/A 
PlatinumTaq® Polymerase                   0.2 µL 1U 
 
Table 2.11.10.2: The PCR programme for amplification of the the scFv gene fragment from 
selected clones. 
Stage  Temp(
o
C) Time (seconds) 
1 (1 cycle)                      94                 120 
2 (25 cycle) 94 
56 
72 
                  15 
                  15 
                  90 
3 (1 cycle) 72 
4 
                 600 
                 600 
 
2.11.11 Direct and inhibition ELISA of scFv fragments in XL1-Blue for all thee rounds. 
Individual colonies (288 in total) were selected and grown O/N at 200 x g and 37°C in single 
wells containing 100 μL SB media with 100 μg/mL carbenicillin (stock plates). The 3 x 96 
well stock plates were then sub-cultured into fresh SB media (180 μL) containing 1 x 505 
(0.5 % (v/v) glycerol, 0.05 % (v/v) glucose final concentration), 1mM MgSO4 and 100 
μg/mL carbenicillin. Glycerol was then added to the O/N stock plates to a final concentration 
of 20% (v/v) and then transferred to a -80°C freezer for long-term storage. Meanwhile, the 
sub-cultured plates were incubated at 37°C at 220 rpm until the cell suspension reached an 
O.D. of ~0.6. Expression was then induced by adding IPTG to a final concentration of 1mM 
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and incubating at 30°C (200 x g) O/N. Also, for each plate of clones, 2 x 96 well plates 
(Maxisorp™, Nunc) were coated with 1 μg/mL TBZ-BSA in PBS solution (100 μL per well) 
and left O/N at 4°C. The following day, the antigen-coated plate was then blocked with a 5 % 
(w/v) milk-PBS solution (200 μL per well) for 1 h at 37°C. Meanwhile, the O/N plates of 
expressed clones were removed from 30°C and subjected to a freeze-thaw protocol for cell 
lysis. In this protocol the plates are placed at -80°C until frozen and then thawed at 37°C (this 
step was repeated a total of 3 times). The plates were centrifuged at 3,220 rpm (Eppendorf 
centrifuge 5810R) for 15 min. The supernatant was removed added (100 μL per well) to its 
corresponding coated/blocked well and incubated at 37°C for 1 h. (A competitive ELISA was 
also performed, whereby the lysate was added to the wells followed by several concentrations 
of the free TBZ). Following incubation, the plates were washed using PBST (x3) and PBS 
(x3) to remove any unbound Fab. The antigen–antibody complex was detected with 100 μL 
per well of 1/2,000 dilution of a HRP-labelled anti-HA that detects proteins tagged with the 
haemagglutinin epitope YPYDVPDYA. After a 1 h 37°C incubation with the secondary 
mAb, TMB was added (100 μL per well) and left react for 15 min at R.T. The reaction was 
quenched by the addition of 50 μL per well of 10 % (v/v) HCl, after which the absorbance 
was read at 450 nm on a Safire 2 plate reader.  
This method was adapted from Barry Mc Donnell (2010).Development of novel antibody-
based diagnostics for the early and rapid detection of cardiac markers. PhD Thesis, DCU, 
Ireland 
2.11.12 Expression studies of the TCB/ABZ avian scFv clones TCB E4 and ABZ D6. 
Both clones were grown overnight in 5 mL of SB (section 2.2.1) containing 100 µg/mL of 
carbenicillin at 37°C at 220 rpm. These were sub-cultured into 4 x 200 ML (2 for E4 and 2 
for D6) of SB containing 100 µg/mL of carbenicillin and grown at 37°C at 220 rpm until the 
O.D. reached 0.6. A 5 mL samples were removed from each flask, two were induced with 10 
mM IPTG and incubated at 30°C overnight. The remaining two were un-induced. The 
remaining cultures were induced with 1 mM IPTG and incubated at 30°C and 37°C. Samples 
(5 mL) were taken every h for 6 h and the remaining cultures were incubated overnight at 
30°C and 37°C at 220 rpm. Each sample was centrifuged at 3,500 x g (Eppendorf 5810 R) for 
10 min at 4°C, and the pellet re-suspended in 5 mL of sonication buffer (1 x PBS, pH 7.4, 0.5 
M NaCl and 20 mM imidazole) and split into 2 x 2.5 mL samples. Half of the samples were 
lysed via the freeze thaw method (freeze at -80°C for 15 min and thaw at 37°C for 15 min 
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repeating cycle thee times), and the other half by sonication. Each sample was analysed for 
activity by direct ELISA (section 2.9.13). 
Expression studies were adapted from Barry Mc Donnell (2010). Development of novel 
antibody-based diagnostics for the early and rapid detection of cardiac markers. PhD Thesis, 
DCU, Ireland 
2.12 Purification, characterisation and assay development for the antiTCB/ABZ  
polyclonal IgY from chicken egg. 
2.12.1 Purification of anti-TCB/ABZ polyclonal IgY from chicken egg. 
This purification was carried out using the Pierce™ chicken IgY “eggcellent” purification kit. 
The method was used as per the product insert. Thee egg yolks were separated from the egg 
whites. The yolk sacs were rinsed with de-ionised water, punctured and the egg yolks 
collected. Cold delipidation solution (provided in the kit) was added (5 times the combined 
original yolk volume) with continuous stirring to ensure the solution was entirely mixed. This 
was incubated for 6 h at 4°C, and centrifuged for 15 min at 3,500 x g (Eppendorf centrifuge 
5810R) at 4
o 
C. The supernatant was decanted and an equal volume of IgY precipitation 
reagent was added. The suspension was incubated at 4°C O/N and centrifuged for 15 min at 
3,500 x g (Eppendorf centrifuge 5810R) at 4°C. The supernatant was discarded and the 
retained pellet was re-suspended in a volume of 1 x PBS pH 7.5, equal to the original egg 
yolk volume. The purified IgY protein was quantified using a pre-programmed ‘IgG’ option 
on the NanoDrop™ ND-1000. 
2.12.2 SDS-PAGE of the purified anti-TCB/ABZ polyclonal IgY. 
Samples containing the purified anti-TCB/ABZ IgY were separated using 12.5 % (w/v) SDS-
PAGE gels (20 µl /Lane) to analyse purity and to determine the apparent molecular weight. 
The gels were prepared, as described in section 2.5, and left to polymerise between two clean 
glass plates. After the stacking gel was poured, a comb was inserted to make wells in 
preparation for loading of the protein samples. The samples were prepared by adding loading 
buffer to a ratio of 1:5 volumes of sample. The gels were placed in an electrophoresis 
apparatus and submerged in electrophoresis buffer (section 2.5). A 20 µg quantity of each 
protein sample was added into each well in a total volume of 20 µL.  A PAGE ruler ™ 
(Fermentas) was added to one well per gel to determine the molecular weight of each protein. 
The apparatus was attached to a power supply and a voltage of 200 V applied. The gels were 
allowed to run until the tracking dye had reached the bottom of the gel, taking approximately 
45 min. The gels were removed from the apparatus and stained using Coomassie stain for 3 h. 
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Finally, the stained gels were de-stained O/N using Coomassie de-stain. The de-stain solution 
was changed 2-3 times (until the background non-specific staining was removed).        
2.12.3 Selection of optimal coating buffers for use with TCB and ABZ in ELISA 
development. 
A number of coating buffers were investigated to determine which buffer best facilitated 
optimum conjugate binding. A 96 well plate (Maxisorp™, Nunc) was coated with varying 
concentrations of TCB-BTG and ABZ-BSA in different buffers as outlined in section 2.5 and 
left O/N at 4°C. The following day, the antigen-coated plate was blocked with a 5 % (w/v) 
milk-PBS solution (200 μL per well) for 1 h at 37°C. A 1/ 100 dilution of the previously 
purified anti-TCB/ABZ was added to each well (100 μL per well) and incubated at 37°C for 1 
h. Following incubation, the plates were washed using PBST (x3) and PBS (x3) to remove 
any unbound pAb. The antigen-pAb complex was detected using 100 μL per well of a 
1/2,000 dilution of a HRP-labelled anti-chicken IgY secondary mAb produced in rabbit. After 
a 1 h incubation at 37°C the plate was washed again with PBST (x3) and PBS (x3) to remove 
any unbound detection antibody. TMB substrate was then added (100 μL per well) and left to 
react for 15 min at R.T.. The reaction was quenched by the addition of 50 μL per well of 10 
% (v/v) HCl, after which the absorbance was determined at 450 nm on a Safire 2 plate reader. 
2.12.4 Checkerboard ELISA of the purified anti-TCB/ABZ pAb antibody.  
A checkerboard ELISA was performed to determine the optimum conjugate coating 
concentration and antibody dilution to be used though-out the assay development. A 96 well 
plate (Maxisorp™, Nunc) was coated with varying concentrations of TCB-BTG and another 
with ABZ-BSA in 1 x TBS (pH 8.0) and left O/N at 4°C. The following day, the antigen-
coated plate was then blocked with a 5 % (w/v) milk-PBS solution (200 μL per well) for 1 h 
at 37°C. Serial dilutions of the purified pAb were made in 0.5 % (w/v) milk in PBST, added 
(100 μL per well) to the corresponding coated/blocked well and incubated at 37°C for 1 h. 
Following incubation, the plates were washed using PBST (x3) and PBS (x3) to remove any 
unbound pAb. The antigen-antibody complex was detected using 100 μL per well of a 
1/2,000 dilution of a HRP-labelled anti-chicken IgY secondary mAb produced in rabbit 
(Sigma #A6154). After a 1 h incubation at 37°C the plate was washed again with PBST (x3) 
and PBS (x3) to remove any unbound detection antibody. TMB substrate was then added 
(100 μL per well) and left to react for 15 min at 37°C. The reaction was quenched by the 
addition of 50 μL per well of 10 % (v/v) HCl, after which the absorbance was determined at 
450 nm on a Safire 2 plate reader. 
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2.12.5 A study of the affect of different solvents used during the extraction of TCB and 
ABZ residues on the pAb anti-TCB/ABZ.  
Most benzimidazoles are not water soluble and are dissolved in solvents such as ethanol and 
methanol. Therefore, before assay development the antibody’s tolerance to solvents such as 
methanol had to be examined. Methanol is generally used as an extraction solvent for ELISA 
because it has less effect on antigen-antibody interactions and HRP activity than other 
solvents. A 96 well plate (Maxisorp™, Nunc) was coated with varying concentrations of 
TCB-BTG and ABZ-BSA in 1 x TBS (pH 8.0) and left O/N at 4°C. The following day, the 
antigen-coated plate was blocked with a 5 % (w/v) milk-PBS solution (200 μL per well) for 1 
h at 37°C. Different concentrations of methanol, ethanol and DMSO were prepared ranging 
from 1-100 %. A 1/1,000 dilution of the antibody was added to each concentration and 100 
µL of the extraction buffer/antibody solution was added to the corresponding wells and 
incubated for 1 h at 37°C. Following incubation, the plates were washed using PBST (x3) and 
PBS (x3) to remove any unbound pAb/buffer The antigen-antibody complex was detected 
using 100 μL per well of a 1/2,000 dilution of an HRP-labelled anti-chicken IgY secondary 
mAb produced in rabbit. After a 1 h incubation at 37°C the plate was washed again with 
PBST (x3) and PBS (x3) to remove any unbound detection antibody. TMB substrate was 
added (100 μL per well) and left to react for 15 min at R.T. The reaction was quenched by the 
addition of 50 μL per well of 10 % (v/v) HCl, after which the absorbance was determined at 
450 nm on a Safire 2 plate reader. 
2.13 Development of an ELISA method for the detection of TCB in spiked milk 
2.13.1 QuEChERs method 
Milk samples (12g) were spiked with free TCB concentrations ranging from 12 μg/mL to 7 
pg/mL. The TCB was extracted from the milk using a slurry containing 
acetonitrile:MgSO4:NaCl (12:4:1 v/w/w) by shaking vigorously by hand for 1 min. The 
samples were centrifuged at 3,500 x g for 10 min at 4
o
C and the supernatants were transferred 
to tubes containing 0.5g of C18 sorbent and 1.5 g MgSO4. Each tube was shaken for 1 min 
and centrifuged at 3,500 x g for 10 min at 4
o
C. Two layers were formed and the upper 
acetonitrile layer (2 mL) was transferred to 2 mL eppendorfs and evaporated to dryness using 
a MiVac Quattro centrifugal concentrator (Mason technologies) at 50
o
C. The extracts were 
reconstituted in 666 µL of DMSO by vortexing for 2 min followed by a brief sonication in a 
sonicator water bath (Mason Technologies) for 10 min. The reconstituted extracts were 
diluted in a 1:1 methanol:water ratio and vortexed for 1 min followed by filtration through a 
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0.22 μm filter. All samples were then further diluted in a ratio of 1: 4 with HBS buffer; pH 
7.4. The anti-TCB pAb was mixed with the milk extracts in a ratio of 1:3 prior to ELISA and 
Biacore™ analysis. (ref) 
2.13.2 Direct centrifugation method 
A 2 mL spiked milk stock solution (10 μg/mL) was prepared and serial dilutions ranging 
from 12 μg/mL to 7 pg/mL were made in organic milk (Organic milk is milk without 
synthetic chemicals, hormones or antibiotics). Each sample was incubated for 30 mins at R.T 
followed by centrifugation at 14,000 rpm at R.T for 30 min. The aqueous phase was gently 
removed using a 200 μl pipette and mixed with a 1/2,560 of anti-TCB pAb in a ratio of 1:1.  
2.13.3 Inhibition ELISA for the detection of TCB in spiked milk samples 
A 96 well plate (Maxisorp™, Nunc) was coated with 1,500 ng/mL TCB-BTG conjugate 
solution (100 μL per well) and incubated O/N at 4°C. On the following day, the antigen-
coated plate was blocked with 200 μL per well with PBS, pH 7.5, containing 5 % (w/v) milk 
marvel and incubated for 1 h at 37°C. The wells were washed once with PBS and 100 μL of 
the extracted TCB samples, pre-mixed with a 1/2,560 anti-TCB pAb, was added to each well 
and incubated for 1 h at 37°C. After incubation the plate was washed 3 times with PBST and 
3 times with PBS. After washing, 100 μL/ well of peroxidase-labelled secondary antibody 
(1/2,000 in PBS containing 0.5 % w/v milk marvel) was added and incubated for 1 h at 37°C. 
Following this, 100 µL per well of TMB was added and incubated for 15 min at R.T. The 
reaction was quenched with 50 µL per well of HCl and the absorbance was then read at 450 
nm on a Safire 2 Tecan plate reader. 
2.14 Development of SPR-based immunoassay using a Biacore™ 3000TM biosensor 
BIAcore™ assay development was carried out on a BIAcore 3000™ instrument using 
carboxymethylated dextran (CM5) sensor chips. The running buffer for all BIAcore™ 
experiments was HBS buffer, pH 7.4, this was was filtered (pore size of 0.45 m) and 
degassed using a filtration apparatus (Millipore sintered glass filtration unit) immediately 
before use. 
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2.14.1 Pre- concentration studies  
Pre-concentration studies were carried out to determine the optimal buffer conditions 
required for maximum binding of the ligand to the un-modified CM5 dextran chip surface. At 
low ionic strength and a pH lower than the iso-electric point of the conjugated-hapten, the 
protein is electrostatically attracted to the negatively charged surface matrix. The TCB-BTG 
conjugate was diluted in 10 mM sodium acetate solution at pHs of 4.0, 4.2, 4.4, 4.6, 4.8 and 
5.0, and injected over a blank surface for 1 minute at a flow rate of 10 µL/min. The pH at 
which the highest binding was observed, was used for TCB-BTG immobilisation. 
 
2.14.2 Immobilisation of TCB-BTG to the CM5 dextran chip surface 
The CM5 dextran surface is a three dimensional surface containing carboxyl groups (COOH) 
attached to the gold surface layer. The surface was activated by injecting a 1:1 mixture of 400 
mM EDC (N-ethyl-N-(dimethyl-aminoprsopyl) carbodiimide hydrochloride) and 100 mM 
NHS (N-hydroxysuccinimide) for 7 minutes at a flow rate of 10 µL/min. Later, TCB-BTG 
(50 μg/mL) conjugate was diluted in the appropriate pH buffer and injected over the activated 
surface for 30 minutes at 10 µL/min. Un-reactive NHS groups were capped by passing 1 M 
ethanolamine hydrochloride, pH 8.5, for 10 minutes at 10 µL/min and non-covalently bound 
proteins removed 
 
2.14.3 Regeneration studies of the TCB-BTG immobilised CM5 chip  
The stability of the immobilised TCB-BTG surface was measured by passing a known 
concentration of antibody over the chip surface, and by regenerating the surface with various 
concentrations of NaOH (10 mM, 20 mM, 50 mM, 100 mM and 200 mM) and HCl  (5 mM, 
10 mM and 20 mM). Glycine (10 mM) at different pH 2.0, 2.5 and 3.0, and NaOH with 0.5 % 
acetonitrile at concentrations of 10 mM, 50 mM, 100 mM and 200 mM were also studied for 
regeneration of the surface. The cycle of regeneration was repeated for approximately 50 
cycles and the binding signal was measured at the end of each regeneration cycle to assess the 
stability and suitability of the immobilised surface for the development of a sensitive and 
reproducible assay. 
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2.14.4 Flow rate, contact time and antibody dilution optimisation.   
The working antibody dilution, contact time and flow rate that was optimum for the 
development of a BIAcore™ inhibition assay was determined. Anti-TCB pAb dilutions were 
prepared (1/10, 1/50, 1/100, 1/125, 1/250, 1/500 and 1/1000) in HBS buffer, pH 7.4, and 
passed over the immobilised flow cell using a range of contact times (1 min, 3 min and 5 
min) and flow rates (10, 20 and 40 μl/min). The combination of dilution, contact time and 
flow rate that yielded a Response Unit (RU) from 100-500 was chosen.  
 
2.14.5 BIAcore™ inhibition buffer curve generation using a TCB-gluteraldehyde linked 
chip.  
PBS containing 50 % (v/v) methanol was spiked with free TCB, concentrations ranging from 
12 ug/mL to 7 pg/mL, and mixed 1:1 with 1/125 dilution of anti-TCB pAb prior to injection 
and placed in the BIAcore™ 3000 auto-sampler and randomly passed over the TCB 
immobilised chip surface (in triplicate) at a flow rate of 10 μl/min for 4 minutes. The surface 
was regenerated with three pulses of 200 mM NaOH at a flow rate of 10 μl/min for 1 min. 
The mean response (RU) was calculated and expressed as a ratio of RU/RU0, where the 
‘spiked’ sample response (RU) was divided by the response obtained from the sample 
containing no free TCB (RU0). A decrease in binding response was observed with increasing 
free TCB concentrations.  
 
2.14.6 BIAcore™ Inhibition milk assay generation using a TCB-gluteraldehyde linked 
chip.  
Milk was spiked with varying concentrations of TCB ranging from 1 µg/mL to 7 pg/mL and 
samples were extracted and prepared as in section 2.13.1. A 1/125 anti-TCB pAb and milk 
extract were mixed in a ratio of 1:3 and incubated for 30 mins at R.T and passed randomly 
over the gluteraldyhyde linked TCB chip at a flow rate of 10 uL /min for 4 min (the 
gluteraldehyde linked chip was donated by Dr. Martin Danaher of Teagasc Ashtown). The 
surface was regenerated using 200 mM NaOH at a flow rate of 10 ul/min for 2 min. Inter-day 
studies were performed for 3 days and the co-efficient of variation and percentage accuracies 
were determined for each concentration from back-calculated concentration values obtained 
from the intra-assay calibration curve.  
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2.15 Development of lateral flow immunoassays for the rapid detection of TCB. 
2.15.1 Optimisation of the anti-TCB IgY concentration for the lateral flow immunoassay 
development.  
Strips of HiFlow Plus (Millipore, HF07504) nitrocellulose membrane was cut to dimensions 
of approximately 5 cm x 1 cm.  TCB-BTG was diluted to a concentration of 1,500 ng/mL in 
spotting buffer and sprayed across the width of the strips approximately 1.5 cm from the 
bottom using the Linomat 5 system (CAMAG) at a flow rate of 400 nL/sec. Anti-MPO 
(control antibody) was diluted to a concentration of 72 μg/mL in spotting buffer and sprayed 
at 3.5 cm up the strip (control line). The membrane was incubated at 37
o
C for 15 min to 
ensure adequate drying of both control and test lines. Following this, each strip was incubated 
for 1 h at 37
o
C in a blocking solution and dried for 5 mins at R.T. Cellulose wicking material 
was attached to the top of each strip and allowed to stand vertically with the bottom of the 
strip touching the surface of a petri dish. Purified anti-TCB pAb was diluted 100, 50, 25 and 
10 µg/mL in running buffer was applied to the strip. All strips were washed with a 200 µL of 
wash buffer. Following this, a 1/2,000 dilution of HRP-labelled anti-chicken antibody in 
running buffer was applied to the strips, and washed with 200 μL of wash buffer followed by 
the addition of 200 µL substrate TMB.  
 
2.15.2 Optimisation of the control line for the lateral flow immunoassay development. 
Strips of HiFlow Plus (Millipore, HF07504) nitrocellulose membrane was cut to dimensions 
of approximately 5 cm x 1 cm. Anti-MPO was diluted in spotting buffer to concentrations 
ranging from 2-600 µg/mL. Half the samples were sprayed across the width of the strips 
approximately 1.5 cm from the bottom, and the other half, 3.5 cm from the bottom of the strip 
using the Linomat 5 system at a flow rate of 400 nL/sec. All membranes were treated as 
described in section 2.15.1  
 
2.15.3 Generation of the competitive lateral flow immunoassay for the detection of TCB in 
spiked PBS and milk samples.  
A strip of HiFlow Plus (Millipore, HF07504) nitrocellulose membrane was cut to dimensions 
of approximately 5 cm x 1 cm. TCB-BTG was diluted to a concentration of 1,500 ng/mL in 
spotting buffer and sprayed across the width of the strips approximately 1.5 cm from the 
bottom using the Linomat 5 system (CAMAG) at a flow rate of 400 nL/sec. Anti-MPO 
(control antibody) was diluted to a concentration of 72 μg/mL in spotting buffer and sprayed 
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at 3.5 cm up the strip (control line). The membrane was incubated at 37
o
C for 15 min to 
ensure adequate drying of both control and test lines. Following this, each strip was incubated 
for 1 h at 37
o
C in a blocking solution and dried for 5 mins at R.T. Cellulose wicking material 
was attached to the top of each strip and allowed to stand vertically with the bottom of the 
strip touching the surface of a petri dish. Samples spiked with TCB (PBS and milk) were 
mixed (ratio 1:1) with 100 µg/mL of anti-TCB IgY. Samples (200 uL) were applied to the 
petri dish and allowed to travel up the length of the nitrocellulose strip via capillary action. 
The nitrocellulose strip was washed with 200 μL of 50 mM sodium phosphate pH 7.5, 
containing 0.05% (v/v) Tween. A 200 µL volume of a 1/2,000 dilution of HRP-labelled anti-
chicken antibody in running buffer was applied to the strip, and washed with 200 μL of wash 
buffer followed by the addition of 200 µL substrate TMB. Blank sample buffer was used as a 
negative control 
2.15.4 Reduction of the GFP using TCEP disulfide reducing gel 
Tris [2-carboxyethyl]phosphine hydrochloride (TCEP)(Thermo scientific, 77712) was used 
for the reduction of the green fluorescent protein’s (GFP) disulphide bonds to allow for the 
conjugation of the hapten to the protein via Sulfo-GMBS chemistry. TCEP is a highly 
effective agent for the reduction of disulfide bonds in proteins and peptides. The TCEP gel 
was washed 3 times with the addition of 300 μL 50 mM PBS, pH 7.5, and 5 mM EDTA. The 
gel matrix was centrifuged at 1,000 x g for 1 min and the supernatant removed. The GFP 
(150 μL) was added to the washed TCEP gel and vortexed for 1 min. The GFP and the TCEP 
were incubated for 1 h at R.T. The sample was centrifuged at 1,000 x g for 1 min. The 
supernatant containing the reduced GFP was removed and stored at 4
o
C.  
2.15.5 Conjugation of TCB to GFP using Sulfo GMBS 
A 50 M excess of Sulfo-GMBS (0.372 mg) was added to 0.525 mg of the hapten TCB and 50 
mM PBS, pH 7.5, was added to a final volume of 1 ml. This reaction was incubated at 4
o
C 
for 4 h. Excess cross-linker was removed by dialysis with 5 L of 50 mM PBS, pH 7.5. 
Following the removal of excess cross-linker, the previously reduced GFP (150 µL) was 
combined with the TCB hapten and the reaction was incubated at 4
o
C O/N.  
2.15.6 GFP lateral flow assay: 
A strip of HiFlow Plus (Millipore, HF07504) nitrocellulose membrane was cut to dimensions 
of approximately 5 cm x 1 cm. Purified anti-TCB pAb was diluted to 100 µg/mL  in spotting 
buffer. The diluted anti-TCB pAb was sprayed across the width of the strip at approximately 
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at 1.5 cm up the strip using the Linomat 5 system at a flow-rate of 400 nL/sec. Anti-GFP 
mAb (control antibody);(Sigma Aldrich, G6539) was diluted to a concentration of 10 μg/mL 
in spotting buffer and sprayed at 3.5 cm up the strip (control line). TCB samples (500, 100, 
50, 25 and 5 ng/mL) and the conjugated TCB-GFP (1/5) were initially prepared in running 
buffer and mixed in a ratio 1:1. Following this, milk was spiked with 500, 100, 50, 25 and 5 
ng/mL of TCB and extracted via QuEChERs method as described in section 2.13.1. The 
conjugated TCB-GFP was diluted 1/5 in running buffer and mixed in a ratio of 1:3 with the 
extracted samples. Cellulose wicking material was attached to the top of each strip and 
allowed to stand vertically with the bottom of the strip touching the surface of a petri dish. A 
200 uL of each sample to be tested was applied to the petri dish and the sample travelled up 
the length of the nitrocellulose strip via capillary action. The strips were then visualised using 
a typhoon 8600 variable mode flourescence imager at excitation and emmission wavelengths 
of 488 nm and 507 nm respectively.  
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Chapter 3 
The generation of an anti-Thiabendazole Fab 
from a monoclonal antibody-secreting 
hybridoma.  
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3.0 Introduction: Murine antibody generation 
Hybridoma technology was first introduced in 1975 by Köhler and Milstein whereby a 
method was described for producing cell lines that secrete a single species of antibody. A 
hybridoma is a cell hybrid that is produced in-vitro by the fusion of a lymphocyte (mouse 
spleenocyte) that produces a specific antibody and a myeloma cell. This hybrid proliferates 
into a clone that produces a continuous supply of monoclonal antibody (Köhler and Milstein, 
1975). This technology has since been applied for the generation of monoclonal antibodies 
(mAb) against a wide variety of targets such as, viruses (Wrammer et al., 2008), bacteria 
(Hearty et al., 2006), and veterinary drug residues. These include the benzimidazoles, 
including albendazole, fenbendazole, oxibendazole and thiabendazole (Bushway et al,. 1995), 
as described in section 1.8.1. 
 
In 1989, Orlandi et al. designed a set of oligonucleotide primers to amplify the cDNA of 
mouse immunoglobulin heavy and light chain variable domains by the Polymerase Chain 
Reaction (PCR). They applied this technique to amplify the variable domains of five 
hybridoma antibodies and to express a mouse-human chimeric antibody that bound to the 
human mammary carcinoma line, MCF-7. They hypothesized that this technique would lead 
to the cloning of antigen-binding specificities directly from immunoglobulin genes, thus 
bypassing hybridoma technology. Ward et al. found that by using PCR they could isolate VH 
domains with good antigen-binding affinities. Diverse libraries of VH genes were cloned from 
murine spleen genomic DNA and expressed and secreted from E. coli and it was suggested 
that the isolation of variable domains may offer an alternative to mAbs and serve as the key 
to building high-affinity human antibodies (Ward et al., 1989). 
 
Marks and co-workers subsequently reported the generation of antibodies via gene 
technology, where variable genes were amplified from hybridomas or B cells, by PCR and 
cloned into expression vectors. Soluble antibody fragments secreted from bacteria were 
screened for binding activities. They revolutionized this approach by successfully displaying 
antibody V domains on the surface of fd bacteriophage. The phage would bind specifically to 
antigen and therefore, could be detected and subsequently isolated (Marks et al., 1990). 
Using this method, McCafferty et al. showed that they could mimic the features of immune 
selection to make human antibodies in bacteria by generating diverse libraries of VH and VL 
by PCR with subsequent expression on the phage surface. Specific antigen-binding phage 
was selected by panning against the target antigen. They established that a single large phage 
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display library could be used to isolate human antibodies against any antigen, thus 
eliminating the requirement of hybridoma technology and immunisation (McCafferty et al., 
1990). These advances in the generation of diverse libraries of variable heavy and light genes 
from genomic DNA and the subsequent expression of these genes on the surface of 
bacteriophage have resulted in an increase in the use of recombinant antibodies for both 
diagnostic and therapeutic purposes (Ward et al., 1989; McCafferty et al., 1990; 
Röthlisberger, Honegger and Pluckthun, 2005).  
 
When generating recombinant antibodies there are many arguments for and against the 
decision to generate a Fab or a scFv library. Hoogenboom suggested that the smaller size of 
the scFv format makes these libraries genetically more stable than Fab libraries 
(Hoogenboom, 2002). However, many scFvs can form dimers and trimers, which may 
complicate selection and characterization. The Fab fragments lack this polymerisation 
tendency and can more easily be incorporated into assays and binding kinetic experiments 
(Hoogenboom, 2002). Studies carried out by Reiter et al. and  Röthlisberger et al.;  indicate 
that some scFv fragments are likely to be less stable than Fab fragments, partly due to the 
lack of intra-molecular disulfide bonds and constant domains and the altered stability of the 
variable domains involved in the antibody construct (Reiter et al., 1994; Röthlisberger, et al.,  
2005). The choice of Fab fragments for use in this study was due primarily to studies 
indicating better performance in biosensor-based assays (Townsend et al., 2006) and their 
increased stability in various matrices which is an important characteristic for environmental 
and veterinary residue diagnostics. 
3.1 Aims  
The aims of the research described in this chapter were: 
a) to construct a recombinant antibody fragment library from an anti-TBZ monoclonal 
antibody-secreting hybridoma cell line received from Dr. David Brandon of the United States 
Department of Agriculture (USDA), 
b) to screen the library against the drug protein carrier conjugate, TBZ-BSA, to isolate an 
antibody specific for TBZ, and  
c) to improve the sensitivity of the antibody by incorporating a double helix (dHLX) gene 
upstream of the anti-His tag and down-stream of the gene III of the pComb3xTT vector thus 
increasing the valency of the antibody. 
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3.2 Results  
3.2 Anti-TBZ antibody-secreting hybridoma cell line screening, purification and 
characterisation.  
3.2.1 Screening of the anti-TBZ antibody-secreting hybridoma cell line, antibody titre and 
isotyping.  
Upon receipt of the anti-TBZ monoclonal antibody-secreting hybridoma cell line stocks were 
cultured, maintained and stored, as described in section 2.8.1. Following the continuous 
culture of the cell line, anti-TBZ monoclonal antibody supernatants were screened for 
binding activity by direct ELISA, as described in section 2.9.13 and represented in the 
schematic in Figure 3.2.1.  
 
 
Figure 3.2.1 Schematic diagram of the direct ELISA format that was used to determine the 
anti-TBZ monoclonal antibody supernatant titre and to screen for positive antibody-
producing clones during the bio-panning process. (1) A 96 well plate was coated with 1 
µg/mL TBZ-BSA conjugate; (2) the plate was ‘blocked’ with a solution of 5 % (w/v) milk 
marvel in PBS. (3) supernatant from the antibody-secreting hybridoma cell line or lysates 
from positive phage-derived clones were added to the plate; (4) the anti-TBZ mAb was 
detected using a horse-radish peroxidase (HRP)-labelled anti-mouse IgG and the recombinant 
phage-derived Fab was detected with a HRP-conjugated anti-HA antibody; (5) TMB HRP-
substrate was added to a 96 well plate and developed at R.T. and the reaction was quenched 
with the addition of 50 µL of 10 % (v/v) HCl.  
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To determine the un-purified anti-TBZ monoclonal antibody titre, a direct ELISA (Figure 
3.2.2) was performed, as described in section 2.9.13. A titre is a  measurement of how much 
antibody is contained in the serum of an antibody-producing animal or in the supernatant of 
an antibody-secreting hybridoma cell line and is expressed as the greatest dilution or 
reciprocal that still gives a positive result. The molarity of the PBS and PBST used for 
dilutions throughout was 10 mM, with a pH of 7.5, unless otherwise stated.  
 
Figure 3.2.2: Plot of the absorbances obtained from the direct ELISA for the titration of the 
anti-TBZ monoclonal antibody supernatant against the conjugate TBZ-BSA and the carrier 
protein BSA. The plate was coated overnight with 1 µg/mL of TBZ-BSA or BSA. The plate 
was subsequently blocked with 5 % (w/v) milk marvel in PBS, and the anti-TBZ supernatant 
was serially diluted 1/10-1/100,000,000 in 0.5 % (w/v) milk marvel PBS. The detection 
antibody used was a HRP-labelled anti-mouse IgG.  
 
 
Titration of the mAb against BSA confirmed that the antibody was specific only for the target 
TBZ as the absorbances recorded were approximately zero. The antibody was also titred 
against uncoated wells and these background absorbance values were subtracted from the 
figures obtained from the coated wells to give the specific binding response. At an antibody 
dilution of 1/10,000,000 against TBZ-BSA there is a significant response thus indicating that 
the mAb titres out at approximately a 1/10,000,000 dilution. Following this initial 
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characterisation, the isotype of the antibody was determined (section 2.8.2) to select the best 
purification strategy, as knowledge of its class and isotype permits selection of the most 
suitable affinity ligand to be applied. The class and subclass of the monoclonal antibodies 
was found to be IgG and IgG1, respectively, and the antibody was found to have kappa light 
chains (Figure 3.2.3). 
 
 
Fig 3.2.3: Picture of the isotyping of the anti-TBZ mAb. Cassette 1 shows that the anti-TBZ 
monoclonal antibody is not of the IgG3, IgM or IgA isotype. Cassette 2 shows the anti-TBZ 
monoclonal antibody to be of the subclass IgG1. Cassette 3 shows anti-TBZ monoclonal 
antibody has kappa chains. 
 
3.2.2 Purification of the anti-TBZ mAb via protein-G affinity chromatography. 
The anti-TBZ mAb was purified using protein-G affinity chromatography (section 2.8.4). The 
purification of the anti-TBZ mAb was confirmed by SDS PAGE (Figure 3.2.4, section 2.9.2).  
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Figure 3.2.4: An SDS-PAGE gel of the purified anti-TBZ monoclonal antibody is shown. The 
gel was stained with Coomassie blue. Lane M (on both sides of the gel), represents the Sigma 
wide standard molecular weight markers; Lane 1 is the ‘flow-through’ diluted 1:20 in PBS; 
Lane 2 is the column wash diluted 1:2 in PBS, and Lane 3 is neat protein-G affinity-purified 
pooled anti-TBZ mAb fraction. The heavy chain and light chains are indicated at 50 kDa and 
25 kDa, respectively.  
3.2.3 Checkerboard ELISA for the optimisation of TBZ-BSA coating concentrations and 
anti-TBZ mAb dilution. 
Following purification of the anti-TBZ mAb, an initial checkerboard ELISA was performed 
to determine the optimal concentration of TBZ-BSA conjugate to use for titre determination 
and further assay development (Figure 3.2.5). 
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Figure 3.2.5: Plot of the absorbances obtained from the checkerboard ELISA for the 
determination of the optimal performance characteristics of the anti-TBZ protein G- purified 
mAb. The ELISA plate was coated with different concentrations of TBZ-BSA (1 µg/mL to 
0.06 µg/mL) in PBS. Wells were subsequently blocked with PBS; containing 5 % (w/v) 
skimmed milk powder. Protein G-purified monoclonal anti-TBZ antibody, serially diluted 
(ranging from 1/10 to 1/100,000,000) in 0.5 % (w/v) milk marvel in PBST, was then added. 
The detection antibody used was a HRP-labelled anti-mouse IgG.  
 
The 250 ng/mL coating concentration of the TBZ-BSA conjugate was chosen as the most 
favourable concentration to give an optimum absorbance of 1 at 450 nm as the responses 
using the two higher concentrations of 1000 and 500 ng/mL, coupled with a high dilution 
factor (1/50,000-1/100,000), were almost identical. The use of a higher concentration of 
antibody would have been wasteful. Wells were also blocked with BSA and the absorbance 
measured was subtracted from the response generated from the absorbance obtained from the 
wells coated with varying concentrations of TBZ-BSA.  
3.2.4 Anti-TBZ mAb competitive assay for the detection of TBZ  
Following this a competitive assay (schematic shown in Figure 3.2.6) was performed to 
establish an IC50 of the purified anti-TBZ mAb (Figure 3.2.7, section 2.9.18). An IC50 (half 
maximal inhibitory concentration) is a measure of the effectiveness of a compound to inhibit a 
biochemical reaction such as antigen/antibody binding. This value can be extrapolated from 
129 
 
an inhibition/competitive curve. In this case the IC50 value refers to the concentration of free 
TBZ required to give 50 % inhibition of the binding of the mAb to the immobilised TBZ-
BSA. 
 
 
Figure 3.2.6: Schematic diagram of competitive ELISA used to screen for positive clones and 
for assay development. (1) a 96 well plate was coated with the TBZ-BSA conjugate; (2) the 
plate is ‘blocked’ with a solution of 5 % (w/v) milk marvel in PBS, pH 7.5; (3) free TBZ was 
added to each well; (4) lysate supernatant containing anti-TBZ Fab, or purified mAb, was 
added to each well; (5) the recombinant phage-derived Fab was detected with a horse-radish 
peroxidase (HRP)-conjugated anti-HA antibody; (6) TMB HRP-substrate was added to a 96 
well plate and developed at R.T. and the reaction was quenched with the addition of 50 µL of 
10 % (v/v) HCl. The absorbance was measured at 450nm. 
. 
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Figure 3.2.7: Normalised plot of the absorbances obtained with the competitive assay using 
protein G-purified anti-TBZ mAb. The plate was coated with 250 ng/mL of TBZ-BSA and 
subsequently blocked with 5 % (w/v) milk marvel in PBS, Free TBZ concentrations (1-
100,000 pg/mL) were prepared in 0.5 % (w/v) milk marvel in PBST -and added to the plate 
followed by a 1/10,000 of anti-TBZ antibody in 0.5 % (w/v) milk marvel in PBST. The 
detection antibody used was a HRP-labelled anti-mouse IgG.  
 
The IC50 of this assay was determined as 50,000 pg/mL using an equation based on the four 
parameter logic fit. The equation is as follows; IC50 = (Absorbance @ Zero drug 
concentration-(Absorbance at zero drug concentration-Absorbance @ maximum drug 
concentration))/2. This antibody can detect TBZ below the required MRL of 100 µg/kg, and, 
thus, there is no requirement for further enhancement. However, the possibility of the 
production of a functional recombinant antibody expressed in bacteria offered a number of 
advantages over the maintenance of a hybridoma cell line. Bacterial stocks may be stored at -
80 indefinitely and can be rapidly thawed and produced in large-scale with the use of 
bioreactors and fermentation procedures. Additionally, their further manipulation at a genetic 
level is feasible with recombinant DNA technology. Advantages of this technology includes, 
(i) antibodies can be produced in bacteria, yeast or plants, and (ii) intrinsic properties such as 
immunogenicity, affinity, specificity and stability of antibodies can be improved by various 
mutagenesis technologies (Pansri et al., 2009). One of the main aims of this research was to 
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generate a recombinant antibody fragment against TBZ and, as a monoclonal antibody-
secreting anti-TBZ hybridoma cell line that had a high affinity to TBZ was readily available, 
it was decided to use this as the functional source of immunoglobulin genes to produce a Fab 
antibody, thus eliminating the requirement of immunisation of an animal. A Fab fragment 
was chosen for construction for several key reasons: 
a)  It was necessary to generate antibodies for a high sensitivity BIAcore™-assay.  
b) A Fab has uniform binding kinetics, is smaller in size than other IgG counterparts and has 
greater stability, thus making it ideal for use in a high sensitivity assay format. 
c) Such a recombinant antibody, as discussed above, has the capacity for re-engineering to 
enhance its specificity or to amplify its selectivity for a broader range of TBZ metabolites. 
3.3 The construction of the anti-TBZ antibody binding fragment (Fab) library. 
The cDNA generated from the RNA extracted from the hybridoma (section 2.8.5) was 
utilized for the initial amplification of the murine variable light (Vλ) and variable heavy (VH) 
chains. The PCR reaction was carried out using the combination primers, described in section 
2.9.1, and the components and reaction programme, outlined in section 2.9.2.  
 
The MSCVK sense primer mixture was combined with a number of MHybJK reverse primers 
to amplify the variable light genes from the cDNA. The variable light sense primers have a 
5´sequence tail that contains the Sfi1 site. This sequence is further recognized by the 
extension primers of the subsequent PCR rounds for the final amplification of the 1,500 bp 
gene product. The reverse primers have human Cκ sequence tails that create the chimeric 
light-chain–pelB fragments. 
 
A mixture of MHyVH sense primers was combined with a mixture of MHyIgGCH1-B 
reverse primers to amplify VH gene segments from cDNA. Each sense primer has a 
5´sequence tail that corresponds to the 3´ end of the pelB leader sequence and is recognized 
by the sense extension primer (leadVH) in the second-round PCR. The reverse primer 
contains a human CH1 sequence tail that is used in the overlap extension PCR to create the 
chimeric heavy chain fragment. All PCR reactions were resolved on a 1 % (w/v) agarose gel 
(Figure 3.3.1). 
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Figure 3.3.1: Amplification of the murine variable light and variable heavy chains using the 
cDNA obtained from the anti-TBZ monoclonal antibody-secreting cell line. Lanes 1 and 6: 1 
Kb Sigma DNA ladder; Lane 2: Vλ chain amplification; Lane 3: VH chain amplification; Lane 
4: negative control and Lane 5: positive control.  
 
There was no amplification for either of the variable chains. The DNA template used for the 
positive control was a previously generated anti-amphetamine Fab fragment prepared ‘in-
house’. 
 
Following this, PCRs were performed varying the concentration of MgCl2 used for the 
amplification of both the variable light and heavy chains. However, there was no 
amplification of either variable chain. In the case of murine genes mouse variable antibody 
regions are generated through somatic DNA recombination. The Vκ  light chain in mice is the 
dominant light chain and is generated by the combination of one of many Vκ genes with four 
Jκ genes (J (joining) genes are the joining segments of polypeptide chains which link the 
variable regions to the constant regions of both the heavy and light chains). The variable 
regions of the heavy chain are formed by the combination of one of several hundred VH genes 
with one of about 30 D (Diversity) segments and one of six JH segments. The cloning of the 
murine antibody repertoire requires many V-specific oligonucleotide primers thus leading to 
a potential loss of diversity and the inability of the some primers to amplify the gene (Barbas 
et al., 2004). Successful amplification of the variable light chains (Figure 3.3.2) was achieved 
using the combination of reverse primers and individual MSCVK primers numbers 2, 3, 4, 5, 
9, 11 and 17. The same approach was used for the amplification of the variable heavy chains 
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(Figure 3.3.3) where successful amplification was accomplished with the MhyVH 8, 9, 10 
and 11 primers.  
 
 
Figure 3.3.2: Optimisation of the variable light kappa chain using one of each forward primer 
from the MSCVK 1-17 primer combination. Lanes 1 and 19: 1 Kb Sigma DNA ladder and 
Lanes 2-18: MSCVK 1-17. Products at 350 bps were successfully amplified using the 
forward primers MSCVK 2, 3, 4, 5, 9, 11 and 17.  
 
 
Figure 3.3.3: Optimisation of the variable heavy chain using one of each forward primer from 
the MhyVH 1-19 primer combination. Lanes 1 and 20: 1 Kb Sigma DNA ladder and Lanes 2-
19; MhyVH 1-19. Products of 350 bps were successfully amplified using primers 8, 9, 10 and 
11. 
 
Subsequently, a 3 x PCR reaction was performed using each primer pair which yielded a 
band using the reaction mix and programme, as described in section 2.9.2. All amplified 
variable light and heavy chains were pooled together, ethanol precipitated and gel-purified.  
The Cκ-pelB leader and CH1 sequences were amplified from pComb3xTT using the reaction 
mix and PCR programme, as described in 2.9.3 and 2.9.4, respectively. The forward primer 
HKC amplified the 5´ region of human Cκ. This is the region used in the overlap extension 
PCR to create the chimeric light chain. The reverse primer Lead B is specific for the 3´end of 
the pelB leader sequence. The forward primer, HIgGCH1-F, for the amplification of the CH1 
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products is specific for the overlap extension that creates the heavy chain Fd region. The 
reverse primer, dpseq, is specific for the decapeptide region of the pComb3xTT. 
A band of the expected size of 400 bp was observed for the Ck-pelB product and the CH1 
product (Figure 3.3.4). A large-scale PCR was carried out for both, and the resulting bands 
were ethanol-precipitated and gel-purified. 
 
 
Figure 3.3.4: Amplification of the Vλ and VH chains (A) and the Ck-pelB and CH1 (B). The 
PCR reactions and programmes are outlined in 2.11.3 and 2.11.5, respectively. Gel (A) Lanes 
1 and 5: 1 Kb Sigma DNA ladder; Lane 2: variable light chain; Lane 3: variable heavy chain 
and lane 4: negative control. Gel (B) Lane 1: constant kappa chain; Lane 2: 1 Kb Sigma 
ladder and Lane 3: constant heavy chain. 
  
Following successful amplification of the variable and constant domains the variable light 
chains were fused with the constant region using PCR to generate the chimeric VL. A 
chimeric heavy chain was similarly constructed. The PCR was carried out, as described in 
section 2.9.6, and the expected band sizes of 800 bp and 750 bp were observed for the 
chimeric light chain and heavy chain, respectively (Figure 3.3.5 (A)). A final PCR was 
performed to combine the chimeric light chain-pelB fragment to the Fd fragment resulting in 
a murine chimeric Fab gene product. This was carried out by splice by overlap extension, as 
described in section 2.9.7. A band at 1,500 bps was observed that corresponds to the correct 
band size for a chimeric Fab gene (Figure 3.3.5 (B)).  
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Figure 3.3.5: Initial overlap of the variable and constant domains (A) and the final splice by 
overlap extension of the chimeric light chains and chimeric heavy chain (B). (A) Lane 1: 
chimeric light chain (800 bp); Lane 2: 1 Kb Sigma DNA ladder and Lane 3: chimeric heavy 
chain (750 bp). (B) Lane 1: 1 Kb Sigma DNA ladder and Lane 2: murine chimeric Fab gene 
product (1,500 bp). 
 
3.4: Transformation and subsequent bio-panning of the anti-TBZ Fab library against 
TBZ-BSA. 
A large-scale (500µl) amplification of the final SOE product was carried out. The PCR 
product was concentrated using ethanol precipitation, quantified using the Nanodrop ND-
1,000 ™ and subsequently cloned into the pComb3xSS vector. The directional cloning was 
performed using Sfi1 and was successfully ligated into the digested pComb vector (section 
2.9.8). The ligation was ethanol-precipitated and transformed into E. coli XL1-Blue electro 
competent cells (section 2.9.9). 
 
The library size obtained was 1.4 x 10
7
. A colony pick PCR was performed, as described in 
section 2.9.10, to ensure that the gene insert was present at 1,500 bps (Figure 3.4.1). The 
transformed library was subjected to three rounds of panning against varying concentrations 
of the TBZ-BSA conjugate immobilised on a solid support (immuno-tube) (section 2.9.12). 
The phage input and output titres of each round of panning are shown in Table 3.4.1. 
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Figure 3.4.1: Colony pick PCR for the amplification of the Fab gene insert from the 
transformed anti-TBZ Fab library. Lanes 1 and 12: 1 Kb Sigma DNA ladder and Lanes 2-11: 
amplification of TBZ Fab gene from 10 different colonies. 
 
Table 3.4.1: The phage input and output titres for all three rounds of bio-panning against 
TBZ-BSA.  
 
Round of bio-
panning 
Colony forming units (CFU) 
 
Input 1 
 
6.3 x 10
11 
Output 1                     7.3 x 10
8 
Input 2 4.4 x 10
12 
Output 2                     5.6 x 10
7 
Input 3 6.4 x 10
12 
Output 3                     6.7 x 10
7 
 
Colonies (96) were selected from each round of panning and cultured overnight in 200 µL of 
media containing 100 µg/mL carbenicillin. All clones were sub-cultured and the expression 
of the Fab was induced with 1 mM IPTG, (section 2.9.1.4). The lysates obtained from the Fab 
clones were used to analyse their specificity to TBZ-BSA immobilised on a microtitre plate 
and for binding to antigen in solution for competitive ELISA (section 2.9.13). A number of 
controls were used in this experiment to ensure all components of the ELISA were 
functioning. 1) wells were coated with TBZ-BSA, subsequently blocked and a 1/20,000 of 
the anti-TBZ mAb was added, followed by the addition of a HRP-labelled anti-mouse IgG to 
ensure the conjugates specificty. 2) wells were coated with an amphetamine conjugate, 
subsequently blocked and a 1/100 dilution of an anti-amphetamine Fab added, followed by 
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the addition of HRP-labelled anti-HA antibody to determine that this antibody was specific 
for the detection of the HA tag from the Fab-secreting clones. (3) All clones were screened 
against BSA (1 µg/mL) to ensure that all positives were not specific to BSA (data not 
shown). Figure 3.4.2 shows the eleven clones that were deemed positive. These clones 
included A1, A10, B11, C9, D7, E6, F2, F5, F9, H1, H4, and H9.  
 
 
Figure 3.4.2: The plot of the absorbances from the positive clones obtained from round one of 
the panning of the anti-TBZ library against TBZ-BSA. Plates were coated with 1 µg/mL of 
TBZ-BSA and subsequently blocked with 5 % (w/v) milk marvel in PBS, Supernatant lysates 
(100 µL) obtained from the growth of each colony (section 2.12) were added to their 
corresponding wells. This was followed by a 1/2,000 dilution of a HRP-labelled anti-HA 
antibody. Any clone that gave an absorbance value of above 0.2 at 450 nm was selected for 
further characterisation. Controls used (1, 2 and 3) were as explained previously to verify the 
conjugate’s (1) and secondary antibody’s (2) specificity. Control 3 was used to determine if 
there was a high level of binding between the Fab-secreting clone and the carrier protein 
BSA.  
 
Overnight cultures were prepared of all 12 clones that had an absorbance above 0.2. These 
were sub-cultured the following day and allowed to grow until the O.D reached 0.6. 
Expression was induced with 1 mM IPTG and grown O/N at 30°C. Lysates were prepared as 
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in section 2.9.14. Each of the Fab-secreting clones was screened by direct ELISA to 
determine their titre against 1 µg/mL of TBZ–BSA immobilised on the surface of the plate 
(Figure 3.4.3).  
 
Figure 3.4.3: Plot of the absorbances obtained from the antibody titres of lysates of 12 
positive clones. TBZ-BSA was coated on the plate which was subsequently blocked with 5 % 
(w/v) milk marvel in PBS. Serial dilutions (1:2) were performed on all antibody lysates and 
100 uL of each dilution was added to the plate. This was followed by a 1/2,000 dilution of a 
HRP-labelled anti-HA secondary antibody. The numbers in the legend correspond to the 
location of each clone on the ELISA plate.  
 
The binding profile of each positive anti-TBZ Fab-secreting clone is illustrated above in 
Figure 3.4.3. During this screening process clones H1 and H4 exhibited low binding to the 
TBZ-BSA conjugate and thus they were discarded. Fresh lysates from the ten remaining 
positive clones were prepared, as lysates stored for longer than 24 hr at 4°C sometimes lose 
their sensitivity. A competitive assay was performed using the freshly prepared lysates and 
serial dilutions of free TBZ. Six of the nine clones showed low levels of displacement by the 
addition of free TBZ (Figure 3.4.4), and, therefore, they were eliminated from further 
characterisation and purification. Three clones (D7, E6 and F2) were selected for further 
study. 
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Figure 3.4.4: Plot of the absorbance’s obtained from the competitive assay for the clones 
secreting anti-TBZ Fab. The plate was coated with 1 µg/mL of TBZ-BSA and subsequently 
blocked with 5 % (w/v) milk marvel in PBS. Serial dilutions of free TBZ were prepared (1-
1,000,000 pg/mL) and added to their corresponding wells followed by a 1/10 dilution of each 
of the antibody lysates. Detection antibody was a HRP-labelled anti-HA antibody 
 
3.5 Purification of the anti-TBZ Fab and the development of a competitve assay for the 
detection of TBZ. 
3.5.1 Purification and antibody titre for the anti-TBZ titre 
The clones that were significantly displaced by the addition of free TCB were D7, E6 and F2. 
The IC50 of the assay from Figure 3.4.4 that incorporated the three clones secreting anti-TBZ 
Fabs was approximately 20,000 pg/mL. These clones were grown on a large-scale, as 
described in section 2.9.14, and subsequently purified via IMAC (section 2.9.15). A problem 
in the large-scale expression of the three clones led to the ineffective purification of F2 and 
D7. However, clone E6 was successfully purified. Following IMAC purification of this anti-
TBZ Fab it was titred against the TBZ-BSA conjugate to determine the working dilution to 
be used for further assays (Figure 3.5.1). 
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Figure 3.5.1: Plot of the titration of the anti-TBZ purified Fab against TBZ-BSA. The ELISA 
plate was coated with 1 µg/mL of TBZ-BSA and subsequently blocked with 5 % (w/v) milk 
marvel in PBS. Dilutions (1/100-1/10,000,000) of the anti-TBZ Fab were prepared in 0.5 % 
(w/v) milk marvel in PBST. The detection antibody was HRP-labelled anti-HA. 
 
3.5.2 Intra and inter-day assays for the anti-TBZ mAb for the detection of TBZ in spiked 
PBS. 
A dilution of 1/1,000 was used for any subsequent assays. When incorporated into a 
competitive assay a 1/500 dilution was mixed with the analyte to give a final working 
dilution of 1/1000 which is the optimum dilution. Inter-day assays were used to evaluate the 
performance of the assay over a period of days. Repeatability (intra-day; Figure 3.5.2)) was 
determined by carrying the assay out three times on the same day using the same batches of 
sample, antibody, analyte and diluents and three replicate measurements of antibody plus 
each free TBZ drug dilution were used. These absorbance values (A) were then divided by 
the absorbance measurement at a zero free drug concentration (A0) to give normalised values 
(A/A0). Using the BIAcore™ evaluation approach based on a 4 parameter best fit equation it 
was possible to calculate the mean, standard deviation, coefficient of variation (CV) and 
percentage accuracies for both the intra and inter-day assays (Tables 3.5.1 and 3.5.2, 
respectively). 
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Figure 3.5.2: Plot of the absorbances obtained from the intra-day competitive assays using the 
anti-TBZ Fab for the detection of free TBZ in PBS. A coating concentration of 1 µg/mL of 
TBZ-BSA, an antibody concentration of 1/1000 and free TBZ dilutions of 2,500-0.041 
ng/mL were used. The detection antibody was HRP-labelled anti-HA. The plotted results 
represent the mean response ± SD of three replicates.  
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Table 3.5.1: Tabulated values for TBZ concentration (pg/ml) of ‘spiked’ PBS, back 
calculated values, and percentage recoveries (% recoveries) obtained for the anti-TBZ 
antibody intra-day assay in ‘spiked’ PBS. Eleven standards were analysed in triplicate three 
times on the same day.  
 
TBZ concentration 
(pg/ml) 
Back calculated 
TBZ concentration 
(pg/mL) 
Percentage 
accuracies 
(%) 
 
250,000 
 
248,500 
 
100 
83,000 67,988 120 
27,700 29,672 93 
9,250 10,065 92 
3,050 3,448 88 
1,020 909 89 
320 295 105 
120 161 74 
40 69 58 
10 14 66 
4 4 88 
 
The inter-assay variation was calculated by performing the assay on five separate occasions. 
The mean, standard deviation, percentage CV’s and back calculated accuracy of all five 
assays were determined and the results are shown in Table 3.5.2. 
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Table 3.5.2: Tabulated values for TBZ concentration (pg/ml) of ‘spiked’ PBS, back 
calculated values, percentage coefficient of variation (% CV) and percentage recoveries (% 
recoveries) obtained for the anti-TBZ Fab antibody inter-day assay in ‘spiked’ PBS. Eleven 
standards were analysed in triplicate on three separate days. 
TBZ concentration 
(pg/ml) 
Back calculated 
TBZ concentration 
(pg/mL) 
Percentage 
accuracies 
(%) 
Coefficients of 
variation (CVs), 
(%) 
 
250,000 
 
245100 
 
98 
 
10 
83,000 72675 91 3 
27,700 28750 103 5 
9,250 9758 105 6 
3,050 3215 105 8 
1,020 1012 99 7 
320 314 98 10 
120 125 104 4 
40 38 95 4 
10 9 90 2 
4 4 100 3 
 
3.5.3 Cross reactivity and limit of detection studies for the anti-TBZ mAb. 
The specificity of the antibody was determined by evaluating its cross-reactivity to the TBZ 
metabolite TBZ-NH2. In some instances cross reactivity with similar compounds indicate that 
the antibody is sufficiently specific, however, when used for the detection of drugs that are 
metabolised a high percentage of cross reactivity to major metabolites may be beneficial. To 
determine the antibodies cross reactivity, the same competitive approach was used, as 
previously described in section 2.9.18, with the free TBZ-NH2 metabolite. This was directly 
compared with the parent molecule as shown in Figure 3.5.3.  
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Figure 3.5.3: Plot of the absorbance’s obtained from the cross-reactivity studies for the anti-
TBZ Fab. Plates were coated overnight with 1 µg/mL TBZ-BSA and subsequently blocked 
with PBS, containing 5 % (w/v) milk marvel. Dilutions of free TBZ and free TBZ-NH2 were 
prepared in PBST containing 5 % (v/v) methanol. The anti-TBZ antibody was diluted 1/1000 
in PBST containing 0.5 % (w/v) milk marvel. The detection antibody used was the HRP-
labelled anti-HA. 
 
The percentage cross reactivity was calculated using the following formula:  
 
100
50
50
2
x
NHTBZIC
TBZIC
 
The IC50 of TBZ and TBZ- NH2 thus have an approximate value of 8 ng/mL for both drugs. 
There indicates almost 100 % cross reactivity of the Fab with TBZ-NH2.  
For the development of an assay for the detection of veterinary residues, two important 
performance characteristics of such confirmatory methods are taken into account,  the 
detection capability (CCβ) and the decision limit (CCα) or the limit of detection (LOD) (Van 
Loco, 2007). The definition of the decision limit (CCα) means the limit at and above which it 
can be concluded with an error probability of α that a sample is non-compliant. According to 
Armbruster and Pry (2008) the LOD is defined as the lowest TBZ concentration, likely to be 
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reliably distinguished from the limit of the blank (LOB) and at which detection is feasible. 
This can be calculated with the formula LOD = LOB + 1.645 (SD of the lowest concentration 
sample) where LOB is the highest analyte concentration expected to be found when replicates 
of blank are tested (Armbruster and Pry, 2008). Detection capability (CCβ) or the Lowest 
Level of Quantification (LLOQ) means the smallest content of the substance that may be 
detected, identified and/or quantified in a sample with an error probability of 5 %. The LOB 
and LOD assays were performed as described in section (2.9.19) The LOD of detection was 
estimated as between 2.5 and 5 ng/mL (µg/kg). The CCβ was established by fortifying 20 
blank samples with 2.5, 5 and 7.5 ng/mL of free TBZ and comparing these to 20 blank 
samples (Figure 3.5.4) and ensuring that they can be detected with 95 % confidence. These 
assays were carried out to fully characterise the assays performance in order to understand its 
capability and limitations, and to ensure that it is ‘fit-for-purpose’.  
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Fig 3.5.4: Graphical representation of the limit of the blank and limit of detection of the anti-
TBZ Fab. The plates were coated with 1 µg/mL of TBZ-BSA overnight and subsequently 
blocked with 5 % (w/v) milk marvel in PBS. PBS containing 5 % (v/v) methanol was 
fortified with 7.5, 5 and 2.5 ng/mL of free TBZ and 50 µL was added to the corresponding 
wells followed by 50 µL of anti-TBZ Fab in 5 % (v/v) methanol. The detection antibody was 
HRP-labelled anti-HA. 
 
3.6 Construction of the modified double helix (dHLX) pComb3xTT Vector  
One of the aims of this research was to generate an ‘in-house’ vector that allowed for the 
rapid enhancement of any recombinant antibody construct using some simple cloning steps. 
The vector was designed to alter the valency of the antibody thus increasing functional 
affinity therefore increasing the sensitivity of the assay to which the antibody is applied. Any 
antibody fragment generated “in-house” could be inserted into the vector via a restriction 
digest, followed by a ligation, and finally transformed, into a bacterial strain of choice. To 
achieve this, the pComb3xTT vector was modified by the insertion of the double helix 
(dHLX) gene. This dHLX domain was amplified from the pAK500 (plasmid vector 
belonging to the Krebber vector series (Krebber et al., 1997) using a set of specifically 
designed primers. The dHLX forward primer acccgtacggacccaaacctagcaccccccct was 
designed to amplify the N-terminus of the dHLX domain for cloning into pComb3xTT via 
the BsiWI site. The dHLX-back primer gcgccgcaccatcatcaccatgttccggacta was designed to 
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amplify the C-terminus of the dHLX domain including the 5 histidines from pAK500 and for 
cloning into pComb3xTT via the BspEI site in pComb3xTT (deleting the HA tag) (see Figure 
3.6.1). 
 
 
 
Figure 3.6.1: Modified pComb3xTT vector. This vector contains two Sfi1 sites that flank 
either sides of the Fab gene region assisting the removal and insertion of other gene 
fragments. The poly His tag was maintained for ease of purification via immobilised metal 
affinity chromatography (IMAC). The HA tag was removed by enzymatic digestion of the 
vector with BsiW1 and BspE1, and replaced by the double helix gene fragment followed by 
the amber stop codon and pIII gene. The origin of replication and the carbenicillin resistance 
gene remained intact.  
 
3.6.1 Modification of the Pcomb 3xTT vector for the insertion of the dHLX gene by PCR. 
The first stage of vector modification was the amplification of the dHLX gene from the 
pAK500 plasmid (Figure 3.6.2 (A)) using a set of designed primers (section 2.10.2). The 200 
bp product was resolved on a 1 % (w/v) agarose gel and subsequently gel purified. In parallel 
to this the anti-TBZ Fab fragment (Figure 3.6.2 (B)) was amplified from the pComb3xSS 
vector using the same PCR reaction, as in section 2.9.12.  
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Figure 3.6.2: Amplification of the dHLX gene (A) by PCR as described in section 2.10.2.1, 
and the Sfi1 digested Fab fragment (B). 
 (A) Lanes 1 and 4: 1 Kb Sigma DNA ladder; Lane 2: 200 bp dHLX gene fragment and lane 
3: negative control where water was used as the template.  
(B) Lane 1: 100 bp Sigma DNA ladder and Lane 2: Sfi1 digested 1,500 bp Fab fragments. 
 
These fragments were gel-purified and digested with the restriction enzyme SfI1 followed by 
an ethanol precipitation and a gel purification (Figure 3.6.3). The Fab fragment was then re-
cloned into the pComb3xTT vector by ligation for further modifications. The ligated vector 
was transformed into XL1 Blue cells. Positive clones were selected via colony pick PCR 
(Figure 3.6.4) and the vector containing the Fab gene was carried forward for the insertion of 
the dHLX gene fragment upstream of the amber stop codon. 
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Figure 3.6.3: Restriction digest of the pComb3xTT vector using the enzyme SfI1 which yields 
a stuffer fragment at ~ 1,800 bp and the vector at 3,600 bp. Lanes 1 and 4: 1 Kb Sigma DNA 
ladder and Lanes 2 and 3: digested pComb vector.  
 
 
Figure 3.6.4: Colony pick PCR for verification that the Fab gene fragment has been 
successfully inserted into the pComb 3xTT vector. Lanes 1 and 10: 1 Kb Sigma DNA ladder 
and Lanes 2-9: PCR amplification of 8 positive colonies selected. 
 
The second stage of modification included the sequential digestion of both the dHLX gene 
and the pComb3xTT vector containing the Fab with the enzymes BsiW1 and BspE1, is shown 
in Figure 3.6.5. This was followed by the ligation of the dHLX gene into the digested vector. 
Positive clones were established by PCR amplification of the dHLX gene from selected 
colonies (Figure 3.6.6). 
 
   
(3) 
   
(4) 
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Figure 3.6.5: Restriction digest of the dHLX gene insert (A) and pComb3xTT (B) with the 
restriction enzymes Bspe1 and Bsw1. Gel (A) Lanes 1 and 3: 1 Kb Sigma DNA ladder and 
Lane 2: 200 bp digested insert. Gel (B) Lanes 1 and 3: 1 Kb Sigma DNA ladder and Lane 2: 
3,600 bp shows the digested vector.  
 
 
Figure 3.6.6: The PCR amplification of the dHLX gene from 4 positive clones. Lane 1: 1 Kb 
Sigma DNA ladder and Lanes 2-5: dHLX positive clones.  
 
3.6.2 Purification of the anti-TBZ dHLX Fab and its implementation into a competitive 
assay for the enhanced detection of TBZ. 
The pComb3xTT now contains the dHLX gene, enhancing the Fab so that the sensitivity and 
affinity was improved. All five clones were purified by affinity chromatography as the poly 
His tag was still intact. Only one Fab-secreting clone was specific to TBZ. This purified 
antibody was titred against the TBZ-BSA conjugate and an optimum dilution of 1/500 
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dilution was established (Figure 3.6.7). This dilution was used in the competitive assay 
format for the detection of TBZ and for the intra and inter-assays to determine reproducibility 
and accuracy (Figures 3.6.8 and Tables 3.6.1 and 3.6.2).   
 
 
Figure 3.6.7: Plot of the absorbance’s obtained from the titre of the purified anti-TBZ Fab 
and anti-TBZ Fab-DHLX The plate was coated with 1 µg/mL of TBZ-BSA overnight and 
subsequently blocked with 5 % (w/v) milk marvel in PBS. The IMAC-purified antibody 
preparation was diluted in PBST containing 0.5 % (w/v) milk marvel. The detection 
antibody used was HRP-labelled anti-HA. 
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Figure 3.6.8: Plot of the intra-day assays for the anti-TBZ dHLX construct. Plates were 
coated with 1 µg/mL of TBZ-BSA overnight and subsequently blocked with 5 % (w/v) milk 
marvel in PBS. Free TBZ dilutions (1µg/mL- 1 pg/mL) were prepared in 5 % (v/v) methanol 
in PBST. The antibody was diluted 1/500 1 % (w/v) milk marvel. 
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Table 3.6.1: Tabulated values for TBZ concentration (pg/ml) of ‘spiked’ PBS, back 
calculated values, and percentage recoveries (% recoveries) obtained for the anti-TBZ dHLX 
Fab antibody intra-day assay in ‘spiked’ PBS. Seven standards were analysed in triplicate, 
three times on the same day. 
TBZ 
concentration 
(pg/mL) 
Back-calculated 
TBZ 
concentrations 
(pg/mL) 
Percentage 
Accuracies (%) 
 
  1,000,000 
 
    989,000 
 
101 
100,000 101,260 99 
10,000 10,765 92 
1,000 989 101 
100 112 89 
10 11 90 
1 1 100 
 
Table 3.6.2: Tabulated values for TBZ concentration (pg/ml) of ‘spiked’ PBS, back 
calculated values, percentage coefficient of variation (% CV) and percentage recoveries (% 
recoveries) obtained for the anti-TBZ dHLX Fab antibody inter-day assay in ‘spiked’ PBS. 
Seven standards were analysed in triplicate over three days. 
TBZ 
concentration 
(pg/mL) 
Back-calculated 
TBZ 
concentrations 
(pg/mL) 
Percentage 
Accuracies (%) 
Coefficients of 
variation (CVs), 
(%) 
 
1,000,000 
 
1,012,602 
 
98 
 
11 
100,000 119,273 83 11 
10,000 99897 100 10 
1,000 1076 93 8 
100 99 101 9 
10 9 101 7 
1 1 100 1 
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The anti-TBZ Fab, the dHLX formatted vector expressing the anti-TBZ Fab,  and the mAb 
were all directly compared via competive ELISA to illustrate the difference in binding 
capabilities to free TBZ between the three (Figure 3.6.9). The IC50 of the anti-TBZ dhlx Fab, 
Fab, and mAb was approximately 800, 1400 and 8000 pg/mL respectively.   
 
 
Figure 3.6.9: Plot of the absorbances obtained from the competitive ELISA for the 
comparison of the anti-TBZ Fab, mAb and dHLX. Plates are coated with 1 µg/mL of TBZ-
BSA overnight and subsequently blocked with 5 % (w/v) milk marvel in PBS, pH 7.5. Free 
TBZ dilutions (1µg/mL- 1 pg/mL) were prepared in 5 % (v/v) methanol in PBS,. Each 
antibody was diluted in 1 % (w/v) milk marvel. The Fab and the dHLX was detected with a 
HRP-labelled anti-His antibody, and the mAb with a HRP-labelled anti-mouse IgG.    
 
To further confirm the bivalency of the dHLX Fab, HPLC was carried out directly comparing 
the Fab and the dHLX Fab using a size exclusion column as outlined in section 2.10.4. A 
calibration curve was prepared using a set of protein standards with given molecular weights 
(670 kDa Thyroglobulin, 150 kDa IgG, 44 kDa Ovalbumin, 17 kDa Myoglobin and 244 
daltons Uridine). The log of these molecular weights were plotted against the retention time 
to give a linear correlation and from this the unknown molecular weights were interpolated 
using Prism™ graphpad software (Figure 3.6.10). The anti-TBZ Fab eluted with a  retention 
time of 15.97 minutes equating in a molecular weight of approximately 64 kDa. The anti-
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TBZ dHLX Fab eluted in two peaks   with retention times of 13.634 and 20.24 correlating  to 
molecular weights of 300 and 57 kDa respectively (Figure 3.6.11).   
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Figure 3.6.10: Calibration curve for the SEC HPLC of the anti-TBZ Fab and dHLX Fab.  The 
log of the molecular weight of each standard was plotted against their corresponding 
retention times. Standards used were 670 kDa Thyroglobulin, 150 kDa IgG, 44 kDa 
Ovalbumin, 17 kDa Myoglobin and 244 daltons Uridine. The unknown samples were 
interpolated using Prism™ Graph pad.  
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Figure 3.6.11: HPLC chromatogram of the purified anti-TBZ Fab and dHLX Fab. The 
molecular weight standards are indicated by the arrows  (670 kDa Thyroglobulin, 150 kDa 
IgG, 44 kDa Ovalbumin, 17 kDa Myoglobin and 244 daltons Uridine). The molecular 
weights of the Fab (63 kDa) and the dHLX with 2 peaks (one at the  57 kDa 300 kDa) are 
highlighted by the red box surrounding the peaks 
 
3.7 Discussion and conclusions. 
In this research a large (1.4 x 10
7
) Fab library was successfully constructed from an anti-TBZ 
hybridoma cell line with some primer optimisation. Following the screening and 
characterisation of the positive clones a highly sensitive Fab was produced and subsequently 
used in the development of an ELISA assay for the detection of TBZ.  Prior to assay 
development the anti-TBZ Fab’s tolerance to solvents was examined. Most benzimidazoles 
are not water soluble and are dissolved in solvents such as ethanol and methanol. Methanol is 
generally used as an extraction solvent for ELISA because it has less effect on antigen-
antibody interactions and HRP activity than other solvents. In this study it was determined 
that methanol at a concentration of 5 % (v/v) was acceptable for the suspension of TBZ and 
had did not affect the antibody’s interaction with the TBZ-BSA conjugate or free TBZ 
binding (results not shown). Limits of the blank were estimated by using blank samples (PBS, 
pH 7.5, 5 % (v/v) MeOH). Following this the LOD was determined by using blank material 
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which was fortified with TBZ at concentrations near the assays limit of detection at 2.5, 5 and 
7.5 ng/mL. The LOD was established using the equation previously discussed. The lowest 
concentration of analyte that was detected 95 % of the time with 95 % confidence was 2.5 
µg/kg (Fig 3.4.5).  
 
According to European legislation (2002/657/EC) the inter-laboratory coefficient of variation 
(CV) for the repeated analysis of a reference or fortified material, under reproducible 
conditions should not exceed 20 % in the case of residues with established MRL’s between 
10 μg/kg–100 μg/kg. For this assay, inter-assay performance was determined on five different 
days, each sample being determined (in triplicate) with different concentration and batches of 
TBZ un-conjugated free drug. The coefficients of variation were established and were within 
regulatory limits with the inter assay ranging from 0.9-9.2 %.  
 
In previous studies monoclonal and polyclonal antibodies have been generated and applied in 
ELISA assays for the detection and quantification of TBZ in different matrices. Brandon et 
al.  (discussed in section 1.18) developed an assay using the anti-TBZ monoclonal antibody 
which had an LOD of 20 µg/kg for TBZ in potatos and apples (Brandon et al., 1993). 
However, as shown in this research, an antibody derivative with an increase in sensitivity five 
times that of the parent monoclonal used in Brandon’s study was generated that has a LOD of 
2.5 µg/kg. This Fab also echibits solvent tolerance with 5 % (v/v) methanol, a property which 
is required for the analysis of hydrophobic compounds. 
 
According to Korpimäki and co-workers, this increase in sensitivity of the Fab fragment is 
unusual in comparison to other antibody formats that have been developed from a 
monoclonal antibody such as scFv and scAb configurations (Korpimäki et al., 2004). 
However, Itoh and colleagues (1999) generated a recombinant Fab fragment against 
pseudouridine and uridine that showed an increase in sensitivity compared to the parental 
monoclonal. They suggested that an increase in sensitivity may be due to the difference in the 
number of antigen binding sites between a Fab fragment and an mAb. Since the Fab fragment 
has only a single antigen binding site, the target antigen can be detected quantitatively. 
However, as the mAb has two antigen binding sites, it is possible for it to react with the 
adsorbed antigen even when one of the antigen binding sites is saturated with free target 
analyte (the antigen to be determined). This may be possible cause for a low sensitivity of a 
mAb-based inhibition ELISA systems (Itoh et al., 1999).  
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When constructing a chimeric Fab library the light chain V regions (both λ and κ) of mice, 
chicken and rabbits are spliced onto a single human Cκ region. This is ostensibly due to the 
dominance of the Vκ in the immunoglobulin repertoires of these animals inferring that Vλ 
clones are likely to be infrequent in resulting immune recombinant antibody libraries (Barbas 
et al., 2001). However, Townsend et al. observed that Fab light chain function and overall 
antibody binding activity were improved by combining the Vλ region (isolated from a murine 
scFv library) with a Cλ region, as opposed to Cκ, implying that the use of a Cλ scaffold in Fab 
library construction improves the isolation of lambda-associated Fabs and there structural 
stability, secretion and overall activity of the final Fab product (Townsend et al., 2006). In 
the research reported in this chapter the same may apply as only the Vκ region was spliced 
onto the Cκ domain thus leading to an increase in the binding activity of the anti-TBZ Fab 
compared to the mAb. 
 
This sensitive anti-TBZ Fab may be used as part of a screening method for the detection of 
TBZ as the assay format is simple, rapid and offers high throughput relative to conventional 
methods used such as LC-MS and HPLC,  
 
This chapter also describes the modification of the pComb vector. Bivalency is an effective 
means for increasing the functional affinity of an antibody to a surface (Pack et al., 1992). 
Pack and Plückthun investigated ways to harvest the gain in avidity by engineering small 
dimerization domains. This allowed the assembly of bivalent “miniantibodies” in the 
periplasm of E.coli based on scFv fragments connected to a hinge peptide and an amphiphatic 
helix (Pack, 1993; Pack and Plückthun, 1992). There are two ways to infer dimerization. Both 
of these designs were evaluated by Pack and Plückthun. The first was the use a four-helix 
bundle designed by Eisenberg and McLachlan. In this approach using naturally occurring 
bundles, the arrangement is anti-parallel and the four helix bundle may be formed by four 
separate molecules, two helix-dimer molecules, or one molecule containing a four helix 
construct (Eisenberg and McLachlan, 1986). The second was the use of a leucine zipper that 
is found as part of a DNA binding domain in various transcription factors. It functions as a 
dimerization domain and its presence generates adhesion forces in parallel alpha helices. One 
leucine zipper consists of multiple leucine residues at seven residue intervals forming an 
amphiphatic alpha helix with a hydrophobic region for dimerization (Pack, 1993). These 
studies showed that homo dimerisation occurred when fusing antibody fragments to the 
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double helix motif resulting in a significantly higher avidity than when fused with the leucine 
zipper (Pack, 1993). 
 
Herein, the double helix gene sequence was amplified from the pAk vector (amino acid 
sequence GELEELLKHLKELLKG-PRK-GELEELLKHLLELLKG). Using the restriction 
enzymes BspE1 and BsiW1 we were able to digest the vector at these restriction sites and slot 
in the dHLX gene region had been amplified from the pAK vector by the use of primers 
designed for the restriction sites and thus ligating them together so that the gene sequence 
reads through. This allows dimerization to occur, assemble in-vivo in E.coli, and secretion 
into the periplasmic space.  
 
The IC50 of the dHLX inter and intra assays show that the engineered Fab can detect TBZ 
concentrations as low as .8 ng/mL, which is an approximate a 2 fold improvement on the 
detection limit of the original Fab. This modified vector has the ability enhance the avidity of 
an antibody construct. This was further confirmed by SEC HPLC where the multitvalency of 
the antibody was shown by the representation of the monomeric Fab at 56 kDa and the 
multivalent dHLX at 300 kDa in Figure 3.6.11. This modified vector system allows for the 
enhancement of avidity for any antibody fragment by simple directional cloning, thus 
improving the antibodies detection capabilities.  
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Chapter 4 
The generation of avian recombinant and 
polyclonal antibodies against Triclabendazole 
and Albendazole. 
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4.0 Introduction: The generation of avian antibodies  
Avian IgY is the major globular protein produced by chickens. It is continually synthesized 
by B cells, secreted into the blood stream and accumulated in the egg yolk (Warr, Magor and 
Higgens, 1995). The IgY of hens provides their progeny with immunity against avian 
pathogens until they have a fully matured immune system. Only three avian immunoglobulin 
subclasses have been identified, IgM, IgA and IgY (Dias da Silva and Tambpurgi, 2010). 
Like IgG, IgY consists of two heavy (65 kDa) and two light (18 kDa) chains. The IgY differs 
in that the heavy chain consists of one variable and four constant domains while the light 
chain is comprised of one variable and one constant region. The Fab region is similar to the 
IgG counterpart, where the Fc portion is responsible for complement activation, opsonisation, 
and mast cell activation. A large amount of IgY is prevalent in the blood (~5 mg/mL), 
however, there is a vast amount contained in the egg yolk (approximately 100-150 mg/yolk) 
(Dong et al., 2008). 
 
 IgY is frequently harvested for use due to advantages such as: (i) the low cost of housing, 
handling and feeding hens, (ii) reduced animal usage as large quantities of eggs can be 
produced on a daily basis for long periods with regular immunisations, (iii) large quantities of 
highly specific IgY are easily collected, (iv) bleeding of the animal is avoided and (v) IgY is 
easily separated and purified from IgA and IgM (Dong et al., 2008; Krief, Letteson and 
Billen, 2002; Tini et al., 2002). Use of intact whole IgY or IgG is advantageous in the field of 
therapeutics as they have a long half-life, the ability to activate complement, and engage Fc 
receptor-mediated effector functions (Schade et al., 2005). However, these Fc receptor 
functions are not required for diagnostic and technical applications as they do not rely on the 
natural effector functions of the antibody. Therefore, antigen binding fragments smaller than 
their IgG/IgY counterparts may be used  (Röthlisberger, Honegger and Pluckthun, 2005). 
 
Phage display technology, as discussed in section 1.9.3, may be applied to the generation of 
avian recombinant antibody fragments. The molecular diversity of the avian species allows 
for the straightforward and relatively successful construction of recombinant libraries 
compared to those from mammals (Andris-Widhopf et al., 2000). The heavy and light chain 
loci in chickens consist of functional variable (V) region genes and joining region (J) and 
multiple diversity (D) segments in the heavy chain genes that are rearranged using standard 
V(D)J recombination’s. To generate a large diverse antibody repertoire, the avian species 
utilises a further type of DNA recombination. Primers are designed that flank the conserved 
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regions around the functional VH and VL chains. These are used to amplify the complete 
range of rearranged variable fragments that facilitate the cloning of highly diverse chicken 
immunoglobulin libraries (Greunke et al., 2008). Avian scFv fragments are often selected for 
the development of recombinant antibody libraries for a number of reasons, (i) they are 
serologically distinct from mammalian immunoglobulins, (ii) the avian antibody repertoire is 
easily and more readily accessed than any other mammals other than the camelids and (iii) 
immunisation of chickens is a convenient way of producing antibodies recognising conserved 
epitopes on mammalian molecules which, because of self-tolerance, are not obtained by 
immunising mice (Davies et al., 1995). Therefore, the choice was made to produce avian 
scFvs against the benzimidazoles TCB and ABZ. 
4.1 Chapter aims:  
The principle aims for the research described in this chapter were:  
a) to produce an avian IgY against the conjugates TCB-BTG and ABZ-HRP,  
b) to generate a validated assay for the detection of TCB and ABZ, and  
c) to construct a recombinant antibody fragment library from the RNA extracted from an 
immunised chicken and to screen the associated library against both TCB and ABZ 
conjugates to isolate specific scFvs. 
4.2 Results  
4.2 Generation of an avian polyclonal antibody against TCB and ABZ 
4.2.1 Serum titres from TCB-BTG and ABZ-HRP immunised chicken 
A serum titre was determined on the chicken following immunisation (section 2.11.1) with 
the TCB-BTG and ABZ-HRP conjugates. Titres of approximately 1/100,000 and 1.1,000,000 
for the immunogens ABZ-HRP (Figure 4.2.1) and TCB-BTG (Figure 4.2.2), respectively, 
were determined indicating that the chicken was ready for removal of the bone marrow and 
spleen for the harvesting of RNA and the further construction of a recombinant antibody 
library.   
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Figure 4.2.1: Avian serum titre plotted against ABZ-BSA. The plate was coated with 1 
µg/mL of ABZ-BSA and the carrier proteins HRP and BSA and subsequently blocked with 5 
% (w/v) milk marvel in PBS. The serum (antibody raised against ABZ-HRP) and the pre-
bleed serum was diluted (1/10-1,000,000) in PBS containing 0.5 % (w/v) milk marvel. The 
detection antibody was AP-labelled anti-chicken IgY.  
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Figure 4.2.2: Avian serum titre plotted against TCB-HRP.  The plate was coated with 1 
µg/mL of TCB-HRP, or the carrier proteins HRP and BTG, and subsequently blocked with 5 
% (w/v) milk marvel in PBS. The serum (antibody raised against TCB-BTG) and the pre-
bleed serum was diluted (1/10-10,000,000) in PBS, pH 7.5, containing 0.5 % (w/v) milk 
marvel. The detection antibody was AP-labelled anti-chicken IgY.  
 
There was a decrease in signal for the high dilutions of serum due to the phenomenon known 
as the Hook or high dose effect. This generates a low apparent response if the 
concentrations/ratios of antigen/antibody are ‘off-scale’. 
 
4.2.2 Purification of anti-TCB/ABZ from egg yolk 
Eggs were collected throughout the immunisation period. The IgY was purified from the egg 
yolk (section 2.12.1) and the purity was confirmed by SDS-PAGE (Figure 4.2.3) (section 
2.12.2). The purified anti-TCB/ABZ polyclonal antibody preparation was used for further 
assay development.  
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Figure 4.2.3: SDS-PAGE gel of the purified anti-TCB/ABZ IgY. Lanes 1 and 5: Fermentas 
Page Ruler™ molecular weight markers; Lane 2: purified anti-TCB/ABZ IgY with bands 
shown at the 72 kDa and 28 kDa; Lane 3: AP-labelled anti-chicken IgY; and lane 4: HRP-
labelled anti-chicken IgY.  
4.3 The development of a competitive ELISA assay using the anti-chicken pAb for the 
detection of TCB and ABZ. 
4.3.1 Optimisation of coating buffers, conjugate and antibody concentrations. 
Prior to assay development coating buffers and concentrations were established to determine 
the lowest concentration of conjugate and the optimal buffer that gave the maximum 
absorbance when using the purified anti-TCB/ABZ pAb at a dilution of 1/100 (section 
2.12.3). The coating buffers used were citrate, pH 4.7, PBS, pH 7.5, TBS, pH 8.0, TBS, pH 
7.4, carbonate, pH 10.3, and sodium acetate, pH 4.8. Plates were coated with dilutions of both 
the ABZ and TCB conjugates ranging between 54-7,000 ng/mL (Figures 4.3.1 and 4.3.2). 
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Figure 4.3.1: Plot of the absorbances obtained from the ELISA for the determination of the 
optimum antigen coating concentration and coating buffer for ABZ-BSA. The plate was 
coated with 54, 109, 218, 875, 1,750, 3,500 and 7,000 ng/mL of ABZ-BSA in the following 
buffers: citrate, pH 4.7; PBS, pH 7.5; TBS, pH 8.0; TBS, pH 7.4; carbonate, pH 10.3, and 
sodium acetate, pH 4.8. A 1/100 dilution of the anti-ABZ pAb was added to each well. The 
detection antibody was HRP-labelled anti-chicken IgY.  
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Figure 4.3.2: Plot of the absorbances obtained from the ELISA for the determination of the 
optimum antigen coating concentration and coating buffer for TCB-BTG. The plate was 
coated with 54, 109, 218, 875, 1,750, 3,500 and 7,000 ng/mL of TCB-BTG in the following 
buffers: citrate pH, 4.7; 1 x PBS, pH 7.5; TBS, pH 8.0; TBS, pH 7.4; carbonate, pH 10.3; and 
sodium acetate, pH 4.8. A 1/100 dilution of the anti-TCB pAb was added to each well. The 
detection antibody was HRP-labelled anti-chicken IgY.  
 
Sub-optimal performance was determined with conjugate diluted in citrate and acetate 
buffers. There was also no significant differentiation in binding between the carbonate, 1 x 
PBS, pH 7.5 and TBS, pH 7.4 and 8.0 buffers when used for the coating of TCB-HRP to the 
plate. However, this antibody was to be used for a multi-analyte detection ELISA and, as 
shown in Figure 4.3.1, the carbonate buffer is not optimal for the coating of ABZ-HRP to the 
plate surface. There was no considerable difference between PBS, pH 7.5, TBS pH 7.4 or 
TBS pH 8.0. However, the buffer chosen was TBS pH 8.0, since in further studies 
implementing these three candidate buffers that there was a slight difference in antibody-
antigen binding performance (results not shown). Following the selection of the optimum 
coating buffer, the optimal concentrations of the conjugate and the antibody were determined 
using a checkerboard ELISA (Figures 4.3.4, 4.3.5 and 4.3.6). The best performing conjugate 
168 
 
and antibody concentration pair while using the lowest concentration of both was selected. 
The values plotted in the following graphs are the absorbance minus the background.  
 
Figure 4.3.3: Plot of the absorbances obtained from the checkerboard ELISA for anti-TCB 
pAb. The plate was coated with TCB-BTG (2,000-100 ng/mL) and subsequently blocked 
with 5 % (w/v) milk marvel in PBS, pH 7.5. Dilutions of the antibody were prepared in the 
following increments 1/20, 1/40, 1/80, 1/100, 1/200, 1/400, 1/800, 1/1,600, 1/3,200, 1/64,000 
and 1/128,000 in 0.5 % (w/v) milk marvel in PBST. The detection antibody was HRP-
labelled anti-chicken IgY.  
 
There was a significant difference shown in absorbance at 450 nm when using a 
concentration of 2,000 or 1,500 ng/mL compared to the lower concentrations. There was no 
apparent dissimilarity between 2,000 and 1,500 ng/mL when coupled with antibody dilutions 
of 1/200, 1/400 and 1/800. However, the antibody dilution and concentration chosen was 
1/200 and 1,500 ng/mL, respectively. This gave an absorbance reading of almost 1 at 450nm.  
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Figure 4.3.4: Plot of the absorbances obtained from the checkerboard ELISA for  anti-ABZ 
pAb. The plate was coated ABZ-BSA (2,000-100 ng/mL) overnight and subsequently 
blocked with 5 % (w/v) milk marvel in PBS, pH 7.5. Dilutions of the antibody were prepared 
in the following increments 1/5, 1/10, 1/20, 1/40, 1/80, 1/100, 1/200, 1/400, 1/800, 1/1,600, 
1/3,200 in 0.5 % (w/v) milk marvel in PBST. The detection antibody used was the anti-
chicken IgY.  
 
There was no substantial difference shown in absorbance at 450 nm when using a 
concentration of 2,000, 1,500, 1,000 and 800 ng/mL. These concentrations gave a high 
absorbance reading of above 2 at 450 nm whereby a reading of 1 is sufficient. There was a 
notable difference between the concentrations 600, 400 and 200 ng/mL when using higher 
dilutions of antibody. However, when using a 1/100 dilution of the antibody the absorbance 
readings are almost identical. The concentration of the ABZ-BSA to be used for further assay 
development was 600 ng/mL as any lower may introduce a variation in concentration as 
pipetting small volumes of conjugate is not always accurate. A 1/100 dilution of the antibody 
was also selected.  
 
4.3.2 Study to demonstrate the affect of various solvents on the anti-TCB/ABZ pAb  
Once these parameters were established the antibody’s stability and specificity in various 
solvents was investigated (Figures 4.3.5-4.3.7). The solvents used for these experiments were 
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methanol (MeOH), ethanol (EtOH) and dimethyl sulphoxide (DMSO). These solvents are the 
most popular routinely used reagents for the extraction of drug residues from meat and milk 
products (Keegan et al., 2009; section 2.11.5).  
 
Figure 4.3.5: Results demonstrating the effect of methanol on the anti-TCB/ABZ pAb. 
Separate plates were coated with 1,500 and 600 ng/mL of TCB-BTG and ABZ-BSA, 
respectively. They were subsequently blocked with 5 % (w/v) milk marvel in PBS, pH 7.5. 
Varying concentrations (0-100 % (v/v)) of methanol were added to the wells followed by a 
1/100 dilution of the anti-TCB/ABZ pAb. The detection antibody was HRP-labelled anti-
chicken IgY.  
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Figure 4.3.6: Results demonstrating the effect of ethanol on the anti-TCB/ABZ pAb. 
Separate plates were coated with 1,500 and 600 ng/mL of TCB-BTG and ABZ-BSA, 
respectively. They were subsequently blocked with 5 % (w/v) milk marvel in PBS, pH 7.5.  
Varying concentrations (0-100 % (v/v)) of ethanol were added to the wells of both plates 
followed by a 1/100 dilution of the anti-TCB/ABZ pAb. The detection antibody was HRP-
labelled anti-chicken IgY.  
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Figure 4.3.7: Results demonstrating the effect of DMSO on the anti-TCB/ABZ pAb. 
Separate plates were coated with 1,500 ng/mL and 600 ng/mL of TCB-BTG and ABZ-BSA 
respectively; and subsequently blocked with 5 % (w/v) milk marvel in PBS, pH 7.5. 
Varying concentrations (0-100 % (v/v)) of DMSO were added to the wells of both plates 
followed by a 1/100 dilution of the anti-TCB/ABZ pAb. The detection antibody was HRP-
labelled anti-chicken IgY. 
 
The studies in Figure 4.3.5-4.3.7 indicate that there is a slight decrease in absorbance when 
comparing the antibodies diluted in PBS with zero % solvent to when they are diluted in 
PBS containing solvent. This shows that the solvent has an affect on the binding of the 
antibody to the immobilised conjugate on the surface of the ELISA plate. However, an 
absorbance of above one is still obtained for the TCB/ABZ pAb binding to the ABZ-BSA 
and TCB-BTG conjugates when diluted in extraction buffers containing up to 60, 50 % 
(v/v) methanol and ethanol respectively. When the anti-TCB/ABZ pAb is diluted in PBS 
containing 30 % (v/v) DMSO this has an affect on the binding of the antibody to the 
conjugate ABZ-BSA shown by a drop in absorbance below one, however, with increasing 
percentage of DMSO (40-60 %) an absorbance of above one is obtained again. With > 70 % 
(v/v) DMSO the absorbance values continue to fluctuate. This pattern indicates that the 
stability of the antibody’s binding to ABZ-BSA in DMSO may be hindered with the 
addition of concentrations above 30 % (v/v) DMSO. The antibody’s binding to TCB-BTG 
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in DMSO decreases with increasing DMSO concentration up to 50 % and further fluctuates 
with the addition of > 60 % (v/v) DMSO.  
4.3.3 Development of anti-TCB/ABZ pAb competitive assays for the detection of   TCB 
and ABZ 
Following this, the assays were performed in 0, 5 and 50 % to determine if the 
concentration of solvent would have any changes in the affinity of the antibody, either 
driving the antibody-antigen reaction towards complex binding or releasing bound antigen 
so that the response is lower. The TCB/ABZ pAb was titred in 5 % (v/v) MeOH, EtOH, 
DMSO and blank PBS (Figure 4.3.8 and 4.3.9). 
 
Figure 4.3.8: Plot of the TCB/ABZ pAb titre in 5 % (v/v) methanol, ethanol or DMSO. 
Plates were coated with 1,500 ng/mL of TCB-BTG overnight and subsequently blocked 
with 5 % milk marvel (w/v) in PBS, pH 7.5. The antibody was serially diluted (1/10-
1/32,000) in PBS, pH 7.5, containing 5 % (v/v) of methanol, ethanol and DMSO. The 
detection antibody was HRP-labelled anti-chicken IgY. The titre was also performed in 
PBS, pH 7.5, to show the lack of affect of the solvents on the antibody binding.  
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Figure 4.3.9: Plot of the TCB/ABZ pAb  titre in 5 % (v/v) methanol, ethanol or DMSO. 
Plates were coated with 600 ng/mL of ABZ-BSA overnight and subsequently blocked with 
5 % milk marvel (w/v) in PBS, pH 7.5. The antibody was serially diluted (1/10-1/32,000) in 
PBS, pH 7.5, containing 5 % (v/v) of methanol, ethanol and DMSO. The detection antibody 
was the HRP-labelled anti-chicken IgY. The titre was also performed in PBS, pH 7.5, to 
show the lack of affect of the solvents on the antibodies binding.  
 
Upon analysis of the titres in figures 4.3.8 and 4.3.9, there appeared to be no significant 
variation of antibody-antigen binding between the three solvents. Therefore, it was decided 
to carry the work forward using only methanol as this is the major reagent used during the 
QuEChers method for the extraction of TCB and ABZ from milk. MeOH does not interfere 
with the antibodies binding to the analyte or HRP.  
 
In addition to this, assays were carried out to examine the competitive nature of the anti-
TBZ/ABZ pAb with free TCB and ABZ (Figure 4.3.10),  
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Figure 4.3.10: Plot of the absorbances obtained from the competitive assay for the detection 
of TCB and ABZ. Separate plates were coated with 1,500 ng/mL and 600 ng/mL of TCB-
BTG and ABZ-BSA respectively overnight and subsequently blocked with 5 % (w/v) milk 
marvel in PBS, pH 7.5. The pAb was diluted 1/2,560 for the TCB assay and 1/100 for the 
ABZ assay in PBS, pH 7.5, containing 1 % (w/v) milk marvel. Free TCB and ABZ were 
serially diluted (1-10,000 ng/mL) in 100 % (v/v) methanol. The detection antibody was HRP-
labelled anti-chicken IgY.  
 
There appeared to be significant displacement with the addition of free TCB with an 
approximate IC50 value of 200 ng/mL, however, there was no notable inhibition with the 
addition of free ABZ (Figure 4.3.10). Following this, competitive assays were performed 
using the free TCB and ABZ  in 5 and 50 % (v/v) methanol in PBS, pH 7.5, (Figure 4.3.11 
and 4.3.12). 
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Figure 4.3.11: Plot of the absorbances obtained from the competitive assay for the detection 
of TCB in 5 and 50 % (v/v) in methanol. The plates were coated with 1,500 ng/mL of TCB-
BTG overnight and subsequently blocked with 5 % (w/v) milk marvel in PBS, pH 7.5, The 
pAb was diluted1/2,560 in PBS, pH 7.5, containing 1 % (w/v) milk marvel. Free TCB and 
ABZ were serially diluted (1-10,000 ng/mL) in 10 and 100 % methanol. The detection 
antibody was HRP-labelled anti-chicken IgY.  
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Fig 4.3.12: Plot of the absorbances obtained from the competitive assay for the detection of 
ABZ in 5 and 50 % (v/v) in methanol. The plates were coated with 600 ng/mL of ABZ-BSA 
overnight and subsequently blocked with 5 % (w/v) milk marvel in PBS, pH 7.5. The pAb 
was diluted 1/100 in PBS, pH 7.5, containing 1 % (w/v) milk marvel. Free ABZ and the 
commercial ABZ endospec were serially diluted (1-10,000 ng/mL) in 10 and 100 % 
methanol. The detection antibody was HRP-labelled anti-chicken IgY.  
 
The IC50 of this TCB assay (Figure 4.3.11) varies between the two solvent concentrations. 
When using 50 % (v/v) methanol it is approximately 1,000 ng/mL, in comparison when using 
5 % (v/v) methanol it is slightly lowered at ~800 ng/mL, thus showing that there is a 
difference in affinity when varying the concentrations of solvent. The same approach was 
adopted with the free ABZ as shown in Figure 4.3.12, where the antibodies binding is 
decreased in 5 % (v/v) methanol. However, there is no significant amount of displacement of 
the antibody with the addition of free ABZ (4.3.12). 
4.3.4 Cross reactivity studies of the anti-TCB/ABZ pAb with various TCB and ABZ 
metabolites. 
The specificity of the antibody was determined by evaluating its cross-reactivity to the both 
the TCB and ABZ metabolites. To determine the antibodies cross reactivity, the competitive 
ELISA method (2.9.18) was used with different batches of TCB (1, 2, 3) and the TCB 
metabolites TCB-SO and TCB-SO2 all in 5 and 50 % (v/v) methanol in PBS, pH 7.5, (Figure 
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4.3.13). The same approach was used for ABZ where different batches of ABZ (1, 2, 3) and 
the metabolites ABZ-NH 2, ABZ-SO and ABZ-SO2 were tested for cross reactivity in both 5 
and 50 % (v/v) methanol in PBS, pH 7.5, (Figure 4.3.14).  
 
 
Figure 4.3.13:  Plot of the absorbances obtained from the cross reactivity assay for the 
detection of TCB in 5 and 50 % (v/v) in methanol. The plates were coated with 1,500 ng/mL 
of TCB-BTG overnight and subsequently blocked with 5 % (w/v) milk marvel in PBS, pH 
7.5. The pAb was diluted 1/2,560 in PBS, pH 7.5, containing 1 % (w/v) milk marvel. Free 
TCB, TCB-SO and TCB-SO2 were serially diluted (1-10,000 ng/mL) in 50 and 5 % (v/v) 
methanol. The detection antibody was HRP-labelled anti-chicken IgY.  
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Figure 4.3.14. Plot of the absorbances obtained from the cross reactivity assay for the 
detection of ABZ in 5 and 50 % (v/v) in methanol. The plates were coated with 600 ng/mL of 
ABZ-BSA overnight and subsequently blocked with 5 % (w/v) milk marvel in PBS, pH 7.5. 
The pAb was diluted 1/250 in PBS, pH 7.5, containing 1 % (w/v) milk marvel. Different 
stocks of free ABZ, ABZ-SO, ABZ-SO2 and ABZ-NH2 were serially diluted (1-10,000 
ng/mL) in 100 and 10 % (v/v) methanol. The detection antibody was HRP-labelled anti-
chicken IgY.  
 
Upon observation of results shown in Figure 4.3.14, the anti-ABZ pAb lacks good 
competitive nature towards free ABZ and its metabolites, consequently it was decided to 
continue the validation with the TCB molecules only.  
4.3.5 Intra and inter-day assays for the anti-TCB pAb for the detection of TCB in spiked 
PBS. 
Inter and intra day assays were performed to ensure reproducibility, precision and accuracy. 
To determine the intra assay variation of the ELISA, three replicate measurements of each of 
the free TCB concentrations were used. These values (A) were again divided by the 
absorbance measurement at the zero free drug concentration (A0) to give normalised values 
(A/A0). From these curves the mean, standard deviation, CV and precision for the inter-assay 
measurements were calculated. The results are shown in Figure 4.3.15 and table 4.3.1. 
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Figure 4.3.15: Intra-day assay calibration curve for the determination of TCB in PBS 
containing 50 % (v/v) MeOH. The competitive assay uses a coating concentration of 1,500 
ng/mL of TCB-BTG, an antibody dilution of 1/2,560 and free TCB dilutions ranging between 
1,000-1 ng/mL. The detection antibody was HRP-labelled anti-chicken IgY. The plotted 
results represent the mean response ± the SD (vertical error bars) of the three replicates of 
each sample during one day.  
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Table 4.3.1: Tabulated values for TCB concentration (pg/ml) of ‘spiked’ PBS, back 
calculated values, and percentage recoveries (% recoveries) obtained for the anti-TCB 
antibody intra-day assay in ‘spiked’ PBS. Ten standards were analysed in triplicate on the 
same day. 
TCB concentration 
(pg/ml) 
Back-calculated 
TCB 
concentration 
(ng/mL) 
Percentage 
accuracies (%) 
 
1,000 
 
1,139 
 
87 
500 521 96 
250 215 116 
125 126 99 
63 68 92 
32 31 100 
16 16 106 
8 6 100 
3 3 100 
1 1 
 
100 
 
 
The inter-assay variation was calculated by performing the assay on five separate occasions. 
All readings were collated together and the mean, standard deviation, percentage CV’s back 
calculated concentrations and percentage accuracies were determined (table 4.3.2). 
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Table 4.3.2: Tabulated values for TCB concentration (pg/ml) of ‘spiked’ PBS, back 
calculated values, percentage coefficient of variation (% CV) and percentage recoveries (% 
recoveries) obtained for the anti-TCB pAb antibody inter-day assay in ‘spiked’ PBS. Ten 
standards were analysed in triplicate on the five separate days. 
TCB concentration 
(pg/ml) 
Back-calculated 
TCB 
concentration 
(ng/mL) 
Percentage 
accuracies (%) 
Coefficients of 
variation (CVs), 
(%) 
 
1,000 
 
1,010 
 
100 
 
19 
500 494 99 12 
250 251 101 9 
125 134 99 11 
63 58 95 10 
32 32 100 5 
16 15 94 5 
8 8 100 2 
3 4 100 5 
1 1 
 
100 12 
 
The inter-day studies show the proposed assay had good precision with CV’s ranging from 19 
% to 2 % between the assay range of 1 ng/mL and 1 pg/mL TCB. The percentage accuracies 
determined in both assays provide an accurate assessment of the measured TCB 
concentrations. Both assays had acceptable concentration values back-calculated from the 
curves. 
 
As discussed in chapter three the LOD is defined as the lowest TCB concentration likely to 
be reliably distinguished from the blank, and at which detection is feasible. This can be 
calculated with the formula LOD = LOB ± 1.645(SD of the lowest concentration sample) 
where LOB is the highest analyte concentration expected to be found when replicates of the 
blank are tested. 
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Figure 4.3.16: Graphical representation of the LOB and LOD of the anti-TCB pAb. The 
plates were coated with 1,500 ng/mL of TCB-BTG overnight and subsequently blocked with 
5 % (w/v) milk marvel in PBS, pH 7.5. PBS, pH 7.5, containing 50 % (v/v) methanol was 
fortified with 50, 100, 150, and 200 ng/mL of free TCB and 50 µL of each were added to the 
corresponding wells followed by 50 µL of a 1/2,500 dilution of anti-TCB pAb in 50 % (v/v) 
methanol. The detection antibody was a HRP-labelled anti-chicken IgY. 
 
The mean and standard deviation of each sample was calculated and from this the LOB was 
established as 1.05 at an absorbance of 450 nm. The mean and standard deviation of the 
samples were calculated and subtracted from the LOB. This gave an LOD absorbance of 
0.749. Reading this from the standard curve generated during the inter and intra day assays 
the “analytical” LOD is approximately 25 ng/mL.  
 
4.3.5 Intra and inter-day assays for the anti-TCB pAv for the detection of TCB-SO and 
TCB-SO2 in spiked PBS. 
Inter and intra assay were also performed for the TCB metabolites TCB-SO and TCB-SO2 in 
PBST containing 50 % (v/v) methanol. Reproducibility and accuracy studies were carried out 
as explained previously for both TCB-SO and TCB-SO2 intra day (Figure 4.3..17 and table 
4.3.3) and inter-day studies (Figure 4.3.18 and table 4.3.4). Additionally, cross reactivity 
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studies were performed and these were established as 100 % and 97.3 % for TCB-SO and 
TCB-SO2 respectively.  
 
 
Figure 4.3.17: Intra-day assay calibration curve for the determination of TCB-SO and TCB-
SO2 in PBS containing 50 % (v/v) MeOH The competitive assay uses a coating concentration 
of 1,500 ng/mL of TCB-BTG, an antibody dilution of 1/2,560 and free TCB dilutions ranging 
between 4,000-3 ng/mL. The detection antibody was HRP-labelled anti-chicken IgY. The 
plotted results represent the mean response ± SD of the three replicates if the fortified 
samples carried out on the same day. 
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Table 4.3.3: Tabulated values for TCB-SO and TCB-SO2 concentration (pg/ml) of ‘spiked’ 
PBS, back calculated values, and percentage recoveries (% recoveries) obtained for the anti-
TCB antibody intra-day assay in ‘spiked’ PBS. Ten standards were analysed in triplicate on 
the same day. 
TCB-SO and SO2 
concentration 
(pg/ml) 
Back-
calculated 
TCB-SO 
concentration 
(pg/mL) 
Percentage 
accuracies 
(%) TCB-
SO 
Back-
calculated 
TCB-SO2 
concentration 
(pg/mL) 
Percentage 
accuracies 
(%) TCB-
SO2 
 
4,000 
 
4,050 
 
99 
 
4,259 
 
94 
2,000 2,125 94 1,809 101 
1,000 1,061 95 1,148 88 
500 489 98 497 100 
250 253 99 242 103 
125 121 103 125 100 
62 64 97 72 86 
31 32 97 32 101 
15 16 94 14 93 
8 
3                          
9 
3 
88 
100 
7 
3.5 
106 
86 
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Figure 4.3.18: Inter-day assay calibration curve for the determination of TCB-SO and TCB-
SO2 in PBS containing 50 % (v/v) MeOH. The competitive assay uses a coating 
concentration of 1,500 ng/mL of TCB-BTG, an antibody dilution of 1/2,560 and free TCB-
SO and TCB-SO2 dilutions ranging between 4,000-3 ng/mL. The detection antibody was 
HRP-labelled anti-chicken IgY. The plotted results represent the mean response ± SD of the 
three replicates if the fortified samples carried out on the same day. 
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Table 4.3.4: Tabulated values for TCB-SO and TCB-SO2 concentration (pg/ml) of ‘spiked’ 
PBS, back calculated values, percentage coefficient of variation (% CV) and percentage 
recoveries (% recoveries) obtained for the anti-TCB pAb antibody inter-day assay in ‘spiked’ 
PBS.. Ten standards were analysed in triplicate over three days.  
 
The competitive assay can detect low levels of TCB-SO and TCB-SO2 (3 pg/mL) with 
acceptable % CV of 2 % and percentage accuracy values of approximately 100 %. The 
percentage accuracies determined in both assay formats provide an accurate assessment of the 
measured TCB-SO and TCB-SO2 concentrations. Both assays had acceptable concentration 
values back-calculated from the curves. 
 
Following the validation of the TCB assay the RNA previously extracted (section 2. 
11.3) was used to construct an avian scFv library. This was panned against both TCB and 
ABZ hapten conjugates to isolate specific clones with high affinity to TCB and ABZ. The 
advantages of this system are discussed in section 4.6. 
4.4 The library construction of the avian anti-TCB/ABZ scFv. 
The cDNA generated from the RNA extracted from the spleen and bone marrow of the 
immunized chicken (section 2.11.3) was utilized for the initial amplification of the avian 
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variable light (Vλ) and variable heavy (VH) chains. The PCR reaction was carried out using 
the primers described in section 2.11.4 and the components and reaction programme outlined 
in sections 2.11.4.1 and 2.11.4.2 respectively.  
 
The short linker primer CSCVHo-F is paired with the CSCG-B reverse primer to amplify VH 
fragments using the cDNA as a template. The sense primers have a sequence tail that is 
compatible to the linker sequence that is used in the overlap extension PCR. The reverse 
primer has a sequence tail containing an SfiI site; this site is recognized by the reverse 
extension primer used in the second-round PCR. 
 
The CSCVK sense primer is combined with the CKJo-B reverse primer to amplify the Vλ 
gene segments and a 5´ sequence tail that contains an SfiI site that is recognized by the sense 
extension primer in the second-round PCR. The reverse primer has a linker sequence tail that 
is used in the overlap extension. 
 
A gradient of MgCl2 was required for the successful amplification of both the variable light 
(350 bp) and heavy chains (400 bp) from both the bone marrow and spleen cDNA (Figures 
4.4.1 and 4.4.2). 
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Figure 4.4.1: Amplification of the variable light and heavy genes from the cDNA generated 
from the TCB/ABZ avian spleen using a MgCl2 gradient ranging from 0-3mM. Lanes 1 and 
6: 1 Kb Sigma DNA ladder; Lane 2 and 7: 0 MgCl2; Lanes 3 and 8: 1 mM MgCl2; Lanes 4 
and 5: 2 mM MgCl2 and lanes 5 and 9: 3 mM MgCl2.  
 
Figure 4.4.2: Amplification of the variable light and heavy genes from the RNA extracted 
from the TCB/ABZ avian bone marrow using 0-3 mM MgCl2 gradient.  Lanes 1 and 6: 1 Kb 
Sigma DNA ladder; Lane 2 and 7: 0 MgCl2; Lanes 3 and 8: 1 mM MgCl2; Lanes 4 and 5: 2 
mM MgCl2 and lanes 5 and 9: 3 mM MgCl2.  
 
 
All PCR products were resolved on a 1 % (w/v) agarose gel and purified (section 2.8.5). 
Following purification the overlap extension PCR was performed as outlined in table 
2.11.5.1. The SOE PCR combines both the VH and VL fragments to construct the final scFv 
fragment. The sense and the reverse primers used (CSC-F and CSC-B) recognize the 
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sequence tails from the first round of amplifications. A MgCl2 gradient was performed for the 
splice by overlap extension for both the spleen and the bone marrow yielding a 750 bp PCR 
product shown in Figure 4.4.3 and 4.4.4 respectively.  
 
 
 
Figure 4.4.3: Final splice by overlap extension (SOE) (750 bp) of the anti-TCB/ABZ scFv 
gene fragment from the avian spleen. Lanes 1 and 8: 1 Kb Sigma DNA ladder; Lane 2: 0 
MgCl2; Lane 3:1 mM MgCl2;  Lane 4: 2 mM MgCl2; Lane 5: 3 mM MgCl2; Lane 6: 4 mM 
MgCl2 and lane 7: 5 mM MgCl2. 
 
 
Figure 4.4.4: Final splice by overlap extension (SOE) (750 bp) of the anti-TCB/ABZ scFv 
gene fragment from avian bone marrow. Lane 1: 1 Kb Sigma DNA ladder; Lane 2: 0 MgCl2; 
Lane 3: 1 mM MgCl2; Lane 4: 2 mM MgCl2; Lane 5: 3 mM MgCl2; Lane 6: 4 mM MgCl2 and 
lane 7: 5 mM MgCl2. 
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Following the successful amplification of the 750 bp fragment, a 5 x reaction of both the 
spleen and bone marrow was performed. All bone marrow products and spleen products were 
pooled and ethanol precipitated. Both products were resolved on a 1 % (w/v) agarose gel and 
purified. The resulting 750 bp for the purified PCR product for the bone marrow is shown in 
Figure 4.4.5. 
 
Figure 4.4.5: Final SOE for the avian scFv from the bone marrow, Lanes 1 and 3: 1 Kb 
Sigma DNA ladder and lane 2: bone marrow scFv fragment 750 bp  
4.5 Transformation and subsequent bio-panning of the anti-TCB/ABZ scFV   library 
against TCB-HRP and ABZ-HRP. 
The PCR product was concentrated by ethanol precipitation (section 2.8.6), quantified using 
the Nanodrop ND-1,000™ and subsequently cloned into the pComb3xSS vector. The 
directional cloning was performed using the restriction enzyme Sfi1 (Figure 4.5.1) and was 
successfully ligated into the digested pComb vector. The ligation was ethanol precipitated 
and transformed into E.coli XL1-Blue electrocompetent cells (see section 2.8.6). 
The library size for bone and spleen was 4.6 x 10
6
 and 6.2 x 10
7 
respectively. A colony pick 
PCR was performed to ensure that the gene insert was present at 750 bps (Figure 4.5.2). The 
transformed library was subjected to 5 rounds of bio-panning against the conjugates TCB-
HRP and ABZ-HRP immobilised to a solid support (immuno-tube). The competitive elution 
strategy was employed (table 2.8.9.1). 
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Figure 4.5.1: Digested 750 bp scFv gene product (A) and the digested pComb3xSS vector at 
3,400 bp (B). Gel (A) Lane 1: 1 Kb Sigma DNA ladder and lanes 2 and 3: 750 bp digested 
PCR product. Gel (B) Lanes 1 and 3: 1 Kb Sigma DNA ladder and lane 2: digested 
pComb3xSS vector.     
 
 
 
Figure 4.5.2: Amplification of the 750 bp gene insert by colony pick PCR for the anti-
TCB/ABZ avian scFv. Lane 1, 9 and 17: 1 Kb Sigma DNA ladder and lanes 2-8: transformed 
scFv gene insert from the bone marrow library and lanes 11-16: transformed scFv gene insert 
from the spleen library. 
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Table 4.5.1: The phage input and output titres for all three rounds of bio-panning against 
TCB-HRP and ABZ-HRP.  
 
Round of 
bio-panning 
Colony forming 
units (CFU) for TCB 
Colony forming 
units (CFU) for 
ABZ 
 
Input 1 
  
5.9 x 10
11 
   
4.6 x 10
11
 
Output 1 7.3 x 10
8 
 2.6 x 10
7 
Input 2  4.4 x 10
12 
  6.2 x 10
11
 
Output 2  1.1 x 10 
8 
 1.8 x 10
7
 
Input 3  6.4 x 10
12 
  5.9 x 10
11
 
Output 3 3.8 x 10
7 
 2.1 x 10
7
 
Input 4 
Output 4 
Input 5 
Output 5 
 3.9 x 10
11 
7.5 x 10
6 
 5.6 x 10
11 
9.4 x 10
7
 
  4.5 x 10
11 
 6.9 x 10
7 
  8.6 x 10
11 
2.3 x 10
7
 
 
Monoclonal phage ELISA’s (Figures 4.5.3-4.5.7) were performed as per section 2.9.1.  Any 
clone that gave an absorbance reading of below 0.2 was regarded as background and were not 
further analysed.  
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Figure 4.5.3: Plot of the absorbances obtained from the monoclonal phage ELISA of the anti-
TCB scFv panned library round 3. The plates were coated with 1 μg/mL of TCB-BTG 
overnight and subsequently blocked with 5 % (w/v) milk marvel in PBS, pH 7.5. The 
individual colony lysates (100 all) were applied to the wells and incubated for 1hr at 37°C. 
The detection antibody was the HRP-labelled anti-HA. 
 
Figure 4.5.4 Plot of the absorbances obtained from the monoclonal phage ELISA of the anti-
TCB scFv panned library round 4. The plates were coated with 1 μg/mL of TCB-BTG 
overnight and subsequently blocked with 5 % (w/v) milk marvel in PBS, pH 7.5. The 
individual colony lysates (100 μL) were applied to the wells and incubated for 1 hr at 37°C. 
The detection antibody was the HRP-labelled anti-HA. 
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Figure 4.5.5: Plot of the absorbances obtained from the monoclonal phage ELISA of the anti-
TCB scFv panned library round 5. The plates were coated with 1 μg/mL of TCB-BTG 
overnight and subsequently blocked with 5 % (w/v) milk marvel in PBS, pH 7.5. The 
individual colony lysates (100 μL) were applied to the wells and incubated for 1 hr at 37°C. 
The detection antibody was the HRP-labelled anti-HA. 
  
 
Figure 4.5.6: Plot of the absorbances obtained from the monoclonal phage ELISA of the anti-
ABZ scFv panned library round 3. The plates were coated with 1 μg/mL of ABZ-BSA 
overnight and subsequently blocked with 5 % (w/v) milk marvel in PBS, pH 7.5. The 
individual colony lysates (100 μL) were applied to the wells and incubated for 1 hr at 37°C. 
The detection antibody was the HRP-labelled anti-HA. 
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Figure 4.5.7: Plot of the absorbances obtained from the monoclonal phage ELISA of the anti-
ABZ scFv panned library round 4. The plates were coated with 1 μg/mL of ABZ-BSA 
overnight and subsequently blocked with 5 % (w/v) milk marvel in PBS, pH 7.5. The 
individual colony lysates (100 μL) were applied to the wells and incubated for 1 hr at 37°C. 
The detection antibody was the HRP-labelled anti-HA. 
 
The clones selected were as follows; TCB round three:  A1, B1, C1, E4, H1, H2; round four; 
A4, C2, H2, H5 and round five: H6. The ABZ positive clones selected were as follows; round 
three: A1, H1 and round four H6, D6. These were amplified using the same PCR conditions 
as the colony pick PCR (Figure 4.5.8). All clones contained the gene of interest. 
 
 
Figure 4.5.8: Gel picture of the gene inserts amplified from the positive clones selected from 
the bio-panning rounds. Lanes 1, 10 and 18: 1 Kb Sigma DNA ladder and lanes 2-9 and 11-
17 are the gene inserts at 750 bp of the positive clones.  
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All positive clones were grown in 5 mL of SB (section 2.4), 100 μg/mL of carbenicillin. 
Following overnight incubation they were sub-cultured and allowed to grow until the O.D. 
reached 0.6. The cultures were induced with 1 mM IPTG and allowed to grow at 30
o
C 
overnight. The resulting lysates were serially diluted and titred against the conjugates TCB-
BTG and ABZ-BSA. There was no colorimetric signal observed on any of the plates. 
Following this observation, two clones TCB-E4 (round 3) and ABZ-D6 (round 4) were 
studied based on their binding profiles (absorbance values of above 0.5 and 0.7 respectively) 
in the initial monoclonal phage ELISA. Expression studies were performed as outlined in 
section 2.11.12. These studies showed that there was no expression at any time point after 
induction (1-6 hr and overnight) or at different temperature (25
o
C or 30°C). It also verified 
the lysis method, either by freeze thaw or sonication does not affect the antibodies binding 
capabilities.   
 
Plasmid preparations (section 2.10.1) of both clones were performed and they were 
transformed into TOP 10F´ and Rosetta cells. The presence of the gene of interest was 
confirmed by a colony pick PCR (Figure.4.5.9). Transformed colonies were selected and 
grown up and analysed as in section 2.11.12. There was no expression observed.  
 
 
Figure 4.5.9: Colony pick PCR for colonies selected from the rosetta strain. Lanes 1 and 17: 1 
Kb Sigma DNA ladder and lanes 2-16: positive gene inserts at 750 bps. 
 
Finally, this library underwent construction twice more, followed by extensive rounds of 
panning. The stringency, elution and panning strategies were varied; however, no clones that 
secreted anti-TCB or anti-ABZ scFv were selected.  
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4.6 Discussion and conclusion.  
The leghorn chicken gave a satisfactory immune response of over 1/100,000, indicating that 
the chicken was producing antibodies against TCB and ABZ. The TCB/ABZ specific IgY 
was purified from the egg yolk (5 mg/mL) and subsequently applied in the development of an 
assay for the detection of TCB and ABZ. Buffers for the optimum coating of the conjugates 
were investigated. TBS pH 8.0 and PBS pH 7.5 were selected for further coating of the 
conjugates. Following this, coating concentrations and optimal antibody dilutions were 
examined and it was found that for the conjugate TCB-BTG a coating concentration of 1,500 
ng/mL and an antibody dilution of 1/2,500 was optimum. In relation to ABZ-BSA, the 
optimum conditions were 600 ng/mL for the coating concentration and the antibody dilution 
was 1/500. The pAb showed stability in PBS, pH 7.5, containing methanol (50 % (v/v)) 
ethanol (60 % (v/v)) and DMSO (~100 % (v/v)). This suggests that the antibody is capable of 
detecting the drug residues when extracted from the samples using these solvents. The Figure 
4.3.13 shows that there is a loss of sensitivity when directly comparing the antibody in 5 and 
50 % (w/v) either by titre or in the competitive assay format.  
 
Using these optimised conditions for the assays the detection ranges of the assay were 
determined. A wide range of free TCB and ABZ concentrations between 3-2,500 ng/mL were 
prepared in PBS containing 50 % (v/v) methanol and assayed within the ELISA test systems. 
The antibody showed competition within this range for TCB, however, there was no 
displacement of the pAb with the free drug ABZ. The ABZ assay development was 
suspended for this reason and the work was carried forward with TCB alone.  
 
The inter–assay precision was determined for TCB on five different days, analysed in 
triplicate with varying concentrations and different batches of free TCB. The reproducibility 
of the assay was proven by the coefficients of variation which are within regulatory limits of 
20 %. The inter assay CVs range from 1.96-19.2 % respectively. At the lowest MRL of 100 
µg/kg for TCB for bovine species the CV’s are calculated as 11.43 % and 2.91 %. The IC50 of 
the assay is 25 ng/mL.  
 
The analytical LOD was calculated by fortifying PBS containing 50 % (v/v) methanol with 
concentrations of free drug 0.5, 1.5, and 2.0 times the concentration of the lowest established 
MRL for TCB. Twenty blank samples of PBS and 50 % (v/v) methanol fortified with free 
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TCB at concentrations of 50,100,150 and 200 ng/mL were analysed and the LOD was 
determined as 25 ng/mL. 
 
The TCB pAb showed high cross reactivity with TCB-SO and TCB-SO2 of 100 and 97 % 
respectively. The reproducibility of the assay was again proven by inter-assay variation and 
the CV %, these ranged between 1.5-5.5 % and 0.12-6.13 % for TCB-SO and for 1- 7.13 % 
for TCB-SO2. The CV’s at the MRL of 100 µg/mL were 5.5 and 6.97 % for TCB-SO for 
TCB-SO2 respectively. These findings for TCB and its metabolites indicate that a robust 
multi-analyte reproducible sensitive assay was developed from an avian IgY and may be 
employed for the detection of free TCB in meat and meat products. 
 
Polyclonal antibodies have definite advantages over monoclonal as they can be generated 
much more rapidly, less expensively and with less technical skill than their recombinant 
counterparts. They are also more stable with regards to conformation as they can withstand 
high salt concentrations and a much broader pH range. However, recombinant antibodies do 
have their advantages, the principal of these being their homogenicity and consistency and 
the fact that they can be generated as a constant and renewable resource. In contrast pAb 
obtained with the same antigen from different animals may have different avidity and the 
quantity of the antibody is limited to the choice of host.  Although pAbs may have better 
specificity as they are produced by a large number of B cell clones each generating antibodies 
to a specific epitope, the concentration and purity levels are higher for monoclonal and 
recombinant antibodies (Lipman, 1998). The main advantage for the generation of 
recombinant fragments is the ability to improve the avidity, affinity and sensitivity of the 
antibody resulting in an antibody with a much greater potential for detecting small drug 
residues at very low levels, much lower than their MRL. Therefore the decision of construct 
of an scFv library was made. 
 
The mRNA extracted from the immunised chicken was used to synthesize cDNA that was 
then utilizes as the starting material for the amplification of the variable chains. Following 
purification, these chains were combined to form the scFv gene fragment. This was digested 
along with the pComb3xSS vector with the restriction enzyme Sfi1 and ligated together. 
Commercial XL1-Blue E.coli cells were used in the library transformation to enhance the 
chances of the ligated plasmid being transformed into the host cell. The library size achieved 
was high. The transformed library was panned against both the TCB-HRP and ABZ-HRP 
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conjugates. The elution methods used were enzymatic (trypsin) and competitive elution using 
the free TCB and ABZ. Varying the conjugate concentration throughout the panning process 
allows for more selective and sensitive scFv fragments to be selected. Eluting by the 
competitive method also allows for the selection of highly specific antibodies.  The outputs 
achieved were high (table 4.5.1) thus indicating that enrichment was occurring throughout the 
process. Colonies were selected for screening from rounds three, four and five against the 
conjugates TCB-BTG and ABZ-BSA. Monoclonal phage Elisa’s were performed and some 
positive colonies that were distinguishable from the back ground and negative control of an 
absorbance of 0.2 were selected for further characterisation. A titre was performed on all of 
the 15 positive clones. However, there was no signal when the antibody was detected with 
TMB. This was repeated and there appeared to be no specificity towards the conjugates or the 
carrier proteins.  
 
To further investigate the clones TCB E4 and ABZ D6 that exhibited a high absorbance in the 
initial monoclonal ELISA expression studies were carried out as in section 2.11.2 yet no 
positive clones were obtained. Su et al. carried out studies on the optimisation of expression 
of an scFv in a number of different E.coli strains. Their scFv was constructed similarly to the 
TCB/ABZ scFv as it was fused to the linked His6 tag (0.66kDa), HA tag (0.99kDa), and pIII 
protein (22.44kDa) at the carboxyl terminal. The translational stop codon (UAG) was placed 
at the junction between the antibody and gIII protein sequences. When they expressed their 
scFv in the amber codon (UAG) suppressor strains ER2537, TG1, and XL1-Blue the stop 
codon suppressor strains do not recognize the stop codon on the transcript and allow the 
scFv-pIII fusion protein to be produced. This scFv-pIII fusion protein is insoluble and tends 
to accumulate in the host cells periplasmic compartment. In these studies it was shown that 
XL1-Blue was the optimal strain for scFv expression along with the aid of glycerol at an 
optimum concentration of 0.05 %. (Su et al., 2003). As this strain was already used and there 
was no expression, plasmid preps were prepared and transformed into the soluble strain TOP 
10F´. This strain has the F trait that is a self-transmissible, low-copy plasmid used for the 
generation of single-stranded DNA when infected with M13 phage; that contains a resistance 
marker to allow maintenance and will often carry the lacI and lacZ∆M15 genotypes.  
 
However, no expression was observed. According to Bukhtiyarova et al., one of the most 
common reasons for poor protein expression of heterologous genes is codon usage bias 
between the expression host and the donor cDNA (avian). The effect of codon 
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incompatibility is especially pronounced in situations when several so-called rare codons 
happen to occur contiguously and close to the amino terminus of the cloned gene. It is 
generally believed that such an event can cause ribosome pausing or frameshifting and, 
possibly, lead to un-coupling transcription from translation and premature termination of the 
product (Bukhtiyarova et al., 2004).  
 
To possibly resolve this problem of expression, plasmid prep’s were prepared and 
transformed into the rosetta cells strain. These cells were selected because they are designed 
to enhance the expression of eukaryotic proteins that contain the 6 rare codons, AUA, AGG, 
AGA, CUA, CCC, GGA d  in E. coli. They also provide universal translation when compared 
to other E.coli. These cells are also derived from a lacZY mutant of BL21 gene that is under 
the control of a T7 promoter to enable precise control of expression levels using IPTG.  
Again all colonies selected from the Rosetta strain for both TCB and ABZ contained the gene 
of interest. These were scaled up to 5 mL culture and induced. There was no expression 
again. These outcomes suggest that the scFv is folded in such a way that maybe the antigen 
sites are inaccessible. It could also be forming aggregates thus reducing its binding capacity. 
Another problem that can occur is that target molecules immobilized on a solid phase 
(immune-tube) by passive adsorption during bio-panning may have epitopes that are hindered 
due to the target molecules themselves or blocking proteins. Since a part of the target 
molecules on the solid phase are denatured by adsorption only a part of the target molecules 
adsorbed on the solid phase are effective for phage binding (Zhuang et al., 2001).  
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Chapter 5 
Development of rapid methods for the 
detection of Triclabendazole 
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5.0 Introduction. 
This chapter gives a detailed account of the development of three methods for the detection 
of triclabendazole (TCB) in milk samples. The research encompassed the development of 
ELISA, BIAcore™-based displacement assays, and lateral flow immunoassays (LFIA) for 
the detection of TCB in milk. Working assays with desired performance characteristics (i.e. 
sensitivity and reproducibility) were validated for both ELISA and BIAcore™.  This chapter 
also describes the fabrication of a novel LFIA using a TCB-GFP conjugate that allows for the 
rapid visualisation and quantification of TCB in milk samples.  
 
5.1 Surface Plasmon resonance.  
Surface Plasmon resonance (SPR) has facilitated the development of a wide range of 
applications for the monitoring of bio-molecular interactions in ‘real-time’.  Consequently 
this has lead to a number of advancements in various research areas such as drug screening, 
antibody development, cell signalling pathways and characterisation of the affinities, kinetics 
and thermodynamics of kinase proteins (Boozer et al., 2006). Surface Plasmon resonance is a 
charge density wave occurring at the interface between a metal and a dielectric (Liedberd et 
al., 1995). When incident light is coupled with the metal interface at angles greater than the 
critical angle, the refracted light exhibits a sharp decrease in reflectivity owing to the resonant 
transfer of energy from the incident light to a surface Plasmon. The incident light wavelength, 
at which this resonance occurs, is dependent on the refractive index in the immediate vicinity 
of the metal surface. The binding of bio-molecules to this surface changes the refractive 
index resulting in a shift in SPR. The change in the SPR signal correlates to the binding of the 
molecules on the surface in ‘real-time’ (see schematic in Figure 5.1.1) (Liedberd et al., 1995). 
This phenomenon is utilised in many biosensor formats, the most prominent of these being 
the Biacore™, which has led to extensive protein-protein interaction studies between 
immobilised bio-molecules and solution-phase analytes (Boozer et al., 2006). 
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Figure 5.1.1: Schematic of the SPR phenomena used by the BIAcore™ system. SPR   occurs 
when surface plasmon waves are excited at a metal/liquid interface. Light is directed at, and 
reflected from, the side of the surface not in contact with sample and SPR causes a reduction 
in the reflected light intensity at a specific combination of angle and wavelength. When 
analyte is passed over the chip surface it binds to the receptor resulting in a change in the 
mass of the surface layer, leading to a shift in the resonance angle (from I to II in the 
diagram). This change in signal is proportional to the amount of ligand bound to the receptor, 
which enables detection of a ligand and determination of the ligand–receptor interaction 
affinities and kinetics (Diagram taken from Thillaivinayagalingam et al., 2010). 
 
The use of SPR to study the interactions between antigens and antibodies offer many 
advantages over current techniques such as ELISA or fluorescence. Firstly, the detection of 
the analyte is ‘label-free’ and direct as the measurements are based on refractive index 
changes. Secondly, measurements can be performed in ‘real-time’ to allow collection of both 
kinetic and thermodynamic data. Lastly, SPR is an adaptable technique that enables the 
detection of a multitude of analytes over a broad range of molecular weights and binding 
affinities (Mc Donnell, 2001).  
 
Using SPR, the Biacore™ system was launched in 1990 by Pharmacia Biosensor (Liedberg et 
al., 1995). This system generally uses a thin gold surface that is chemically altered with 
carboxylated dextran to allow covalent coupling of the ligand, whilst eliminating non-specific 
binding (Lofa and Jonsson, 1990). The Biacore™ also has an integrated liquid handling 
system to transport samples and reagents to the adsorption and detection spot, combining this 
with SPR it enables the quantification of protein-ligand interactions (Sjolander and 
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Urbanicsky, 1991). The binding and dissociation of the analyte to the immobilised ligand is 
followed in ‘real-time’ and presented in a sensogram of response versus time. (Stenberg et 
al., 1991).  
 
Szabo et al. determined a basic experimental protocol for examining the binding interaction 
between two molecules using BIAcore™. This may be condensed down to a four step 
process that briefly includes: 1) immobilization or capture of one of the binding partners; 2) 
injection of the second binding partner and the recording of the ‘real-time’ reaction 
occurring; 3) studies are then performed using varying concentrations of the second binding 
partner, and 4) appropriate kinetic models and rate constants are determined dependant on 
each binding pair (Szabo et al., 1995). This model is utilised across the board for a range of 
applications already highlighted and is also widely used for the development of assays for the 
detection of proteins, veterinary residues and controlled and banned substances within a 
range of matrices.  
 
Although both ELISA and Biacore™ systems are recognized as quick and sensitive 
techniques for the detection of small drug residues, proteins and cancer markers, there is a 
significant increase in the development of other low-cost, rapid, qualitative diagnostic 
methods such as the lateral flow immuno-assay (LFIA). This method is a popular tool for 
diagnostics and identification of various analytes, and is widely applied to the medical arena, 
life science research, water and food monitoring, and illicit drug detection (Qian and Bau, 
2004; Geertruida et al., 2009).  
 
5.2 Lateral Flow Immuno-assays (LFIAs). 
LFIAs are one of the simplest, non-instrument and user-friendly format that produces results 
in a short time. They have vast commercial potential even though they are regarded as semi-
quantitative or qualitative (Li et al., 2009). LFIAs essentially, are prefabricated strips of 
carrier material that contain a dry reagent that is activated when a fluid sample is applied. The 
format of a LFIA is analogous to the ELISA system. However, LFIA may be used on site by 
untrained personnel, for example, for the detection of high levels of progesterone in an 
agricultural environment (Posthuma-trumpie et al., 2009).  
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The principle of an LFIA is the movement of a sample, usually an extract containing the 
analyte of interest, along a porous membrane that consists of immobilized test and control 
ligands at pre-determined locations on the strip (Figure 5.2.1). The membrane is generally 
thin and fragile and is attached to a plastic layer for cutting and handling. LFIAs may be 
constructed from a number of materials including nylon, polyethersulfone and polyethylene 
(Posthuma-Trumpie et al., 2009). However, a more popular choice is the use of nitrocellulose 
(Lonnberg et al., 2001; Zhu et al., 2002; Van dam et al., 2004). The type of membrane is an 
important factor in LFIA development, as it affects the assay sensitivity, specificity and 
consistency (Xiang, 2009). Membranes have different pore sizes and capillary rates, which 
are the most significant factors that can affect the transport of the material up the strip 
(Henderson and Stewart, 2002). The capillary rate is the speed at which the sample moves 
along the strip and, thus, a membrane with a higher capillary rate requires a shorter time to 
complete the assay and vice-versa (Wen et al., 2005). 
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Figure 5.2.1: Schematic diagram of a LFIA device. The sample containing the analyte of 
interest is applied to the sample pad which may contain previously dried proteins, detergents 
and buffer salts. The test line consists of antibody, protein or hapten-conjugate immobilised 
onto the nitrocellulose strip. The control line may be made up of an anti-species enzyme-
labelled antibody to indicate the completion of the assay. The absorbent pad consists of 
material e.g. cellulose filters that are used to wick the fluid through the membrane (Diagram 
taken from Gessler et al., 2007). 
 
The LFIA is designed to detect the presence or absence of an unwanted compound or analyte. 
Antibodies to the analyte are used as recognition elements for the assays. Varying formats are 
used for LFIA depending on the analyte of interest. When the analyte is a small molecule 
such as a hapten, which has only one epitope, the assay configuration is limited to the 
competitive format. However, if the analyte is a larger molecule, with more than one 
available epitope, the sandwich configuration is applied. The competitive assay format has 
two variations; i) the specific antibody is sprayed onto a test line and a mixture of sample 
analyte and labelled analyte is applied. Therefore, both analytes compete for binding to the 
test line (Laitinin, 1996; Ho and Wauchoppe, 2002; Wen et al., 2005), and ii) the hapten-
conjugate is sprayed onto the strip, and a mixture of the antibody and sample analyte is added 
to the conjugate pad (O’Keefe, 2003). In the situation where a labelled antibody is not 
available a secondary antibody may be applied, followed by the addition of substrate for the 
visualisation of the presence/absence of the analyte. The sandwich LFIA is created by 
preparing the test line with an analyte-specific antibody. The conjugate release pad contains a 
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second, labelled, anti-analyte antibody. The analyte in the sample will bind to the second 
antibody during the movement of the liquid up the membrane. 
 
In this research the competitive approach was used for all assay formats due to the small size 
of the TCB hapten.  
 
5.3 Results  
5.3.1 Further development of an ELISA assay for the detection of TCB in spiked milk 
samples. 
In chapter four, the anti-TCB pAb was used for the development of an ELISA assay for the 
detection of TCB in spiked buffer samples with a LOD of 25 ng/mL. The following section 
details the further development of the assay using TCB extracted from spiked organic milk. 
 
Organic milk was spiked with TCB concentrations ranging between 1 μg/mL and 7 pg/mL. 
The TCB residues were extracted from the milk using two different methods, a) direct 
centrifugation (section 2.13.2); and b) a modified QuEChERs method (section 2.13.1) 
(Keegan et al., 2010). Briefly, QuEChERs was a method developed to streamline pesticide 
residue extraction providing analytical chemists with a quick, easy, cheap, effective, rugged 
and safe (QuEChERs) procedure (Wilkowska and Bizuik, 2011). The method includes a 
single phase extraction of sample with acetonitrile followed by liquid-liquid partitioning 
formed by the addition of anhydrous MgSO4 and NaCl. The removal of residual water and 
clean-up are performed simultaneously by using a rapid procedure, called dispersive solid 
phase extraction (dSPE), whereby MgSO4 and a primary amine sorbent (PSA) are mixed with 
the acetonitrile extract. The dSPE combined with the PSA effectively removes any polar 
matrix components such as organic acids, polar pigments and sugars (Anastassiades et al., 
2003).   
 
Following the extraction of TCB from the milk using the QuEChERs and direct 
centrifugation methods, the residues were diluted and mixed with a 1/2,560 dilution of the 
anti-TCB pAb, and used in a competitive ELISA, as described in section 2.13.3.  Both 
methods were directly compared, as shown in Figure 5.3.1. 
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The QuEChERs method was selected for future further extraction of TCB from organic milk 
samples as the graph indicates that this method yields a slightly more robust/effective 
extraction process. Following this the reproducibility and the precision of the assay were 
determined. Intra-day assays were carried out three times (three replicates per assay) on the 
same day using the same batch of extracted residue sample, anti-TCB antibody and diluents. 
Inter-day assays were performed using the same extracted residue sample analysed repeatedly 
over a period of days. The assay precision is represented by the percentage coefficient of 
variation (% CV) which is the standard deviation expressed as a percentage of the mean. 
Figure 5.3.2 represents the anti-TCB intra-day assay and table 5.3.1. contains the inter-assay 
data including percentage CV’s, back calculated concentrations and percentage recoveries. 
The assay was evaluated using BIAevaluation 4.1 software and the data was fitted using a 4 
parameter fit equation. 
 
The LOB of the assay was determined by measuring the mean response of twenty blank 
samples that were extracted, evaporated and reconstituted and mixed with a 1/2,560 dilution 
of anti-TCB pAb. These samples gave an average absorbance of 1.47 and a standard 
deviation of 0.18 at an optical density of 450 nm. Three times the standard deviation was 
subtracted from the average absorbance, and the value was extrapolated from the calibration 
curve to give a LOD of approximately 609 pg/mL.   
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Figure 5.3.1: Comparison of methods for the extraction of TCB from spiked milk samples. 
Plates were coated with 1,500 ng/ml of TCB-BTG overnight and subsequently blocked with 5 
% (w/v) BSA in PBS. Anti-TCB pAb (1/2,560) was mixed with reconstituted extracted TCB 
samples at concentrations ranging from 12,000-7 pg/mL and incubated for 30 min at RT. The 
detection antibody was HRP-labelled anti-chicken IgY. 
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Figure 5.3.2: Inter-day assay curve for the determination of TCB in spiked milk samples. 
Plates were coated with a 1,500 ng/ml of TCB-BTG and subsequently blocked with 5 % 
(w/v) BSA in PBS. Anti-TCB pAb (1/2,560) was mixed with TCB reconstituted extracted 
samples with concentrations ranging from 12,000-7 pg/mL. The detection antibody was 
HRP-labelled anti-chicken IgY. The plotted results represent the mean response ± 1SD of 
three replicates. 
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Table 5.3.1: Tabulated values for TCB concentration (pg/ml) of ‘spiked’ milk samples, back 
calculated values, percentage coefficient of variation (% CV) and percentage recoveries (% 
recoveries) obtained for the anti-TCB pAb antibody inter-day assay in ‘spiked’ milk. Fifteen 
extracted TCB standards ranging between 12,000,000-7pg/mL were analysed in triplicate on 
three separate days. 
TCB concentration 
spiked into organic milk 
(pg/mL) 
Back calculated 
TCB (pg/mL) 
Percentage 
recoveries  
% CV 
12,000,000 11,042,433 108 3 
4,000,000 4,0906,250 97 5 
1,800,000 1,733,562 103 12 
444,000 436,158 101 12 
148,000 140,501 105 1 
48,000 44,502 108 17 
16,000 14,224 112 14 
5,000 5,378 93 2 
1,500 1155 129 12 
609 653 94 12 
203 197 103 12 
63 57 110 14 
21 19.8 106 8 
7 7.67 92 6 
 
5.4 BIAcore™ assay development for the detection of TCB. 
Following the successful anti-TCB ELISA development, a BIAcore™ competitive assay was 
generated for the automated rapid detection of TCB in spiked milk samples.  
5.4.1 Pre-concentration studies for the immobilisation of TCB-BTG to a CM5 dextran chip 
surface.   
Pre-concentration studies allow for the determination of the optimal buffer conditions for 
maximum binding of the ligand to the surface of an un-modified CM5 dextran chip. Briefly, 
under low ionic strength and a pH lower than the isoelectric point of the conjugated hapten, 
the protein will become electrostatically attracted to the surface matrix. The highest pH at 
which the protein is attracted to the surface is the chosen one. Experimentally, the conjugate 
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TCB-BTG was diluted in a 10 mM sodium acetate buffer with the pH ranging from 3.8. to 
5.0. The pre-concentration study was carried out as in section 2.13.4, and is presented in 
Figure 5.4.1. The optimal pH chosen for the immobilisation of TCB-BTG to the chip was 4.0.  
 
 
Figure 5.4.1: Pre-concentration studies for the immobilisation of TCB-BTG to the CM5 
dextran chip surface. TCB-BTG was diluted to a concentration of 50 μg/mL in 10 mM 
sodium acetate solutions of pH 3.8, 4.0, 4.2, 4.4, 4.6, 4.8 and 5.0 and passed over the surface 
of a CM 5 dextran chip at a flow rate of 10 µL/min.  The optimal pH for the immobilisation 
of the TCB-BTG CM5 dextran surface was pH 4.0, as the highest level of apparent binding 
was observed. 
 
5.4.2 Immobilisation of conjugate TCB-BTG to the dextran chip surface. 
The most frequently reported and widespread technique to bind proteins to a BIAcore™ chip 
is amine coupling. This direct coupling method allows for the binding of the protein via 
primary amine groups present in lysine residues, or at the n-terminus of the protein, to the 
chip surface (Thillaivinayagaingham et al., 2010). Immobilisation of the protein is carried out 
in three major steps. The first step is to activate the carboxymethyl groups with N-
hydroxysuccinimide (NHS), thus creating a highly reactive succinimide ester which reacts 
with amine and other nucleophilic groups on proteins. The second, or coupling step, is to 
inject the protein in pre-concentration buffer, thereby achieving high protein concentrations 
214 
 
which drive the coupling reaction. The third and final stage is the blocking step, which blocks 
any remaining activated carboxymethyl groups by passing over the chip, high concentrations 
of ethanolamine. The ethanolamine aids in the elution of any non-covalently bound material 
(Biacore™ sensor handbook, BR-1005-71). The immobilisation of TCB-BTG to the chip is 
described in section 2.13.4 and is shown in Figure 5.4.2. Approximately 12,500 RU was 
immobilised on the dextran surface of flow cell number 2.  
 
Following the successful immobilisation of the conjugate to the chip surface, regeneration 
studies were performed to establish the least harsh conditions to remove any bound antibody 
or sample and return the chip surface back to the baseline. Table 5.4.1 shows a list of 
regeneration solutions and their concentrations. The experiment was carried out as described 
in section 2.13.6 (Results not shown). The regeneration solution selected was 200 mM 
NaOH, at a flow rate of 10 μL/min.  
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Figure 5.4.2: Immobilisation of the TCB-BTG conjugate to the surface of the CM5 dextran 
chip. HBS, pH 7.4, is initially passed over the CM5 chip surface. (I) the surface is the 
activated with a mixture of 0.05 M NHS/ 0.2 M EDC which results in an increase in SPR 
signal due to the bulk refractive index change; (II) a 50 μg/ml TCB-BTG-conjugate solution, 
diluted in sodium acetate buffer, pH 4.0, was passed over the activated surface and (III) NHS-
esters are deactivated by an injection of 1 M ethanolamine, pH 8.5, over the surface.  
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Table 5.4.1: Regeneration solutions and their corresponding concentrations. Each buffer was 
passed over the chip surface at flow rates of 5, 10 and 20 μL/min. 
Solution Concentration 
(mM) 
NaOH 10  
 20 
 50  
 100  
 200 
HCl 5  
 10  
 20 
Glycine, pH 2.0. 10  
Glycine, pH 2.5. 10  
Glycine, pH 3.0. 10  
NaOH with 0.5 %(v/v) 
Acetonitrile 
           10 
 50  
 100  
 200  
 
 
5.4.3 Regeneration of the TCB-BTG CM5 chip surface 
Following the successful immobilisation of the conjugate to the surface and the selection of a 
regeneration solution for the removal of bound material, an experiment was designed (section 
2.13.7) to establish the optimal flow rate, contact time and anti-TCB antibody dilution to be 
used. The highest response (RU) obtained was 150 RU, using a 500 μg/mL anti-TCB 
antibody concentration and flow rate of 40 μl/min for 5 min (results not shown). 
Subsequently a 500 μg/mL anti-TCB antibody dilution was mixed with 1 μg/mL of free TCB, 
in HBS buffer, and passed over the immobilised chip using the optimised conditions.  
However, the antibody failed to be displaced by the addition of free TCB. TCB-BTG was 
immobilised to a new flow cell as the harsh conditions employed during the regeneration 
scouting may have degraded the modified chip surface. After re-immobilisation a 
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significantly low level of antibody binding and displacement by the addition of free TCB was 
observed. Following other immobilisation studies with different TCB conjugates a 
gluteraldehyde-linked TCB chip was donated by Teagasc, Ashtown (immobilisation 
chemistry currently IP protected). This chip was used for all further assay development.  
 
5.4.4 Development of a BIAcore™ inhibition assay for the detection of TCB in spiked PBS.   
Prior to the development of a BIAcore™ assay for the detection of TCB in spiked milk 
samples an antibody titre was performed and a working concentration of 40 μg/mL was 
determined (results not shown). For the generation of standard curves in buffer, samples were 
prepared by spiking PBS containing 50 % (v/v) methanol with concentrations of free TCB 
ranging from 1 μg/mL to 7 pg/mL. Samples were mixed with 40 μg/mL of anti-TCB pAb and 
passed over the TCB-glutaraldehyde-immobilised chip surface at a flow rate of 10 μl/min for 
4 min. The surface was regenerated with 200 mM NaOH (section 2.13.8). Both intra- and 
inter-day assays (Figure 5.4.3) were carried out to determine the reproducibility and precision 
of the assay. The resulting data was plotted using BIAevaluation software (version 4.1) and 
four-parameter equations fitted to each data set for analysis. Table 5.4.2 shows the TCB 
concentration (pg/ml), back calculated values, % CV and percentage recoveries (% recovery) 
for the spiked buffer inter-day BIAcore™ assay.  
 
The LOB of the assay was determined by measuring the mean response of twenty blank 
samples (137.5 RU) (40 μg/mL dilution of anti-TCB pAb and PBS containing 50 % (v/v) 
methanol in PBS) and subtracting three standard deviations (3 x 8.33), to give a response 
reading of 112.75 RU. This value was extrapolated from the calibration curve to give a LOD 
of 4 ng/mL. 
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Figure 5.4.3: BIAcore™ inter-day assay for the detection of TCB residues extracted from 
spiked HBS. Eleven concentrations of TCB (1,000,000-7 pg/mL) were spiked into PBS 
containing 50 % (v/v) methanol, mixed with 40 μg/mL of anti-TCB pAb and passed across 
the TCB-glutaraldehyde-immobilised chip surface. A blank sample of PBS containing 50 % 
(v/v) methanol was also run for subtractive analysis. A 4-parameter equation calibration 
curve of the mean RU values was plotted against the TCB concentrations (pg/mL) on the x-
axis (logarithmic scale) using Biaevaluation software 4.1. 
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Table 5.4.2: Tabulated values for TCB concentration (pg/ml) of ‘spiked’ PBS samples, back 
calculated values, percentage coefficient of variation (% CV) and percentage recoveries (% 
recoveries) obtained for the anti-TCB pAb antibody inter-day assay in ‘spiked’ PBS. Eleven 
extracted TCB standards were diluted in buffer ranging between 1,000,000-7 pg/mL and 
analysed in triplicate on three separate days. 
TCB concentration 
spiked into organic 
milk (pg/mL) 
Back calculated 
TCB (pg/mL) 
Percentage 
recoveries  
% 
% CV 
1,000,000 1,202,171 120 3 
333,000 254,737 76 1 
111,000 107,828 97 2 
37,000 25,278 68 1 
12,000 15,829 128 2 
4,000 4,089 99 1 
1,500 1,659 121 1 
456 502 110 2 
150 181 119 2 
50 70 140 1 
16 11.5 120 2 
 
 
5.4.5 Development of a BIAcore™ assay for the detection of TCB in spiked milk samples. 
Following the successful generation of a spiked buffer assay for the detection of TCB, the 
method was further developed using spiked organic milk samples. The QuEChERs approach 
was again utilised for the extraction of TCB from spiked organic milk and the residues 
prepared as described in section 2.13.1. A BIAcore™ inhibition assay was performed, as 
described in section 2.13.5. The resulting data was plotted using BIAevaluation software 
(version 4.1) and four-parameter equations fitted to each data set for analysis (Figure 5.4.4). 
Table 5.4.3 represents the TCB concentration (pg/ml), back calculated values, % CV and 
percentage recoveries (% recoveries) for the spiked milk inter-day assay. The LOD of the 
assay was calculated, as previously described in section 5.4.4, and extrapolated from the 
curve to give a value of 203 pg/mL.  
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Figure 5.4.4: BIAcore™ inter-day assay for the detection of TCB residues extracted from 
spiked organic milk samples. Eleven concentrations of TCB were spiked into milk 
(12,000,000-7 pg/mL), extracted via the QuEChERs method and mixed with 40 μg/mL of 
anti-TCB pAb and passed across the TCB-glutaraldehyde-immobilised chip surface. A blank 
sample of un-spiked milk was also run for subtraction analysis. A 4-parameter equation 
calibration curve of the mean RU values was plotted against the TCB concentrations (pg/mL) 
on a logarithmic x-axis using Biaevaluation software 4.1. 
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Table 5.4.3: Tabulated values for TCB concentration (pg/ml) of ‘spiked’ milk samples, back 
calculated values, percentage coefficient of variation (% CV) and percentage recoveries (% 
recoveries) obtained for the anti-TCB pAb antibody inter-day assay in ‘spiked’ milk. 
Fourteen extracted TCB standards, 12,000,000-7pg/mL, were analysed in triplicate on three 
separate days. 
TCB concentration in 
spiked milk (pg/mL) 
Back Calculated TCB 
in spiked milk  
(pg/mL) 
Percentage 
recovery (%) 
 
% CV 
12,000,000 11,042,473 109 2 
4,000,000 4,096,250 98 9 
1,800,000 1,733,562 104 9 
444,000 693,516 64 3 
148,000 140,501 105 14 
48,000 44502 108 11 
16,000 155534 103 1 
5,000 5378 93 10 
1,500 1577 95 9 
609 853 71 10 
203 175 106 12 
                    69 57 121 10 
21 22 95 6 
                    7 7.7 91 3 
 
 
5.5 Development of a LFIA for the detection of TCB in spiked milk samples.  
ELISA and BIAcore™ assays have proven to be highly sensitive assay platforms for the 
detection of anti-parasitic drugs. However, because of the long incubation (ELISA), contact 
and run-time (BIAcore™) a LFIA-based method for the rapid detection of TCB was 
developed. Preliminary assays were performed to provisionally determine if the TCB 
metabolite could be detected using the LFIA format.  
A competitive assay format was employed whereby the conjugate, TCB-BTG, was coated as 
the test line on the nitrocellulose strips. Samples were prepared which contained a mixture of 
free TCB and anti-TCB pAb. In the LFIA assay the free TCB will bind to the anti-TCB pAb 
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added to the samples and this in turn will prevent this antibody binding to the test line on the 
strip.  The greater the amount of free TCB in the sample the smaller the amount of antibody 
that can bind to the TCB-BTG conjugate on the test line. i.e. there is an inverse relationship 
of concentration and intensity of signal at the test line. Any antibody binding to the test line 
will be detected using a HRP-labelled anti-chicken antibody following reaction of the HRB 
label with the substrate, TMB. Following the successful optimisation and development of the 
proof-of-concept for the LFIA, TCB was conjugated to Green Fluorescent Protein (GFP) for 
the development of a novel LFIA for the rapid visualisation and quantitation of the TCB 
residues in milk samples.  
5.5.1 LFIA optimisation  
Preliminary experiments were performed to optimise several components of the assay which 
included antigen coating/spotting and sample running buffer (section 2.13.10). Table 5.5.1 
illustrates the combinations of coating and running buffers used for the optimisation of the 
LFIA (results not shown). It was established from these experiments that the most favourable 
conditions for the assay was combination D. A 50 mM sodium phosphate, pH 7.5, buffer was 
used for the washing of the LFIA strip between the application of the sample and HRP-
labelled anti-chicken antibody.  
 
Throughout this LFIA development the control used was an anti-MPO avian scFv that was 
previously generated and purified ‘in-house’. The detection antibody was a HRP-labelled 
anti-chicken antibody (1/1,000 dilution) and the corresponding substrate was TMB, unless 
otherwise stated. Once the optimal coating, running, and wash buffers were established an 
initial experiment was carried out to determine the optimum concentration for the coating of 
TCB-BTG to the nitrocellulose strips (results not shown). Following this, an experiment was 
performed to determine the optimum antibody concentration to be used throughout the assay 
development as described in section 2.15.1. However, as shown in Figure 5.5.1, the control 
line was not as pronounced in comparison to the test line, therefore, further experiments were 
required to determine the optimal concentration of anti-MPO for the control line (2.15.2). 
Ultimately the optimal concentration of anti-MPO scFv that gave a corresponding clear line 
was 72 μg/mL (Figure 5.5.2). Further optimisation was carried out using different 
concentrations of anti-TCB pAb with 100 μg/mL chosen for further development of the 
LFIA.  
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Table 5.5.1: Buffer combinations for the development of the TCB LFIA,  
Combination  Coating  Buffer Sample/Running buffer 
A Borate + (0.1 % (w/v) BSA, 0.05 % 
(v/v) Tween, 0.01 % (v/v) Triton X) 
Borate + (0.05 % (v/v) Tween) 
B Borate + (0.1 % (w/v) BSA, 0.05 % 
(v/v) Tween, 0.01 % (v/v) Triton X) 
50mM sodium phosphate, pH 
7.5, + (0.05 % (v/v) Tween) 
C Borate + (0.1 % (w/v) BSA, 0.05 % 
(v/v) Tween, 0.01 % (v/v) Triton X) 
50mM sodium phosphate, pH 
7.5. 
D 50mM sodium phosphate, pH 7.5. + 
(1 % (w/v) trehalose) 
50mM sodium phosphate, pH 
7.5, + (0.05 % (v/v) Tween) 
E 50mM sodium phosphate, pH 7.5. + 
(1 % (w/v) trehalose) 
50mM sodium phosphate, pH 
7.5. 
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Figure 5.5.1: Developed nitrocellulose membrane strips from the LFIA antibody optimisation 
experiment. Test lines were sprayed on the nitrocellulose strips (1-4) using the conjugate 
TCB-BTG at a concentration of 1,500 ng/mL in coating buffer. A control line, consisting of 
50 µg/mL chicken anti-MPO scFv in coating buffer, was also sprayed on each strip. Antibody 
dilutions were prepared in running buffer at concentrations ranging from 10-100 µg/mL and 
applied to their corresponding strips. A HRP-labelled anti-chicken antibody was used for 
detection. Test lines: Strip 1: 100 μg/mL of anti-TCB IgY; Strip 2: 50 μg/mL of anti-TCB 
IgY; Strip 3: 20 μg/mL of anti-TCB IgY; and Strip 4: 10 μg/mL of anti-TCB IgY. Control 
line: Strips 1-4: 50 μg/mL of anti-MPO scFv. 
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Figure 5.5.2: Developed nitrocellulose membrane strips from the LFIA control line antibody 
coating optimisation experiment. Two control lines were sprayed on the nitrocellulose strips 
(1-7) using different concentrations of chicken anti-MPO scFv ranging from 600-2 µg/mL in 
coating buffer. A HRP-labelled anti-chicken IgY antibody was used for detection. Control 
line 1: Strip 1: 1 µg/mL of anti-MPO; Strip 2: 2 µg/mL of anti-MPO; Strip 3: 4 µg/mL of 
anti-MPO; Strip 4: 8 µg/mL of anti-MPO; Strip 5: 16 µg/mL of anti-MPO; Strip 6: 24 µg/mL 
of anti-MPO; Strip 7: 36 µg/mL of anti-MPO. Control line 2: Strip 1: 72 µg/mL of anti-MPO; 
Strip 2: 142 µg/mL of anti-MPO; Strip 3: 200 µg/mL of anti-MPO; Strip 4: 300 µg/mL of 
anti-MPO; Strip 5: 400 µg/mL of anti-MPO; Strip 6: 500 µg/mL of anti-MPO and Strip 7: 
600 µg/mL of anti-MPO scFv.  
5.5.2 Development of a competitive LFIA for the detection of TCB.  
Following the successful optimisation of the concentrations and dilutions required for the 
control and test lines, the assay was further developed for the detection of TCB in running 
buffer and finally, following extraction, from spiked milk samples. Nitrocellulose strips and 
samples were prepared, and the assay performed, as described in section 2.15.3. It was 
established that TCB can be detected format down to 100 ng/mL of what (Figure 5.5.3), using 
a competitive LFIA Following this confirmation, organic milk (Glenisk) was spiked TCB and 
the residues were extracted, as per the modified QuEChERs method described in section 
2.13.1. The samples were prepared and the LFIA performed, as in section 2.15.3. An inverse 
relationship was observed between the band strength and the concentration of TCB, where a 
clear pattern was evident between the addition of a sample containing a high concentration of 
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TCB and the band intensity. A distinct band was observed for the ‘negative control’ strip, 
where the sample contains no analyte, further validating the sensitivity and specificity of the 
LFIA. This assay has the capability to quantitatively detect TCB residues between 50 and 
100ng/mL, which is below the EU recommended MRL of 100 ng/mL (Figure 5.5.4 and 
5.5.5).  
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Figure 5.5.3: Developed nitrocellulose membrane strips from the LFIA competitive assay for 
the detection of TCB in spiked buffer. Test lines were sprayed on the nitrocellulose strips (1-
6) with a 1,500 ng/mL concentration of the conjugate TCB-BTG in coating buffer. A control 
line, consisting of 72 µg/mL chicken anti-MPO scFv in coating buffer, was also sprayed on 
each strip. All strips were blocked with 50 mM sodium phosphate buffer, pH 7.5, containing 
5 % (w/v) milk marvel. PBS containing 50 % (v/v) methanol was spiked with concentrations 
of TCB ranging from 25-500 ng/mL, mixed with 100 µg/mL of the chicken anti-TCB IgY 
and applied to the bottom of the strip where the sample flowed up via capillary action. A 
HRP-labelled anti-chicken IgY was used for detection. Test lines: Strip 1: sample containing 
500 µg/mL of free TCB; Strip 2: sample containing 250 µg/mL of free TCB; Strip 3: sample 
containing 100 ng/mL of free TCB; Strip 4: Sample containing 50 ng/mL of free TCB; Strip 
4: Sample containing 25 ng/mL of free TCB; Strip 6: Negative control (sample containing no 
TCB). Control line 1-6: 72 μg/mL of the anti-MPO scFv. 
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Figure 5.5.4: Developed nitrocellulose membrane strips from the LFIA competitive assay for 
the detection of TCB in spiked milk. Nitrocellulose strips (1-6) were sprayed at the test line 
with a 1,500 ng/mL concentration of the conjugate TCB-BTG in coating buffer. Each strip 
was also sprayed with a control line consisting of 72 µg/mL anti-MPO scFv in coating buffer. 
All strips were blocked with 50 mM sodium phosphate buffer, pH 7.5, containing 5 % (w/v) 
milk marvel. Milk samples were spiked with concentrations of TCB ranging from 100-1000 
ng/mL and extracted as per the QuEChERs method. The resulting residues were mixed with 
100 µg/mL of the chicken anti-TCB pAb IgY and applied to the bottom of the strip where the 
sample flowed up via capillary action. A HRP-labelled anti-chicken IgY was used for 
detection. Test lines: Strip 1: sample containing 1 µg/mL of free TCB; Strip 2: sample 
containing 500 ng/mL of free TCB; Strip 3: sample containing 250 ng/mL of free TCB; Strip 
4: sample containing 100 ng/mL of free TCB; Strip 5; Negative control (sample containing 
no TCB). Control line: Strips 1-5: 72 μg/mL of the anti-MPO scFv. 
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Figure 5.5.5: Developed nitrocellulose membrane strips from the LFIA competitive assay for 
the detection of TCB in spiked milk. Test lines were sprayed on the nitrocellulose strips (1-5) 
with a 1,500 ng/mL concentration of the conjugate TCB-BTG. A control line, consisting of 
72 µg/mL chicken anti-MPO scFv in coating buffer, was also sprayed on each strip. All strips 
were blocked with 50 mM sodium phosphate buffer, pH 7.5, containing 5 % (w/v) milk 
marvel. Milk samples were spiked with concentrations of TCB ranging from 5-50 ng/mL and 
extracted as per the QuEChERs method. The resulting residues were mixed with a 100 
µg/mL of the chicken anti-TCB pAb IgY and applied to the bottom of the strip where the 
sample flowed up via capillary action. A HRP-labelled anti-chicken IgY was used for 
detection. Test lines: Strip 1: sample containing 50 ng/mL of free TCB; Strip 2: sample 
containing 25 ng/mL of free TCB; Strip 3: sample containing 5 ng/mL of free TCB; Strip 4: 
Negative control (sample containing no TCB). Control line: Strips 1-5: 72 μg/mL of the anti-
MPO scFv. 
 
5.6 Development of a LFIA incorporating the conjugate TCB-BTG.  
Following the successful development of a LFIA for the detection of TCB, a novel LFIA was 
generated which employed a conjugated green fluorescent protein (GFP) to TCB for the 
visualisation of TCB in milk samples. This conjugation was carried out by first reducing the 
GFP with tris-[2-carboxyethyl]-phosphine hydrochloride (TCEP) followed by the covalent 
conjugation of the TCB-GFP with the heterobifunctional cross-linker sulfo-GMBS. Next the 
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LFIA was developed integrating the GFP conjugate for the rapid detection of TCB in 
extracted milk samples.   
 
5.6.1 Conjugation of GFP to the hapten TCB. 
TCEP was used for the reduction of disulphide bonds in GFP for the conjugation of TCB via 
sulfo-GMBS chemistry. Briefly, TCEP is a highly effective agent for the reduction of 
disulfide bonds in proteins, peptides and other disulfide bond-containing molecules over a 
wide pH range (Reugg and Rudinger, 1977). It is a moderately stable compound and does not 
undergo rapid oxidation which often occurs with other reagents such as β-mercapthoethanol 
or dithiothreitol (DTT). The reduction of the GFP by TCEP is described in section 2.15.4.  
 
Following successful reduction of GFP, the conjugation was carried out via sulfo-GMBS 
chemistry. Sulfo-GMBS is a heterobifunctional cross linker that contains N-
hydroxysuccinamide (NHS) ester and maleimide groups that facilitate covalent conjugation 
of amine and sulfydryl-containing molecules. NHS esters react with amines at pH 7.9, to 
form amide bonds while the maleimide reacts with the sulfydryl groups at pH 6.5-7.5, to form 
stable thioether bonds. Sulfo-GMBS is used in a two step scheme for the conjugation of 
hapten-carrier protein conjugates. Firstly the amine-containing protein (GFP) is reacted with 
a several-fold molar excess of the cross linker (Kitagawa et al., 1981). This is followed by the 
removal of excess reagent by de-salting or dialysis and, finally, the sulfydryl-containing 
molecule (TCB) is added to the reaction to react with the maleimide groups already attached 
to the first protein (GFP) (Section 2.15.5). 
 
5.6.2 GFP-TCB LFIA development  
Following the conjugation of GFP to TCB a LFIA was developed. In this format there was 
competition between the unlabelled TCB and the TCB labelled with GFP in solution for 
binding to the immobilised anti-TCB pAb IgY. The test lines (approximately 1.5 cm from the 
bottom of the strip), on the nitrocellulose paper were coated with 100 μg/mL dilution of anti-
TCB pAb in 50mM sodium phosphate, pH 7.5, + (1 % (w/v) trehalose) coating buffer. The 
control line used throughout this study was an anti-GFP mAb, supplied by Sigma-Aldrich. 
The control lines (approximately 3.5 cm from the bottom of the strip) on the nitrocellulose 
paper were coated with 10 µg/mL of an anti-GFP mAb in 50mM sodium phosphate, pH 7.5, 
+ (1 % (w/v) trehalose) coating buffer. Running buffer consisting of 50mM sodium 
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phosphate, pH 7.5, + 0.05 % (v/v) Tween was spiked with concentration of TCB ranging 
between 5-500 ng/mL and added to a  1/5 dilution of the conjugated TCB-GFP in a ratio of 
1:3. Samples were also prepared by spiking milk with concentrations of TCB ranging 
between 5-500 ng/mL which were subsequently extracted via the QuEChERs method. The 
resulting TCB residues were diluted with a 1/5 dilution of the conjugate TCB-GFP in a 1:3 
ratio prior to application to the strip (section 2.15.6). The strips were visualised using a 
Typhoon 8600 variable mode fluorescence imager at excitation and emission wavelengths of 
488 nm and 507 nm, respectively (Figure 5.6.1). This figure shows that the response is 
negatively correlated to the analyte concentration i.e. the more TCB present, less 
fluorescence is observed and where there is little or no analyte present a higher signal is 
detected, this proof of concept assay indicates that this LFIA has the capability to detect TCB 
in milk extracts between 50 and  100 ng/mL.   
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Figure 5.6.1: Novel lateral flow assay for the detection of TCB using conjugated TCB-GFP. 
Test lines were sprayed on the nitrocellulose strips (1-5) with 100 μg/mL of chicken anti-
TCB pAb in coating buffer. A control line, consisting of 10 µg/mL anti-GFP mAb in coating 
buffer, was also sprayed on each strip. Milk samples were spiked with concentrations of TCB 
ranging from 5-500 ng/mL, and extracted via the QuEChERs method. The resulting TCB 
residues were mixed with a 1/5 dilution of the conjugate TCB-GFP prior to application to the 
strip. Test lines: Strip 1: sample containing 500 ng/mL of free TCB; Strip 2: sample 
containing 100 ng/mL of free TCB; Strip 3: sample containing 50 ng/mL of free TCB; Strip 
4: sample containing 25 ng/mL of free TCB; Strip 5: 5 ng/mL of free TCB; Strip 6: Negative 
control (sample containing no TCB). Control line: Strips 1-6: 10 μg/mL of anti-GFP mAb. 
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5.7 Discussion  
This chapter gives a detailed description of the development of three separate methods 
(ELISA, BIAcore™ and LFIA) for the detection of TCB in spiked milk samples.  
 
During the further development of the ELISA assay, two different methods were used for the 
extraction of TCB from spiked milk samples, direct centrifugation and a modified 
QuEChERs method. As shown in Figure 5.3.1 the QuEChERs method was revealed to be the 
more robust extraction procedure of the two. This was the extraction process used throughout 
the course of this research. The residues remaining subsequent to extraction and evaporation 
were re-constituted and assayed to determine the within (intra) and between day (inter) 
precision. The % CV at the low end of the curve for both 7 and 21 pg/mL was 6 %. This is 
similar for the high end of the assay where the % CV’s are 3 and 5 % for 12,000,000 and 
4,000,000 pg/mL respectively. There is a higher level of imprecision for the linear portion of 
the curve with % CV’s as high as 17 % at a concentration of 48,000 pg/mL. According to 
legislation this % CV is still acceptable for assays detecting veterinary residues and may be 
expected for inter assays as more variability is being introduced. The % recoveries for this 
assay were between 92-129 %. According to EU legislation acceptable limits of single 
recovery should normally be in the range 60–140 %. Recoveries outside of this range 
however, usually require re-analysis of the batch between and within assay.  
http://ec.europa.eu/food/plant/resources/qualcontrolen.pdf. As previously discussed the LOD 
of the ELISA assay was determined to be 609 pg/mL, 164 times below the recommended 
MRL of 100 ng/mL for TCB.  
 
Following the ELISA assay development, a BIAcore™ assay was generated for the 
automated detection of TCB. The method was initially developed using PBS containing 50 % 
(v/v) methanol spiked with varying concentrations of TCB, following the success of this 
procedure this platform was also used for the detection of TCB in spiked milk samples.  
 
Originally BIAcore™ dextran CM5 chips were immobilised with ~50 μg/mL of TCB-BTG in 
sodium acetate buffer pH 4.0, giving an approximate RU of 12,500. A high concentration of 
approximately 500 μg/mL of antibody was required to give a low response of approximately 
100 RU. Passing varying concentrations of free TCB over the flow cell failed to displace the 
antibody, therefore it was deemed that the chip had become degraded. The chip was re-
immobilised with TCB-BTG and again with TCB-HRP at a number of different 
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concentrations. These chips appeared to be unstable after numerous regenerations with 200 
mM NaOH. Upon receipt of the donated TCB gluteraldhyde linked chip, buffer recalibration 
curves were generated and inter and intra-assays performed. In buffer, the anti-TCB pAb had 
a LOD of  4 ng/mL. The precision was low across the full range of the assay with % CV’s 
ranging between 0.44-3.02 %. Recoveries varied throughout the assay reaching as high as 
140 % at a concentration of 50 pg/mL. However, as already discussed this is still an 
acceptable % recovery for veterinary drug residues from milk and meat matrices. For the 
extracted residues from spiked milk samples the LOD was 203 pg/mL. The % CV’s for this 
assay were significantly higher in comparison to that of the buffer assay. The low end % 
CV’s for 21 and 7 pg/mL were 6 and 3 % respectively, however, when observing the linear 
range of the assay these were notably higher and reached a % CV of 15 % at 148,000 pg/mL. 
This indicates that there was substantial variation introduced during the inter day assays. The 
% recoveries of the assay ranged between 71 and 121 %.  
 
A number of BIAcore™ assays have been developed for the detection of benzimidazoles 
extracted from real meat and milk samples. Keegan et al. generated a BIAcore™ screening 
assay for the detection of the parent molecules ABZ, FBZ, FLU, MBZ and OXI and their 
corresponding metabolites from incurred milk samples. This work was carried out using a 
sheep pAb raised against methyl 5 (6)-[(carboxypentyl)-thiol]-2-benzimidazole carbamate 
protein conjugate and had a LOD of 2.7 ng/mL and a detection capability of 5 ng/mL for all 
eleven benzimidazoles reported (Keegan et al., 2009). In a different study they describe the 
development of two BIAcore™ assays for eleven 11 benzimidazole carbamate (BZT) and 
four amino-benzimidazole veterinary drug residues in liver tissue. The BZT assay was 
reported to have an LOD of 32 ng/mL and a detection capability of 50 ng/mL (Keegan et al., 
2011). There have been no publications to support the generation of a BIAcore™ assay for 
the detection of TCB in any matrix.  
 
In this research the development of a LFIA using an enzyme labelled antibody for the 
detection of TCB in milk samples was described. The detection capability of the assay was 
approximately 75 ng/ml which is below the recommended MRL of 100 ng/ml. In membrane 
based assays enzyme labels are often used as the colour produced by the substrate conversion 
can be detected visually, however, this can be difficult to quantify (Bonenberger and 
Doumanas, 2006). Therefore, a fluorescent LFIA was developed employing a TCB-GFP 
conjugate which was prepared via sulfo-GMBS chemistry. Coating the anti-TCB pAb onto 
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the nitro-cellulose surface allowed for the capture of the TCB-GFP. Mixing samples 
containing TCB with the TCB-GFP conjugate and applying this to the strip allowed for the 
competition between the conjugated and free TCB. The more TCB in the sample the less 
binding sites available for the TCB-GFP on the strip surface, therefore the less florescence 
emitted and vice versa. Using a Typhoon 8600 variable mode fluorescence imager we were 
able to quantify that the LFIA assay has a detection capability of 75 ng/mL (Figure 5.6.1).  
 
There is no research currently published for the development of an LFIA for the detection of 
TCB. However, Smidova et al. reported the development of an LFIA for the detection of 
TBZ in fruit juice. Using a carbon black labelled secondary anti-mouse antibody they were 
able to detect TBZ down to 0.001 mg/kg, below the current MRL which is currently set at 5 
mg/kg (Smidova et al., 2009). Additionally, colloidal gold labels are currently a popular 
choice for researchers due to their emission of vivid colour caused by localised SPR and 
excellent chemical stability (Liu et al., 2011; Guo et al., 2009). This approach has been 
successful for the detection of many chemical analytes such as the sulphonamides, 
clenbuteral, kanamycin, and toxins such as Aflatoxin B1, aflatoxin B2 and ochratoxin (Ngom 
et al., 2010). Other labelling techniques are also being explored, such as fluorescent latex 
beads, liposome containing fluorescent of bioluminescent dyes, magnetic particles and raman 
active tags (Posthuma-Trumpie et al., 2009; Song and Knotts, 2008). This novel TCB-GFP 
LFIA is not without its drawbacks, even though it is a rapid method for the quantification of 
TCB in acetonitrile extracted samples the complex and expensive fluorescence imagery 
required for its detection will limit the market for such testing systems.   
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Chapter six 
Overall conclusions 
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6.1 Overall conclusions 
The aim of the work described in this research was the generation of polyclonal and 
recombinant antibodies for the detection of benzimidazoles. Antibodies selected were 
characterized by ELISA and SDS PAGE and implemented into the development of ELISA, 
BIAcore™ and LFIA assays.  
Chapter three describes the generation of an anti-TBZ Fab using RNA isolated from an anti-
TBZ antibody secreting hybridoma cell line. The antibody library was constructed using 
methods and primers based on the studies by Barbas et al. (2001). Anti-TBZ Fab clones were 
isolated by phage display and colonies secreting the anti-TBZ Fab (thirteem) were screened 
and selected via ELISA. Clones E6, D2 and F7 demonstrated an affinity to TBZ and were 
expressed in large-scale, purified using IMAC and the purity verified by SDS-PAGE. The 
clone E6 was characterised and chosen for all further studies. A competitive assay was 
developed for the detection of TBZ in buffer containing 5% (v/v) methanol. Intra- and inter-
day studies evaluated the assays reproducibility and precision. The limit of detection of the 
anti-TBZ assay was approximately 2.5 ng/mL, forty times below the recommended MRL for 
TBZ. 
The second phase of the research in chapter three encompassed the modification of the 
pComb3xTT vector.  The vector was designed to alter the valency of the antibody thus 
increasing functional affinity therefore increasing the sensitivity of the assay to which the 
antibody is applied. The dHLX gene was amplified from the pAk500 vector and inserted into 
the pComb vector system using specifically designed primers and the restriction enzymes 
BspE1 and BsiW1. This vector allowed for dimerization to occur, assembly in-vivo in E.coli, 
and the secretion of the dimerized antibody fragment into the periplasmic space. HPLC 
results indicate that dimerisation occurred when fusing the Fab fragment to the double helix 
motif thus resulting in an enhanced avidity. 
Chapter four describes the generation of an avian polyclonal antibody raised against the 
conjugate TCB-BTG. A leghorn New Zealand chicken was immunized with the conjugates 
TCB-BTG and ABZ-HRP. Initial serum titres showed a significant response to both 
conjugates. Anti-chicken IgY was purified from the yolks of the eggs obtained during the 
immunization period and the purity was verified by SDS PAGE. Experiments were carried 
out to determine the optimal conditions for coating the optimisation studies were performed 
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to ascertain the most favourable conditions for the conjugate to the ELISA plate surface and 
the selection of an antibody dilution for the detection of TCB and ABZ. Cross reactivity 
studies and initial competitive assays were performed for both TCB and ABZ. However, the 
pAb could not be displaced by ABZ indicating that the antibody was not ABZ specific. Assay 
development was carried forward for TCB only. The affect of solvents on the antibodys 
performance was established and a competitive assay was developed for the detection of TCB 
in PBS containing 50 % (v/v) methanol. The limit of detection of the assay was determined as 
25 ng/mL, four times lower than the recommended MRL for TCB.  
Another aspect of the research described in chapter four was the construction of an avian 
scFv library from RNA extracted from the previously immunized chicken. A large library 
size was obtained and bio-panned using both competitive and enzymatic elution techniques. 
Colonies selected were grown in 5 mL cultures and the lysates screened for binding activity. 
No binding occurred and the clones were subjected to a colony pick PCR where the 750 bp 
confirmed the presence and the successful ligation of the gene fragment into the pComb 
vector. The vector containing the gene fragment was transformed into other E.coli strains to 
aid the soluble expression of the scFv. However, when colonies were selected, grown in 10 
mL cultures, no binding between the lysate and the TCB/ABZ conjugates occurred. These 
outcomes suggest that the scFv is folded in such a way that maybe the antigen sites are 
inaccessible or that it may be forming aggregates thus reducing its binding capacity. 
The studies in chapter five describe the further development of an ELISA for the detection of 
TCB in spiked milk samples. Milk was spiked with concentrations of free TCB ranging from 
12,000,000-7 pg/mL, and extracted using a modified QuEChERS method. The resulting 
residues were reconstituted in PBS containing 50 % (v/v) methanol and analysed by ELISA. 
The limit of detection of this assay was approximately 609 pg/mL. This is significantly lower 
than the limit of detection of the assay in which TCB in spiked buffer samples was detected, 
and is also 164 times lower than the recommened MRL.  
Following the success of the ELISA assay for the detection of extracted TCB residues from 
milk, a Biacore™™ assay was developed. The conjugate TCB-BTG was immobilized to a 
CM5 dextran chip via amine coupling. However, initial studies showed that the anti-TCB 
pAb could not be displaced from the surface by passing high levels of TCB over the flow 
cell. Other attempts at chip generation proved unsuccessful and a gluteraldehyde linked TCB 
chip was donated by by Dr Martin Danaher of Teagasc, Ashtown. A Biacore™ inhibition 
239 
 
curve was generated for the detection of TCB in PBS containing 50 % (v/v) methanol with a 
limit of detection of 4 ng/mL. Following this, milk was spiked with TCB ranging from 
12,000,000-7 pg/mL and extracted via the QuEChERS method. An inhibition assay was 
generated, and the precision and reproducibility was evaluated by performing intra and inter-
day studies. The limit of detection of the assay was 209 pg/mL.  
Two LFIAs were developed, one that was analogous to a competitive ELISA and one 
incorporating a conjugated TCB-GFP molecule. The former LFIA was developed by coating 
anti-TCB pAb to the nitrocellulose surface, applying samples that contain various 
concentrations of TCB to strip, and detecting the presence of TCB with a HRP labeled anti-
chicken IgY. This proof of concept assay allowed for the detection of TCB im spiked milk 
samples between 50-100 ng/ml and may be used as a confirmatory assay for the presence of 
TCB in samples. Following the success of this assay development, TCB was conjugated to 
GFP via Sulfo-GMBS chemistry. Nitrocellulose was again coated with the anti-TCB pAb. 
Mixing samples containing TCB with the TCB-GFP conjugate and applying this to the strip 
allowed for the competition between the conjugated and free TCB. The amount of TCB was 
measured via fluorescence and the detection capability of this assay was between 50-100 
ng/mL. 
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Figure 8.1: Vector map of the plasmid pComb3X used in this research for the phage display 
of recombinant antibody fragments (Barbas et al., 2001). 
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Figure 8.2: Vector map of the plasmid pComb3XSS used in this research for the phage 
display of recombinant antibody fragments (Barbas et al., 2001). 
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Figure 8.3: Vector map of the plasmid pComb3XTT used in this research for the phage 
display of recombinant antibody fragments (Barbas et al., 2001). 
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Figure 8.4: Vector maps of the pAK plasmid series. The pAK 500  (E) was used for the 
isolation of the DHLX gene fragment for the modification of the pComb vector as described 
in chapter 3.6 (Krebber et al., 1996). 
 
